Finerenone for use in a method of preventing or treating heart failure in a patient receiving a cyp3a4 inhibitor or a cyp3a4 inducer

Abstract

NOT VISIBLE DUE TO STATUS OF PATENT

Description

[0001]BHC231046 US14 -1- A method of preventing or treating heart failure in a patient using (4S)-4-(4-cyano-2-methoxy- phenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide FieldThe disclosure refers to a method of preventing or treating heart failure in a patient using (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide (INN: finerenone). Background INCORPORATION BY REFERENCE All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference to the same extent as if each individual publication, patent, or patent application wasspecifically and individually indicated to be incorporated by reference. To the extent publications andpatents or patent applications incorporated by reference contradict the disclosure contained in the text ofthe specification, the specification is intended to supersede and / or take precedence over any such contradictory material. Steroidal Mineralocorticoid Receptor Antagonists (MRAs), spironolactone and eplerenone, are recommended in the treatment of patients with heart failure with reduced ejection fraction (HFrEF) and especially those with ejection fraction below 30%, but their role at higher ejection fractions has not been well established. Broad use of steroidal MRAs has further been limited in part due to safety concerns around risks of hyperkalemia and renal dysfunction. These risks may be reduced by the unique pharmacological properties of the non-steroidal MRA finerenone. Heart failure with preserved ejection fraction (HFpEF) which affects around 50% of the overall heart failure population with increasing prevalence has one of the greatest unmet needs in cardiovascular medicine [Butler et al. Developing therapies for heart failure with preserved ejection fraction: current state and future directions, JACC HeartFail. 2 (2) (2014) 97–112, https: / / doi.org / 10.1016 / j.jchf.2013.10.006]. More recently, the steroidalmineralocorticoid receptor antagonist spironolactone was investigated in patients with HFpEF in a trial called TOPCAT [Pitt et al. Spironolactone for heart failure with preserved ejection fraction, N. Engl. J.Med. 370 (15) (2014) 1383–1392, https: / / doi.org / 10.1056 / NEJMoa1313731.]. Although spironolactonedid not demonstrate benefit with respect to the primary composite endpoint in this global trial, there wasa nominal benefit in patients recruited in North and South America. Subsequent analyses of TOPCAT have revealed significant regional variation of event rates and drug adherence with different treatment effects [Patel et al., Designing future clinical trials in heart failure with preserved ejection fraction: lessonsfrom TOPCAT, Curr. Heart Fail. Rep. 14 (4) (2017) 217–222, https: / / doi.org / 10.1007 / s11897-017-0336-x; Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, BHC231046 US14 -2- Gordeev I, Heitner JF, Lewis EF, O'Meara E, Rouleau JL, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, McKinlay SM, Pitt B. Regional variation in patients and outcomes in theTreatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.Circulation. 2015 Jan 6;131(1):34-42. doi: 10.1161 / CIRCULATIONAHA.114.013255. Epub 2014 Nov 18. PMID: 25406305.]. Finerenone is a novel potent and selective non-steroidal MRA. Finerenone’s unique binding mode determines potency, selectivity, and blockade of cofactor association with the MR in the nucleus, while its specific physicochemical properties determine tissue penetration and distribution [Kolkhof et al.Nonsteroidal antagonists of the mineralocorticoid receptor, Curr. Opin. Nephrol. Hypertens. 24 (5) (2015)417–424, https: / / doi.org / 10.1097 / MNH.0000000000000147.]. In addition, pharmacokinetic and drug metabolism properties of finerenone yield a short half-life, no active metabolites, and a renal elimination of less than 1% [R. Heinig et al. Pharmacokinetics of the novel nonsteroidal mineralocorticoid receptor antagonist finerenone (BAY 94-8862) in individuals with renal impairment, Clin. Pharmacol. Drug Dev. 5 (6) (2016) 488–501, https: / / doi.org / 10.1002 / cpdd.263., M. Gerisch, et al. Biotransformation of finerenone, a novel nonsteroidal mineralocorticoid receptor antagonist, in dogs, rats, and humans, in vivoand in vitro, Drug Metab. Dispos. 46 (11) (2018) 1546–1555, https: / / doi.org / 10.1124 / dmd.118.083337.].The combination of these major parameters translates into a downstream cardiovascular and renal gene expression profile with a deduced MRA pharmacology that clearly differentiates from steroidal MRAs. Finerenone’s mode of action counteracts multiple components which are also key drivers of the HFpEFpathophysiology [Kolkhof, Lawatscheck, Filippatos and Bakris. Int. J. Mol. Sci. 2022;23:9243, Sweeneyet al. EMBO Mol. Med. 2020;12:e1086]. Finerenone has been characterized in several preclinicalcardiorenal models which develop heart failure and was shown to demonstrate improvement of systolic and diastolic function [Kolkhof et al. Finerenone, a novel selective nonsteroidal mineralocorticoidreceptor antagonist protects from rat cardiorenal injury. J. Cardiovasc. Pharmacol. 2014 Jul;64(1):69-78.https: / / doi.org / 10.1097 / FJC.0000000000000091., Grune et al. Selective Mineralocorticoid Receptor Cofactor Modulation as Molecular Basis for Finerenone's Antifibrotic Activity. Hypertension. 2018 Apr;71(4):599-608. https: / / doi.org / 10.1161 / HYPERTENSIONAHA.117.10360., Lachaux et al. Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenoneopposes metabolic syndrome-related cardio-renal dysfunction. Diabetes Obes. Metab. 2018Oct;20(10):2399-2407. https: / / doi.org / 10.1111 / dom.13393., Lima Posada et al. Benefits of the non- steroidal mineralocorticoid receptor antagonist finerenone in metabolic syndrome-related heart failurewith preserved ejection fraction. Int. J. Mol. Sci. 2023, Jan 28;24(3):2536.].However, rodent heart failure models usually develop a mixture of systolic and diastolic dysfunction.There is no rodent animal model which completely recapitulates all aspects of human HFpEF with allaspects [Withaar et al. European Heart Journal (2021) 42, 4420–4430,https: / / doi.org / 10.1093 / eurheartj / ehab389]. Therefore, it is currently unknown whether finerenone is able BHC231046 US14 -3- to improve outcomes in human heart failure with preserved ejection fraction (HFpEF), heart failure withmid-range ejection fraction (HFmrEF), heart failure with reduced ejection fraction (HFrEF) or humanheart failure (HF) ≥40%. The term heart failure (HF) is sometimes called "cardiac insufficiency" andsometimes HF is still called "cardiac failure." Sometimes HFrEF is referred to as systolic heart failure (and HFpEF as diastolic HF). Steroidal mineralocorticoid receptor antagonists reduce morbidity and mortality in patients with heart failure and reduced ejection fraction and in myocardial infarction complicated by left ventricular systolic dysfunction, but their efficacy in those patients with heart failure with mildly reduced or preserved ejection has not been established. According to TOPCAT trial [Already abbreviated above.] (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist), spironolactone did not reduce the primary endpoint in the trial. There remains a high unmet need in patients with heart failure and mildly reduced or preserved ejection fraction despite the recent availability of therapeutic options, including sodium-glucose co-transporter-2 inhibitors. In contrast to the steroidal MRAs spironolactone and eplerenone, finerenone is a highly selective non- steroidal mineralocorticoid receptor antagonist with distinct physiochemical properties, resulting in a more balanced tissue distribution between the heart and kidney compared with steroidal mineralocorticoid receptor antagonists. In two large outcomes trials in participants with chronic kidney disease and Type-2 diabetes, finerenone was well tolerated and reduced kidney disease progression and cardiovascular events, including heart failure hospitalizations, and is approved for the treatment of these patients in many countries. We designed the Study to Evaluate the Efficacy and Safety of Finerenone on Morbidity and Mortality in Participants With Heart Failure and Left Ventricular Ejection Fraction ≥40% (FINEARTS- HF) trial to test the hypothesis that finerenone, in addition to usual therapy, would reduce the composite of cardiovascular death and total heart failure events in patients with heart failure with mildly reduced orpreserved ejection fraction. The FINEARTS-HF trial (see example 2) and its outcomes are describedbelow. Summary of the DisclosureAn object of the present disclosure is to provide a new method of preventing or treating heart failure.A further object is to provide a new and / or improved method of treating or preventing symptomatic heart failure.Another object is to provide a new and / or improved method for reducing the risk of cardiovascular deathin patients with heart failure. A further object is to provide a new and / or improved method of reducing the risk of hospitalization for heart failure in patients. BHC231046 US14 -4-Another object is to provide a new and / or improved method for reducing the risk of urgent heart failurevisits in patients. A further object is improving symptoms or preventing worsening of symptoms of heart failure. No prior trial of HFmrEF / HFpEF have specifically targeted those with recent worsening heart failure event. This problem is solved by the method or methods as described below:The disclosure refers to a method of preventing or treating heart failure in a patient, comprisingadministering to the patient a therapeutically effective amount of the compound (I) or a hydrate, solvate, pharmaceutically acceptable salt thereof, or a polymorph thereof. The non-steroidal mineralocorticoid receptor antagonist (MRA) finerenone lessens the effects ofmineralocorticoid receptor overactivation by ligands such as aldosterone and cortisol. Finerenone has thechemical name (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6- naphthyridine-3-carboxamide, and has the chemical structure of formula (I): The synthesis, pharmacological properties, and pharmaceutical formulations / dosage forms of finerenone are described in US Patent No.8,436,180, which is hereby incorporated by reference herein in its entirety. The use described herein refers to finerenone, a polymorph thereof, a solvate thereof, a hydrate thereof, a BHC231046 US14 -5- salt thereof and / or a pharmaceutically acceptable salt thereof. Detailed Desccription DefinitionsFor interpreting this specification, the following definitions will apply. If any definition set forth belowconflicts with the usage of that word in any other document, including any document incorporated herein by reference, the definition set forth below shall always control for purposes of interpreting this specification and its associated claims unless a contrary meaning is clearly intended (for example in the document where the term is originally used).Whenever appropriate, terms used in the singular will include the plural and vice versa. The use of “a”herein means “one or more” unless stated otherwise or where the use of “one or more” is clearlyinappropriate. The use of "or" means "and / or" unless stated otherwise. The use of “comprise”, “comprises”“comprising”, “include”, “Includes”, and “including” are interchangeable and are not limiting. The terms“such as,” “for example,” and “e.g.” are not intended to be limiting. For example, the term “including”shall mean “including, but not limited to”.“Solvates” for the purposes of the disclosure are those forms of the compounds or their salts where solventmolecules form a stoichiometric complex in the solid state and include, but are not limited to for example water, ethanol and methanol. “Hydrates” are a specific form of solvates, where the solvent molecule is water. Hydrates of thecompounds of the disclosure or their salts are stoichiometric compositions of the compounds or salts withwater, such as, for example, monohydrate, dihydrates, trihydrate, hemihydrate, sesquihydrate.“Salts” for the purposes of the present disclosure are preferably “pharmaceutically acceptable salts” offinerenone. Suitable pharmaceutically acceptable salts that can be used in the combination according tothe disclosure are well known to those skilled in the art and include salts of inorganic acids, organic acids,inorganic bases, alkaline cations, alkaline earth cations and organic bases. In one embodiment the pharmaceutically acceptable salt can be selected from mandelic acid acetate, benzoate, besylate, bromide, camsylate, carbonate, citrate, edisylate, estolate, fumarate, gluceptate, gluconate, glucuronate, hippurate, iodide, isethionate, lactate, lactobionate, malate, maleate, mesylate, methylsulfate, napsylate, nitrate, oxalate, pamoate, phosphate, stearate, succinate, sulfate, tartrate, bitartrate, tosylate, calcium, diolamine, lithium, lysine, magnesium, meglumine, N-methylglucamine, olamine, potassium, tromethamine,tris(hydroxymethyl)aminomethane, benzenesulfonate, ethanesulfonate and zinc. Salts and / complexes canalso be formed with at least one of the following acids: hydrochloric acid, hydrobromic acid, sulfuric acid, phosphoric acid, methane sulphonic acid, trifluoromethanesulfonic acid, benzenesulfonic acid, p-toluene sulfonic acid, 1-naphthalenesulfonic acid, 2-naphthalenesulfonic acid, acetic acid, trifluoroacetic acid, BHC231046 US14 -6- malic acid, tartaric acid, citric acid, lactic acid, oxalic acid, succinic acid, fumaric acid, maleic acid,benzoic acid, salicylic acid, and / or phenylacetic acid. Furthermore, the compound according to formula(I) can also form co-crystals with the aforementioned acids. “Pharmaceutically acceptable” as used herein, refers a material, such as a carrier or diluent, which does not abrogate the biological activity or properties of the compound, and is relatively nontoxic, i.e., the material may be administered to an individual without causing undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained. The phrase “pharmaceutically acceptable salt” refers to a formulation of a compound that does not cause significant irritation to an organism to which it is administered and does not abrogate the biological activity and properties of the compound. In some embodiments, pharmaceutically acceptable salts are obtained by reacting a compound disclosed herein with acids. Pharmaceutically acceptable salts are also obtained by reacting a compound disclosed herein with a base to form a salt. In one embodiment the pharmaceutically acceptable salt can be selected from hydrochloride, sulfate, mesylate, tosylate, tartrate, citrate, benzenesulfonate, ethanesulfonate, maleate, and phosphate.Polymorphic form of finerenone is disclosed in U.S. Patent No. 10,399,977, which is hereby incorporatedherein by reference in its entirety. In the methods of the present disclosure, the compound to be administered may be finerenone of the formula (I) in crystalline form of polymorph I characterized in that the x-ray diffractogram of the compound exhibits peak maxima of the 2-theta angle at 8.5, 14.1, 17.2,19.0, 20.5, 25.6, 26.5 degrees. In the methods of the present disclosure, the compound to be administeredmay be finerenone of the formula (I) in crystalline form of polymorph I characterized in that the IR spectrum (IR-ATR) of the compound exhibits band maxima at 3475, 2230, 1681, 1658, 1606, 1572, 1485, 1255, 1136 and 1031 cm-1. In the methods of the present disclosure, the compound to be administered may be finerenone of the formula (I) in crystalline form of polymorph I characterized in that the Raman spectrum of the compound exhibits band maxima at 3074, 2920, 2231, 1601, 1577, 1443, 1327, 1267, 827 and 155 cm−1. Experimental conditions for the measurement of these crystalline form parameters are found in the examples. In one embodiment, finerenone of the formula (I) in crystalline form of polymorph I is used. In one embodiment, finerenone is the compound of the formula (I) in crystalline form of polymorph I BHC231046 US14 -7- wherein the x-ray diffractogram of the compound exhibits peak maxima of the 2-theta angle at 8.5, 14.1,and 19.0 degrees. In one embodiment, finerenone is the compound of the formula (I) in crystalline formof polymorph I, wherein the x-ray diffractogram of the compound further exhibits any one f-peak maxima of the 2-theta angle at 17.2, 20.5, 25.6, and 26.5. In one embodiment, finerenone is the compound of the formula (I) in crystalline form of polymorph I, wherein the IR spectrum of the compound exhibits any one of band maxima at 3475, 2230, 1681, 1658, 1606, 1572, 1485, 1255, 1136 and 1031 cm-1. In one embodiment, finerenone is the compound of the formula (I) in crystalline form of polymorph I, wherein the IR spectrum of the compound exhibits band maxima at 3475, 2230, 1681, 1658, 1606, 1572, 1485,1255, 1136 and 1031 cm-1. In one embodiment, finerenone is the compound of the formula (I) in crystallineform of polymorph I, wherein the Raman spectrum of the compound exhibits any one of band maxima at 3074, 2920, 2231, 1601, 1577, 1443, 1327, 1267, 827 and 155 cm-1. In one embodiment, finerenone is the compound of the formula (I) in crystalline form of polymorph I, wherein the Raman spectrum of the compound exhibits band maxima at 3074, 2920, 2231, 1601, 1577, 1443, 1327, 1267, 827 and 155 cm-1. In one embodiment, finerenone is the compound of the formula (I) in crystalline form of polymorph I,wherein the compound has a melting point of 252 ºC.In one embodiment the method according to the disclosure is used for the treatment and / or prevention ofheart failure. In one embodiment, the heart failure is selected from the group consisting of symptomatic heart failure, heart failure with improved ejection fraction (HFimpEF), heart failure with mid-range ejection fraction (HFmrEF), heart failure preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF), chronic heart failure (CHF), congestive heart failure, acute heart failure, chronic heart failure, worsening chronic heart failure (WCHF), and hospitalization for heart failure. In one embodiment, the heart failure is symptomatic heart failure. In one embodiment, the heart failure is heart failure with improved ejection fraction (HFimpEF). In one embodiment, the heart failure is heart failure with mid-range ejection fraction (HFmrEF). In one embodiment, the heart failure is preserved ejection fraction (HFpEF). In one embodiment, the heart failure is heart failure with reduced ejection fraction (HFrEF). In one embodiment, the heart failure is chronic heart failure (CHF). In one embodiment, the heart failure is congestive heart failure. In one embodiment, the heart failure is acute heart failure. In BHC231046 US14 -8- one embodiment, the heart failure is chronic heart failure. In one embodiment, the heart failure is worsening chronic heart failure (WCHF). In one embodiment, the heart failure is hospitalization for heart failure.In one embodiment, the method according to the disclosure improves symptoms of heart failure. In thisembodiment the heart failure can be selected from the group consisting of symptomatic heart failure, heart failure with improved ejection fraction (HFimpEF), heart failure with mid-range ejection fraction (HFmrEF), heart failure preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF), chronic heart failure (CHF), congestive heart failure, acute heart failure, chronic heart failure, worsening chronic heart failure (WCHF), and hospitalization for heart failure.In one embodiment, the method according to the disclosure prevents worsening of symptoms of heartfailure. In this embodiment the heart failure can be selected from the group consisting of symptomatic heart failure, heart failure with improved ejection fraction (HFimpEF), heart failure with mid-range ejection fraction (HFmrEF), heart failure preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF), chronic heart failure (CHF), congestive heart failure, acute heart failure, chronic heart failure, worsening chronic heart failure (WCHF), and hospitalization for heart failure. In one embodiment, the hospitalization duration for heart failure is equal to or below 6 months. In one embodiment, the hospitalization duration for heart failure was equal to or above 6 months. In one embodiment, the hospitalization duration for heart failure is equal to or below 12 months. In one embodiment, the hospitalization duration for heart failure is equal to or greater than 12 months. In oneembodiment, the hospitalization duration for heart failure is any prior heart failure hospitalization of anyduration. In one embodiment, the hospitalization duration for heart failure is equal to or below 6 months prior to randomization. In one embodiment, the hospitalization duration for heart failure was equal to or above 6 months prior to randomization. In one embodiment, the hospitalization duration for heart failure is equal to or below 12 months prior to randomization. In one embodiment, the hospitalization duration for heart failure is equal to or above 12 months prior to randomization. In one embodiment, the hospitalization duration for heart failure is any prior heart failure hospitalization of any duration prior to randomization. In one embodiment, the hospitalization duration for heart failure is equal to or below 6 months prior to treatment with finerenone. In one embodiment, the hospitalization duration for heart failure was equal to or above 6 months prior to treatment with finerenone. In one embodiment, the hospitalization duration for heart failure is equal to or below 12 months prior to treatment with finerenone. In one embodiment, the hospitalization duration for heart failure is equal to or above 12 months prior to treatment with finerenone. In one embodiment, the hospitalization for heart failure is any prior heart failure hospitalization of any duration prior to treatment with finerenone. BHC231046 US14 -9- Unless otherwise stated, the terms used herein are used in the manner customary to those skilled in the art. The chemical definitions are used according to IUPAC. The term “equal to or below” or “≤” is used in the sense of two alternatives. These alternatives are, on the one hand, that a number and / or range is either less than a certain number and / or a specific range, or on the other hand, that a number and / or range is both equal to and less than a certain number and / or a specific range, optionally only less than or either equal to or less than a certain number and / or a specific range. The term “equal to or above” or “≥” is used in the sense of two alternatives. These alternatives are, on the one hand, that a number and / or range is either greater than a certain number and / or a specific range, or on the other hand, that a number and / or range is both equal to and greater than a certain number and / or a specific range, optionally only greater than or either equal to or greater than a certain number and / or a specific range.In each instance, the two alternatives are utilized as interchangeable options, defined as two or more options that can be substituted for one another in the context of synonymsIn one embodiment, the “heart failure” is classified by the definition of the New York Heart Association(NYHA) Functional Classification (The Criteria Committee of the New York Heart Association. (1994). Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels (9th ed.). Boston: Little, Brown & Co. pp. 253–256.). This definition is considered a way of describing the extent of functional limitation due to symptoms caused by HF. It places patients in one of four categories based on how much they are limited during physical activity; the limitations / symptoms are in regard to normalbreathing and varying degrees in shortness of breath and / or angina. In practice, sometimes only twosymptoms are considered relevant. NYHA Class I (Symptoms): Presence of cardiac disease. No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, dyspnea (shortness of breath). NYHA Class II(Symptoms): Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity resultsin fatigue, palpitation, dyspnea. NYHA Class III (Symptoms): Marked limitation of physical activity.Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, or dyspnea. NYHA Class IV (Symptoms): Unable to carry on any physical activity without discomfort. Symptoms of heart failure at rest. If any physical activity is undertaken, discomfort increases. In one embodiment, the heart failure is selected from New York Heart Association (NYHA) class I, II, IIIand IV. In one embodiment, the heart failure is selected from NYHA class II, III and IV. In oneembodiment, the heart failure is NYHA class II. In one embodiment, the heart failure is NYHA class III.In one embodiment, the heart failure is NYHA class IV.In one embodiment, method for treating symptomatic heart failure in a patient, comprising administering to the patient a therapeutically effective amount of the compound (I) BHC231046 US14 -10- or a hydrate thereof, solvate thereof, pharmaceutically acceptable salt thereof, or a polymorph thereof.In one embodiment, the present disclosure provides a method for preventing symptomatic heart failure in a patient, comprising administering to the patient a therapeutically effective amount of the compound (I) or a hydrate thereof, solvate thereof, pharmaceutically acceptable salt thereof, or a polymorph thereof.In one embodiment, the present disclosure provides a method for lowering the risk of symptomatic heart failure in a patient, comprising administering to the patient a therapeutically effective amount of the compound (I) or a hydrate thereof, solvate thereof, pharmaceutically acceptable salt thereof, or a polymorph thereof.In one embodiment, the present disclosure provides a method for treating symptomatic heart failure withleft ventricular ejection fraction (LVEF) equal to or above 30% in a patient, comprising administering tothe patient a therapeutically effective amount of the compound (I) BHC231046 US14 -11- or a hydrate thereof, solvate thereof, pharmaceutically acceptable salt thereof, or a polymorph thereof.In one embodiment, the present disclosure provides a method for preventing symptomatic heart failurewith left ventricular ejection fraction (LVEF) equal to or above 30% in a patient, comprising administeringto the patient a therapeutically effective amount of the compound (I) or a hydrate thereof, solvate thereof, pharmaceutically acceptable salt thereof, or a polymorph thereof.In one embodiment, the present disclosure provides a method for lowering the risk of symptomatic heartfailure with left ventricular ejection fraction (LVEF) equal to or above 30% in a patient, comprisingadministering to the patient a therapeutically effective amount of the compound (I) or a hydrate thereof, solvate thereof, pharmaceutically acceptable salt thereof, or a polymorph thereof.In one embodiment, the present disclosure provides a method for treating symptomatic heart failure withleft ventricular ejection fraction (LVEF) of equal to or above 40% in a patient, comprising administering BHC231046 US14 -12- to the patient a therapeutically effective amount of the compound (I) or a hydrate thereof, solvate thereof, pharmaceutically acceptable salt thereof, or a polymorph thereof.In one embodiment, the present disclosure provides a method for preventing symptomatic heart failurewith left ventricular ejection fraction (LVEF) equal to or above 40% in a patient, comprising administeringto the patient a therapeutically effective amount of the compound (I) or a hydrate thereof, solvate thereof, pharmaceutically acceptable salt thereof, or a polymorph thereof.In one embodiment, the present disclosure provides a method for lowering the risk of symptomatic heartfailure with left ventricular ejection fraction (LVEF) equal to or above 40% in a patient, comprisingadministering to the patient a therapeutically effective amount of the compound (I) or a hydrate thereof, solvate thereof, pharmaceutically acceptable salt thereof, or a polymorph thereof.In one embodiment, the present disclosure provides a method for reducing the risk of cardiovascular BHC231046 US14 -13- death, hospitalization for heart failure, and / or urgent heart failure visits in patients with heart failure, comprising administering to the patient a therapeutically effective amount of the compound (I) or a hydrate thereof, solvate thereof, pharmaceutically acceptable salt thereof, or a polymorph thereof.In one embodiment, the present disclosure provides a method for reducing the risk of cardiovascular death, hospitalization for heart failure, and / or urgent heart failure visits in patients with heart failure with leftventricular ejection fraction (LVEF) equal to or above 30 %, comprising administering to the patient atherapeutically effective amount of the compound (I) or a hydrate thereof, solvate thereof, pharmaceutically acceptable salt thereof, or a polymorph thereof.In one embodiment, the present disclosure provides a method for reducing the risk of cardiovascular death, hospitalization for heart failure, and / or urgent heart failure visits in patients with heart failure with leftventricular ejection fraction (LVEF) equal to or above 40%, comprising administering to the patient atherapeutically effective amount of the compound (I) BHC231046 US14 -14-or a hydrate thereof, solvate thereof, pharmaceutically acceptable salt thereof, or a polymorph thereof.In one embodiment, the present disclosure provides a method for reducing the risk of cardiovascular death in patients with heart failure, comprising administering to the patient a therapeutically effective amount of the compound (I) or a hydrate thereof, solvate thereof, pharmaceutically acceptable salt thereof, or a polymorph thereof.In one embodiment, the present disclosure provides a method for reducing the risk of cardiovascular deathin patients with heart failure with left ventricular ejection fraction (LVEF) equal to or above 30 %,comprising administering to the patient a therapeutically effective amount of the compound (I) or a hydrate thereof, solvate thereof, pharmaceutically acceptable salt thereof, or a polymorph thereof.In one embodiment, the present disclosure provides a method for reducing the risk of cardiovascular deathin patients with heart failure with left ventricular ejection fraction (LVEF) equal to or above 40%,comprising administering to the patient a therapeutically effective amount of the compound (I) BHC231046 US14 -15- or a hydrate thereof, solvate thereof, pharmaceutically acceptable salt thereof, or a polymorph thereof.In one embodiment, the present disclosure provides a method for reducing the risk of hospitalization for heart failure in patients with heart failure, comprising administering to the patient a therapeutically effective amount of the compound (I) or a hydrate thereof, solvate thereof, pharmaceutically acceptable salt thereof, or a polymorph thereof.In one embodiment, the present disclosure provides a method for reducing the risk of hospitalization forheart failure in patients with heart failure with left ventricular ejection fraction (LVEF) equal to or above30 %, comprising administering to the patient a therapeutically effective amount of the compound (I) or a hydrate thereof, solvate thereof, pharmaceutically acceptable salt thereof, or a polymorph thereof.In one embodiment, the present disclosure provides a method for reducing the risk of hospitalization forheart failure in patients with heart failure with left ventricular ejection fraction (LVEF) equal to or above BHC231046 US14 -16- 40%, comprising administering to the patient a therapeutically effective amount of the compound (I) or a hydrate thereof, solvate thereof, pharmaceutically acceptable salt thereof, or a polymorph thereof.In one embodiment, the present disclosure provides a method for reducing the risk of urgent heart failure visits in patients with heart failure, comprising administering to the patient a therapeutically effective amount of the compound (I) or a hydrate thereof, solvate thereof, pharmaceutically acceptable salt thereof, or a polymorph thereof.In one embodiment, the present disclosure provides a method for reducing the risk of urgent heart failurevisits in patients with heart failure with left ventricular ejection fraction (LVEF) of equal to or above 30%, comprising administering to the patient a therapeutically effective amount of the compound (I) or a hydrate thereof, solvate thereof, pharmaceutically acceptable salt thereof, or a polymorph thereof.In one embodiment, the present disclosure provides a method for reducing the risk of urgent heart failure BHC231046 US14 -17-visits in patients with heart failure with left ventricular ejection fraction (LVEF) of equal to or above 40%,comprising administering to the patient a therapeutically effective amount of the compound (I) or a hydrate thereof, solvate thereof, pharmaceutically acceptable salt thereof, or a polymorph thereof.In one embodiment, the present disclosure provides a method that improves symptoms of heart failurewith left ventricular ejection fraction (LVEF) equal to or above 40%, comprising administering to thepatient a therapeutically effective amount of the compound (I) or a hydrate thereof, solvate thereof, pharmaceutically acceptable salt thereof, or a polymorph thereof.The heart failure is selected from the group consisting of symptomatic heart failure, heart failure with improved ejection fraction (HFimpEF), heart failure with mid-range ejection fraction (HFmrEF), heart failure preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF), chronic heart failure (CHF), congestive heart failure, acute heart failure, chronic heart failure, worsening chronic heart failure (WCHF), and hospitalization for heart failure. In one embodiment, the present disclosure provides a method that prevents worsening of symptoms ofheart failure with left ventricular ejection fraction (LVEF) equal to or above 40%, comprisingadministering to the patient a therapeutically effective amount of the compound (I) BHC231046 US14 -18- or a hydrate thereof, solvate thereof, pharmaceutically acceptable salt thereof, or a polymorph thereof.The heart failure is selected from the group consisting of symptomatic heart failure, heart failure withimproved ejection fraction (HFimpEF), heart failure with mid-range ejection fraction (HFmrEF), heart failure preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF), chronic heart failure (CHF), congestive heart failure, acute heart failure, chronic heart failure, worsening chronic heart failure (WCHF), and hospitalization for heart failure. In one embodiment, the present disclosure provides a method for reducing the risk of cardiovascular death, hospitalization for heart failure, and / or urgent heart failure visits in adults with heart failure with left ventricular ejection fraction (LVEF) of ≥ 40%In one embodiment, the patient has heart failure with left ventricular ejection fraction (LVEF) of equal toor below 30 %.Left ventricular ejection fraction (LVEF) is the central measure of left ventricular function. This indication of how well one’s heart is pumping out blood can help to diagnose and track heart failure. LVEF is the fraction of chamber volume ejected in systole (stroke volume) in relation to the volume of the blood in the ventricle at the end of diastole (end-diastolic volume). It is a measurement, expressed as a percentage (%), of how much blood the left ventricle pumps out with each contraction. An LVEF of 60 % means that 60 % of the total amount of blood in the left ventricle is pushed out with each heartbeat. A normal heart’sLVEF is between 55 and 70 %. The simplest classification as per the American College of Cardiology(ACC) that is used clinically as follows: Hyperdynamic = LVEF greater than 70% Normal = LVEF 50% to 70% (midpoint 60%) Mild dysfunction = LVEF 40% to 49% (midpoint 45%) Moderate dysfunction = LVEF 30% to 39% (midpoint 35%) Severe dysfunction = LVEF less than 30% In one embodiment, the patient has a LVEF selected from the group consisting of less than 30%, 30% to39%, 40% to 49%, 45 %, 50% to 70%, 60 %, and greater than 70%. In one embodiment, the patient has a BHC231046 US14 -19-LVEF of selected from equal to or above 70%, equal to or above 50 % to equal to or below 70 %, equalto or above 60%, equal to or below 60 %, equal to or above 50 % to equal to or below 60 %, equal to orabove 45 %, equal to or below 45 %, and equal to or above 40 % to equal to or below 49 %.In one embodiment, the present disclosure includes treatment of a patient who has a LVEF of equal to orabove 30%, 35%, 39%, 40%, 45 %, 49%, 50 %, 55%, 65 % or 70 %. In one embodiment, the patient hasa LVEF equal to or above 30 %. In one embodiment, the patient has a LVEF equal to or above 35 %. Inone embodiment, the patient has a LVEF equal to or above 39 %. In one embodiment, the patient has aLVEF equal to or above 40 %. In one embodiment, the patient has a LVEF equal to or above 45 %. In oneembodiment, the patient has a LVEF equal to or above 49 %. In one embodiment, the patient has a LVEFequal to or above 50 %. In one embodiment, the patient has a LVEF equal to or above 55 %. In oneembodiment, the patient has a LVEF equal to or above 59 %. In one embodiment, the patient has a LVEFequal to or above 60 %. In one embodiment, the patient has a LVEF equal to or above 65 %. In oneembodiment, the patient has a LVEF equal to or above 70 %. In one embodiment, the patient has a LVEFequal to or above 75 %. In one embodiment, the patient has a LVEF equal to or below 30%, 35%, 39%, 40%, 45 %, 49%, 50 %,55%, 65 % or 70 %. In one embodiment, the patient has a LVEF equal to or below 30 %. In oneembodiment, the patient has a LVEF equal to or below 35 %. In one embodiment, the patient has a LVEFequal to or below 39 %. In one embodiment, the patient has a LVEF equal to or below 40 %. In one embodiment, the patient has a LVEF equal to or below 45 %. In one embodiment, the patient has a LVEFequal to or below 49 %. In one embodiment, the patient has a LVEF equal to or below 50 %. In oneembodiment, the patient has a LVEF equal to or below 55 %. In one embodiment, the patient has a LVEFequal to or below 59 %. In one embodiment, the patient has a LVEF equal to or below 60 %. In oneembodiment, the patient has a LVEF equal to or below 65 %. In one embodiment, the patient has a LVEFequal to or below 70 %. In one embodiment, the patient has a LVEF equal to or below 75 %.In one embodiment, the patient has a LVEF selected from 44 ±3 %, equal to or above 41 to equal to orbelow 47 %, equal to or above 41 to equal to or below 44 %, equal to or above 44 to equal to or below 47%, 54 ±3 %, equal to or above 51 to equal to or below 57 %, equal to or above 51 to equal to or below 54%, equal to or above 54 to equal to or below 57 %, 64 ±5 %, equal to or above 59 to equal to or below 69%, equal to or above 59 to equal to or below 64 %, equal to or above 64 to equal to or below 69 %, 53 ±8 %, equal to or above 45 to equal to or below 61 %, equal to or above 45 to equal to or below 53 %, and equal to or above 53 to equal to or below 61 %. In one embodiment, the patient has heart failure according to NYHA class II, III or IV, and a LVEF of equal to or above 30%, 35%, 39%, 40%, 45 %, 49%, 50 %, 55%, 65 % or 70 %. In one embodiment, the patient has heart failure according to NYHA class II, III or IV, and a LVEF of equal to or below 30%, 35%, 39%, 40%, 45 %, 49%, 50 %, 55%, 65 % or 70 %. BHC231046 US14 -20- In one embodiment, the patient has heart failure according to NYHA class II, and a LVEF of equal to or above 30%, 35%, 39%, 40%, 45 %, 49%, 50 %, 55%, 60, 65 % or 70 %. In one embodiment, the patient has heart failure according to NYHA class II, and a LVEF of equal to or above 30%. In one embodiment,the patient has heart failure according to NYHA class II, and a LVEF equal to or above 35%. In oneembodiment, the patient has heart failure according to NYHA class II, and a LVEF equal to or above 39%. In one embodiment, the patient has heart failure according to NYHA class II, and a LVEF of equal to or above 40%. In one embodiment, the patient has heart failure according to NYHA class II, and a LVEF of equal to or above 45 %. In one embodiment, the patient has heart failure according to NYHA class II, and a LVEF of equal to or above 49%. In one embodiment, the patient has heart failure according to NYHA class II, and a LVEF of equal to or above 50 %. In one embodiment, the patient has heart failure according to NYHA class II, and a LVEF of equal to or above 55%. In one embodiment, the patient has heart failure according to NYHA class II, and a LVEF of equal to or above 60%. In one embodiment, the patient has heart failure according to NYHA class II, and a LVEF of equal to or above 65 %. In one embodiment, the patient has heart failure according to NYHA class II, and a LVEF of equal to or above 70 %. In one embodiment, the patient has heart failure according to NYHA class II, and a LVEF of equal to or below 30%, 35%, 39%, 40%, 45 %, 49%, 50 %, 55%, 60, 65 % or 70 %. In one embodiment, the patient has heart failure according to NYHA class II, and a LVEF of equal to or below 30%. In one embodiment, the patient has heart failure according to NYHA class II, and a LVEF of equal to or below 35%. In one embodiment, the patient has heart failure according to NYHA class II, and a LVEF of equal to or below 39%. In one embodiment, the patient has heart failure according to NYHA class II, and a LVEF of equalto or below 40%. In one embodiment, the patient has heart failure according to NYHA class II, and aLVEF of equal to or below 45 %. In one embodiment, the patient has heart failure according to NYHA class II, and a LVEF of equal to or below 49%. In one embodiment, the patient has heart failure according to NYHA class II, and a LVEF of equal to or below 50 %. In one embodiment, the patient has heart failure according to NYHA class II, and a LVEF of equal to or below 55%. In one embodiment, the patient has heart failure according to NYHA class II, and a LVEF of equal to or below 60%. In one embodiment, the patient has heart failure according to NYHA class II, and a LVEF of equal to or below 65 %. In one embodiment, the patient has heart failure according to NYHA class II, and a LVEF of equal to or below 70 %. In one embodiment, the patient has heart failure according to NYHA class III, and a LVEF of equal to or above 30%, 35%, 39%, 40%, 45 %, 49%, 50 %, 55%, 60, 65 % or 70 %. In one embodiment, the patienthas heart failure according to NYHA class III, and a LVEF of equal to or above 30%. In one embodiment,the patient has heart failure according to NYHA class III, and a LVEF of equal to or above 35%. In oneembodiment, the patient has heart failure according to NYHA class III, and a LVEF of equal to or above39%. In one embodiment, the patient has heart failure according to NYHA class III, and a LVEF of equalto or above 40%. In one embodiment, the patient has heart failure according to NYHA class III, and a BHC231046 US14 -21-LVEF of equal to or above 45 %. In one embodiment, the patient has heart failure according to NYHAclass III, and a LVEF of equal to or above 49%. In one embodiment, the patient has heart failure accordingto NYHA class III, and a LVEF of equal to or above 50 %. In one embodiment, the patient has heart failureaccording to NYHA class III, and a LVEF of equal to or above 55%. In one embodiment, the patient hasheart failure according to NYHA class III, and a LVEF of equal to or above 60%. In one embodiment, thepatient has heart failure according to NYHA class III, and a LVEF of equal to or above 65 %. In oneembodiment, the patient has heart failure according to NYHA class III, and a LVEF of equal to or above70 %. In one embodiment, the patient has heart failure according to NYHA class III, and a LVEF of equal to or below 30%, 35%, 39%, 40%, 45 %, 49%, 50 %, 55%, 60, 65 % or 70 %. In one embodiment, the patienthas heart failure according to NYHA class III, and a LVEF of equal to or below 30%. In one embodiment,the patient has heart failure according to NYHA class III, and a LVEF of equal to or below 35%. In oneembodiment, the patient has heart failure according to NYHA class III, and a LVEF of equal to or below39%. In one embodiment, the patient has heart failure according to NYHA class III, and a LVEF of equalto or below 40%. In one embodiment, the patient has heart failure according to NYHA class III, and aLVEF of equal to or below 45 %. In one embodiment, the patient has heart failure according to NYHAclass III, and a LVEF of equal to or below 49%. In one embodiment, the patient has heart failure accordingto NYHA class III, and a LVEF of equal to or below 50 %. In one embodiment, the patient has heartfailure according to NYHA class III, and a LVEF of equal to or below 55%. In one embodiment, thepatient has heart failure according to NYHA class III, and a LVEF of equal to or below 60%. In oneembodiment, the patient has heart failure according to NYHA class III, and a LVEF of equal to or below65 %. In one embodiment, the patient has heart failure according to NYHA class III, and a LVEF of equalto or below 70 %.In one embodiment, the patient has heart failure according to NYHA class IV, and a LVEF of equal to or above 30%, 35%, 39%, 40%, 45 %, 49%, 50 %, 55%, 60, 65 % or 70 %. In one embodiment, the patienthas heart failure according to NYHA class IV, and a LVEF of equal to or above 30%. In one embodiment,the patient has heart failure according to NYHA class IV, and a LVEF of equal to or above 35%. In oneembodiment, the patient has heart failure according to NYHA class IV, and a LVEF of equal to or above39%. In one embodiment, the patient has heart failure according to NYHA class IV, and a LVEF of equalto or above 40%. In one embodiment, the patient has heart failure according to NYHA class IV, and aLVEF of equal to or above 45 %. In one embodiment, the patient has heart failure according to NYHAclass IV, and a LVEF of equal to or above 49%. In one embodiment, the patient has heart failure accordingto NYHA class IV, and a LVEF of equal to or above 50 %. In one embodiment, the patient has heartfailure according to NYHA class IV, and a LVEF of equal to or above 55%. In one embodiment, thepatient has heart failure according to NYHA class IV, and a LVEF of equal to or above 60%. In oneembodiment, the patient has heart failure according to NYHA class IV, and a LVEF of equal to or above BHC231046 US14 -22- 65 %. In one embodiment, the patient has heart failure according to NYHA class IV, and a LVEF of equalto or above 70 %.In one embodiment, the patient has heart failure according to NYHA class IV, and a LVEF of equal to or below 30%, 35%, 39%, 40%, 45 %, 49%, 50 %, 55%, 60, 65 % or 70 %. In one embodiment, the patienthas heart failure according to NYHA class IV, and a LVEF of equal to or below 30%. In one embodiment,the patient has heart failure according to NYHA class IV, and a LVEF of equal to or below 35%. In oneembodiment, the patient has heart failure according to NYHA class IV, and a LVEF of equal to or below39%. In one embodiment, the patient has heart failure according to NYHA class IV, and a LVEF of equalto or below 40%. In one embodiment, the patient has heart failure according to NYHA class IV, and aLVEF of equal to or below 45 %. In one embodiment, the patient has heart failure according to NYHAclass IV, and a LVEF of equal to or below 49%. In one embodiment, the patient has heart failure accordingto NYHA class IV, and a LVEF of equal to or below 50 %. In one embodiment, the patient has heartfailure according to NYHA class IV, and a LVEF of equal to or below 55%. In one embodiment, thepatient has heart failure according to NYHA class IV, and a LVEF of equal to or below 60%. In oneembodiment, the patient has heart failure according to NYHA class IV, and a LVEF of equal to or below65 %. In one embodiment, the patient has heart failure according to NYHA class IV, and a LVEF of equalto or below 70 %.In one embodiment, the patient has heart failure according to -NYHA II and LVEF equal to or above 50 % to equal to or below 60 %- NYHA II and LVEF equal to or above 40 % to equal to or below 60 %,- NYHA II and LVEF equal to or above 40 % to equal to or below 50 %,- NYHA II and LVEF 50% to 70%,- NYHA II and LVEF 40% to 49%,- NYHA II and LVEF 30% to 39%,- NYHA III and LVEF equal to or above 50 % to equal to or below 60 %- NYHA III and LVEF equal to or above 40 % to equal to or below 60 %,- NYHA III and LVEF equal to or above 40 % to equal to or below 50 %,- NYHA III and LVEF 50% to 70%,- NYHA III and LVEF 40% to 49%,- NYHA III and LVEF 30% to 39%,- NYHA IV and LVEF equal to or above 50 % to equal to or below 60 %- NYHA IV and LVEF equal to or above 40 % to equal to or below 60 %,- NYHA IV and LVEF equal to or above 40 % to equal to or below 50 %,- NYHA IV and LVEF 50% to 70%,- NYHA IV and LVEF 40% to 49%, or BHC231046 US14 -23- -NYHA IV and LVEF 30% to 39%.In one embodiment, the patient has an estimated glomerular filtration rate (eGFR) equal to or above 15mL / min / 1.73m2. Glomerular filtration rate (GFR) is the volume of fluid filtered from the renal (kidney) glomerular capillaries into the Bowman's capsule per unit time. The GFR is typically recorded in units of volume per time, e.g., milliliters per minute (mL / min). eGFR is estimated GFR (eGFR) and is a mathematically derived entity based on a patient’s serum creatinine level, age, sex and race. This is usually calculated by the laboratory analyzing the blood sample and reported along with the serum creatinine result. “Normal” GFR is approximately 100 but is often reported as >90 (“greater than 90”) or >60 (“greater than 60”). It is for this reason that patients (and some doctors) sometimes quote the eGFR as a percentage of normalkidney function. eGFR is expressed as mL / min / 1.73m2.In one embodiment, the patient has an eGFR of selected from equal to or above 15, 20, 25, 30, 35, 40, 45,50, 55, 60, 65, 70, 75, 80, 85, and 90 mL / min / 1.73m2. In one embodiment, the patient has an eGFR ofequal to or above 15 mL / min / 1.73m2. In one embodiment, the patient has an eGFR of equal to or above20 mL / min / 1.73m2. In one embodiment, the patient has an eGFR of equal to or above 25 mL / min / 1.73m2.In one embodiment, the patient has an eGFR of equal to or above 30 mL / min / 1.73m2. In one embodiment,the patient has an eGFR of equal to or above 35 mL / min / 1.73m2. In one embodiment, the patient has aneGFR of equal to or above 40 mL / min / 1.73m2. In one embodiment, the patient has an eGFR of equal toor above 45 mL / min / 1.73m2. In one embodiment, the patient has an eGFR of equal to or above 50mL / min / 1.73m2. In one embodiment, the patient has an eGFR of equal to or above 55 mL / min / 1.73m2. Inone embodiment, the patient has an eGFR of equal to or above 60 mL / min / 1.73m2. In one embodiment,the patient has an eGFR of equal to or above 65 mL / min / 1.73m2. In one embodiment, the patient has aneGFR of equal to or above 70 mL / min / 1.73m2. In one embodiment, the patient has an eGFR of equal toor above 75 mL / min / 1.73m2. In one embodiment, the patient has an eGFR of equal to or above 80mL / min / 1.73m2. In one embodiment, the patient has an eGFR of equal to or above 85 mL / min / 1.73m2. Inone embodiment, the patient has an eGFR of equal to or above 90 mL / min / 1.73m2.In one embodiment, the patient has an eGFR of selected from equal to or below 15, 20, 25, 30, 35, 40, 45,50, 55, 60, 65, 70, 75, 80, 85, and 90 mL / min / 1.73m2. In one embodiment, the patient has an eGFR ofequal to or below 15 mL / min / 1.73m2. In one embodiment, the patient has an eGFR of equal to or below20 mL / min / 1.73m2. In one embodiment, the patient has an eGFR of equal to or below 25 mL / min / 1.73m2.In one embodiment, the patient has an eGFR of equal to or below 30 mL / min / 1.73m2. In one embodiment,the patient has an eGFR of equal to or below 35 mL / min / 1.73m2. In one embodiment, the patient has aneGFR of equal to or below 40 mL / min / 1.73m2. In one embodiment, the patient has an eGFR of equal toor below 45 mL / min / 1.73m2. In one embodiment, the patient has an eGFR of equal to or below 50mL / min / 1.73m2. In one embodiment, the patient has an eGFR of equal to or below 55 mL / min / 1.73m2. In BHC231046 US14 -24-one embodiment, the patient has an eGFR of equal to or below 60 mL / min / 1.73m2. In one embodiment,the patient has an eGFR of equal to or below 65 mL / min / 1.73m2. In one embodiment, the patient has aneGFR of equal to or below 70 mL / min / 1.73m2. In one embodiment, the patient has an eGFR of equal toor below 75 mL / min / 1.73m2. In one embodiment, the patient has an eGFR of equal to or below 80mL / min / 1.73m2. In one embodiment, the patient has an eGFR of equal to or below 85 mL / min / 1.73m2. Inone embodiment, the patient has an eGFR of equal to or below 90 mL / min / 1.73m2.In one embodiment, the patient has an eGFR of equal to or above 15 to equal to or below 90mL / min / 1.73m2. In one embodiment, the patient has an eGFR of equal to or above 15 to equal to or below60 mL / min / 1.73m2. In one embodiment, the patient has an eGFR of equal to or above 15 to equal to orbelow 45 mL / min / 1.73m2. In one embodiment, the patient has an eGFR of equal to or above 15 to equalto or below 30 mL / min / 1.73m2. In one embodiment, the patient has an eGFR of equal to or above 25 toequal to or below 90 mL / min / 1.73m2. In one embodiment, the patient has an eGFR of equal to or above25 to equal to or below 60 mL / min / 1.73m2. In one embodiment, the patient has an eGFR of equal to orabove 25 to equal to or below 45 mL / min / 1.73m2. In one embodiment, the patient has an eGFR of equalto or above 25 to equal to or below 30 mL / min / 1.73m2. In one embodiment, the patient has an eGFR ofequal to or above 30 to equal to or below 90 mL / min / 1.73m2. In one embodiment, the patient has an eGFRof equal to or above 30 to equal to or below 60 mL / min / 1.73m2. In one embodiment, the patient has aneGFR of equal to or above 30 to equal to or below 45 mL / min / 1.73m2. In one embodiment, the patient hasan eGFR of equal to or above 45 to equal to or below 90 mL / min / 1.73m2. In one embodiment, the patienthas an eGFR of equal to or above 45 to equal to or below 60 mL / min / 1.73m2. In one embodiment, thepatient has an eGFR of equal to or above 60 to equal to or below 90 mL / min / 1.73m2.In one embodiment, the patient has an Urine Albumin to Creatinine Ratio (UACR) of equal to or above 5mg / g. The Urine Albumin to Creatinine Ratio is a result of measuring albumin in urine. The albumin concentration is not related to the urine volume, but to the creatinine concentration in the urine. The unit is "mg / g". The usual ranges are as follows: “normal”: below 30 mg / g; “Microalbuminuria”: 30 to 300mg / g; “Macroalbuminuria”: 300 to 3000 mg / g; “Major proteinuria”: above 3,000 mg / g. Albuminuria, asassessed via UACR estimations, serves as an early marker of cardiovascular and kidney disease as wellas an important marker in predicting the risk for development and progression of HF.In one embodiment, the patient has an UACR of equal to or above 10 mg / g. In one embodiment, thepatient has an UACR of equal to or above 15 mg / g. In one embodiment, the patient has an UACR of equalto or above 20 mg / g. In one embodiment, the patient has an UACR of equal to or above 25 mg / g. In oneembodiment, the patient has an UACR of equal to or above 30mg / g. In one embodiment, the patient hasan UACR of equal to or above 35 mg / g. In one embodiment, the patient has an UACR of equal to or above40 mg / g. In one embodiment, the patient has an UACR of equal to or above 45 mg / g. In one embodiment, BHC231046 US14 -25-the patient has an UACR of equal to or above 50 mg / g. In one embodiment, the patient has an UACR ofequal to or above 55 mg / g. In one embodiment, the patient has an UACR of equal to or above 60 mg / g. Inone embodiment, the patient has an UACR of equal to or above 65 mg / g. In one embodiment, the patienthas an UACR of equal to or above 70 mg / g. In one embodiment, the patient has an UACR of equal to orabove 75 mg / g. In one embodiment, the patient has an UACR of equal to or above 80 mg / g. [Ina: 85mg / g?] In one embodiment, the patient has an UACR of equal to or above 90 mg / g. In one embodiment,the patient has an UACR of equal to or above 95mg / g. In one embodiment, the patient has an UACR ofequal to or above 100 mg / g. In one embodiment, the patient has an UACR of equal to or above 105 mg / g.In one embodiment, the patient has an UACR of equal to or above 110 mg / g. In one embodiment, thepatient has an UACR of equal to or above 125 mg / g. In one embodiment, the patient has an UACR ofequal to or above 130 mg / g. In one embodiment, the patient has an UACR of equal to or above 135 mg / g.In one embodiment, the patient has an UACR of equal to or above 140 mg / g. In one embodiment, thepatient has an UACR of equal to or above 145 mg / g. In one embodiment, the patient has an UACR ofequal to or above 150 mg / g. In one embodiment, the patient has an UACR of equal to or above 155 mg / g.In one embodiment, the patient has an UACR of equal to or above 160 mg / g. In one embodiment, thepatient has an UACR of equal to or above 165 mg / g. In one embodiment, the patient has an UACR ofequal to or above 170 mg / g. In one embodiment, the patient has an UACR of equal to or above 175 mg / g.In one embodiment, the patient has an UACR of equal to or above 180 mg / g. In one embodiment, thepatient has an UACR of equal to or above 185 mg / g. In one embodiment, the patient has an UACR ofequal to or above 190 mg / g. In one embodiment, the patient has an UACR of equal to or above 195 mg / g.In one embodiment, the patient has an UACR of equal to or above 200 mg / g. In one embodiment, thepatient has an UACR of equal to or above 205 mg / g. In one embodiment, the patient has an UACR ofequal to or above 210 mg / g. [Ina: What about 215 & 220 mg / g?] In one embodiment, the patient has anUACR of equal to or above 225 mg / g. In one embodiment, the patient has an UACR of equal to or above230 mg / g. In one embodiment, the patient has an UACR of equal to or above 235 mg / g. In oneembodiment, the patient has an UACR of equal to or above 240 mg / g. In one embodiment, the patient hasan UACR of equal to or above 245 mg / g. In one embodiment, the patient has an UACR of equal to orabove 250 mg / g. In one embodiment, the patient has an UACR of equal to or above 255 mg / g. In oneembodiment, the patient has an UACR of equal to or above 260 mg / g. In one embodiment, the patient hasan UACR of equal to or above 265 mg / g. In one embodiment, the patient has an UACR of equal to orabove 270 mg / g. In one embodiment, the patient has an UACR of equal to or above 275 mg / g. In oneembodiment, the patient has an UACR of equal to or above 280 mg / g. In one embodiment, the patient hasan UACR of equal to or above 285 mg / g. In one embodiment, the patient has an UACR of equal to orabove 290 mg / g. In one embodiment, the patient has an UACR of equal to or above 295 mg / g. In oneembodiment, the patient has an UACR of equal to or above 300 mg / g. In one embodiment, the patient hasan UACR of equal to or above 305 mg / g. In one embodiment, the patient has an UACR of equal to orabove 310 mg / g. [Ina: 315, 320 mg / g?] In one embodiment, the patient has an UACR of equal to or above BHC231046 US14 -26-325 mg / g. In one embodiment, the patient has an UACR of equal to or above 330 mg / g. In oneembodiment, the patient has an UACR of equal to or above 335 mg / g. In one embodiment, the patient hasan UACR of equal to or above 340 mg / g. In one embodiment, the patient has an UACR of equal to orabove 345 mg / g. In one embodiment, the patient has an UACR of equal to or above 350 mg / g. In oneembodiment, the patient has an UACR of equal to or above 355 mg / g. In one embodiment, the patient hasan UACR 1of equal to or above 360 mg / g. In one embodiment, the patient has an UACR of equal to orabove 365 mg / g. In one embodiment, the patient has an UACR of equal to or above 370 mg / g. In oneembodiment, the patient has an UACR of equal to or above 375 mg / g. In one embodiment, the patient hasan UACR of equal to or above 380 mg / g. In one embodiment, the patient has an UACR of equal to orabove 385 mg / g. In one embodiment, the patient has an UACR of equal to or above 390 mg / g. In oneembodiment, the patient has an UACR of equal to or above 395 mg / g. In one embodiment, the patient hasan UACR of equal to or above 400 mg / g. In one embodiment, the patient has an UACR of equal to orabove 405 mg / g. In one embodiment, the patient has an UACR of equal to or above 410 mg / g. In oneembodiment, the patient has an UACR of equal to or above 415 mg / g. In one embodiment, the patient hasan UACR of equal to or above 420 mg / g. In one embodiment, the patient has an UACR of equal to orabove 425 mg / g. In one embodiment, the patient has an UACR of equal to or above 430 mg / g. In oneembodiment, the patient has an UACR of equal to or above 435 mg / g. In one embodiment, the patient hasan UACR of equal to or above 440mg / g. In one embodiment, the patient has an UACR of equal to orabove 445 mg / g. In one embodiment, the patient has an UACR of equal to or above 450 mg / g. In oneembodiment, the patient has an UACR of equal to or above 455 mg / g. In one embodiment, the patient hasan UACR of equal to or above 460 mg / g. In one embodiment, the patient has an UACR of equal to orabove 465 mg / g. In one embodiment, the patient has an UACR of equal to or above 470 mg / g. In oneembodiment, the patient has an UACR of equal to or above 475 mg / g. In one embodiment, the patient hasan UACR of equal to or above 480 mg / g. In one embodiment, the patient has an UACR of equal to orabove 485 mg / g. In one embodiment, the patient has an UACR of equal to or above 490 mg / g. In oneembodiment, the patient has an UACR of equal to or above 495 mg / g. In one embodiment, the patient hasan UACR of equal to or above 500 mg / g. In one embodiment, the patient has an UACR of equal to orabove 505 mg / g. In one embodiment, the patient has an UACR of equal to or above 510 mg / g. In oneembodiment, the patient has an UACR of equal to or above 515 mg / g. In one embodiment, the patient hasan UACR of equal to or above 520 mg / g. In one embodiment, the patient has an UACR of equal to orabove 525 mg / g. In one embodiment, the patient has an UACR of equal to or above 530 mg / g. In oneembodiment, the patient has an UACR of equal to or above 535 mg / g. In one embodiment, the patient hasan UACR of equal to or above 540 mg / g. In one embodiment, the patient has an UACR of equal to orabove 550 mg / g. In one embodiment, the patient has an UACR of equal to or above 555 mg / g. In oneembodiment, the patient has an UACR of equal to or above 560 mg / g. In one embodiment, the patient hasan UACR of equal to or above 565 mg / g. In one embodiment, the patient has an UACR of equal to orabove 570 mg / g. In one embodiment, the patient has an UACR of equal to or above 575 mg / g. In one BHC231046 US14 -27-embodiment, the patient has an UACR of equal to or above 580 mg / g. In one embodiment, the patient hasan UACR of equal to or above 585 mg / g. In one embodiment, the patient has an UACR of equal to orabove 590 mg / g. In one embodiment, the patient has an UACR of equal to or above 595 mg / g. In oneembodiment, the patient has an UACR of equal to or above 600 mg / g. In one embodiment, the patient hasan UACR of equal to or above 700 mg / g.In one embodiment, the patient has an UACR of equal to or below 5 mg / g. In one embodiment, the patienthas an UACR of equal to or below 10 mg / g. In one embodiment, the patient has an UACR of equal to orbelow 15 mg / g. In one embodiment, the patient has an UACR of equal to or below 20 mg / g. In oneembodiment, the patient has an UACR of equal to or below 25 mg / g. In one embodiment, the patient hasan UACR of equal to or below 30 mg / g. In one embodiment, the patient has an UACR of equal to or below35 mg / g. In one embodiment, the patient has an UACR of equal to or below 40 mg / g. In one embodiment,the patient has an UACR of equal to or below 45 mg / g. In one embodiment, the patient has an UACR ofequal to or below 50 mg / g. In one embodiment, the patient has an UACR of equal to or below 55 mg / g.In one embodiment, the patient has an UACR of equal to or below 60 mg / g. In one embodiment, thepatient has an UACR of equal to or below 65 mg / g. In one embodiment, the patient has an UACR of equalto or below 70 mg / g. In one embodiment, the patient has an UACR of equal to or below 75 mg / g. In oneembodiment, the patient has an UACR of equal to or below 80 mg / g. [Ina: 85 mg / g?] In one embodiment,the patient has an UACR of equal to or below 90 mg / g. In one embodiment, the patient has an UACR ofequal to or below 95 mg / g. In one embodiment, the patient has an UACR of equal to or below 100 mg / g.In one embodiment, the patient has an UACR of equal to or below 105 mg / g. In one embodiment, thepatient has an UACR of equal to or below 110 mg / g. [Ina: 115 and 120 mg / g?] In one embodiment, thepatient has an UACR of equal to or below 125 mg / g. In one embodiment, the patient has an UACR ofequal to or below 130 mg / g. In one embodiment, the patient has an UACR of equal to or below 135 mg / g.In one embodiment, the patient has an UACR of equal to or below 140 mg / g. In one embodiment, thepatient has an UACR of equal to or below 145 mg / g. In one embodiment, the patient has an UACR ofequal to or below 150 mg / g. In one embodiment, the patient has an UACR of equal to or below 155 mg / g.In one embodiment, the patient has an UACR of equal to or below 160 mg / g. In one embodiment, thepatient has an UACR of equal to or below 165 mg / g. In one embodiment, the patient has an UACR ofequal to or below 170 mg / g. In one embodiment, the patient has an UACR of equal to or below 175 mg / g.In one embodiment, the patient has an UACR of equal to or below 180 mg / g. In one embodiment, thepatient has an UACR of equal to or below 185 mg / g. In one embodiment, the patient has an UACR ofequal to or below 190 mg / g. In one embodiment, the patient has an UACR of equal to or below 195 mg / g.In one embodiment, the patient has an UACR of equal to or below 200 mg / g. In one embodiment, thepatient has an UACR of equal to or below 205 mg / g. In one embodiment, the patient has an UACR ofequal to or below 210mg / g. In one embodiment, the patient has an UACR of equal to or below 225 mg / g.In one embodiment, the patient has an UACR of equal to or below 230 mg / g. In one embodiment, thepatient has an UACR of equal to or below 235 mg / g. In one embodiment, the patient has an UACR of BHC231046 US14 -28-equal to or below 240 mg / g. In one embodiment, the patient has an UACR of equal to or below 245 mg / g.In one embodiment, the patient has an UACR of equal to or below 250 mg / g. In one embodiment, thepatient has an UACR of equal to or below 255 mg / g. In one embodiment, the patient has an UACR ofequal to or below 260 mg / g. In one embodiment, the patient has an UACR of equal to or below 265 mg / g.In one embodiment, the patient has an UACR of equal to or below 270 mg / g. In one embodiment, thepatient has an UACR of equal to or below 275 mg / g. In one embodiment, the patient has an UACR ofequal to or below 280 mg / g. In one embodiment, the patient has an UACR of equal to or below 285 mg / g.In one embodiment, the patient has an UACR of equal to or below 290 mg / g. In one embodiment, thepatient has an UACR of equal to or below 295 mg / g. In one embodiment, the patient has an UACR ofequal to or below 300 mg / g. In one embodiment, the patient has an UACR of equal to or below 305 mg / g.In one embodiment, the patient has an UACR of equal to or below 310 mg / g. In one embodiment, thepatient has an UACR of equal to or below 315 mg / g. In one embodiment, the patient has an UACR ofequal to or below 320 mg / g. In one embodiment, the patient has an UACR of equal to or below 325 mg / g.In one embodiment, the patient has an UACR of equal to or below 330 mg / g. In one embodiment, thepatient has an UACR of equal to or below 335 mg / g. In one embodiment, the patient has an UACR ofequal to or below 340 mg / g. In one embodiment, the patient has an UACR of equal to or below 345 mg / g.In one embodiment, the patient has an UACR of equal to or below 350 mg / g. In one embodiment, thepatient has an UACR of equal to or below 355 mg / g. In one embodiment, the patient has an UACR ofequal to or below 360 mg / g. In one embodiment, the patient has an UACR of equal to or below 365 mg / g.In one embodiment, the patient has an UACR of equal to or below 370 mg / g. In one embodiment, thepatient has an UACR of equal to or below 375 mg / g. In one embodiment, the patient has an UACR ofequal to or below 380 mg / g. In one embodiment, the patient has an UACR of equal to or below 385 mg / g.In one embodiment, the patient has an UACR of equal to or below 390 mg / g. In one embodiment, thepatient has an UACR of equal to or below 395 mg / g. In one embodiment, the patient has an UACR ofequal to or below 400 mg / g. In one embodiment, the patient has an UACR of equal to or below 405 mg / g.In one embodiment, the patient has an UACR of equal to or below 410mg / g. [Ina: 415, 420 mg / g?] In oneembodiment, the patient has an UACR of equal to or below 425 mg / g. In one embodiment, the patient hasan UACR of equal to or below 430 mg / g. In one embodiment, the patient has an UACR of equal to orbelow 435 mg / g. In one embodiment, the patient has an UACR of equal to or below 440 mg / g. In oneembodiment, the patient has an UACR of equal to or below 445 mg / g. In one embodiment, the patient hasan UACR of equal to or below 450 mg / g. In one embodiment, the patient has an UACR of equal to orbelow 455 mg / g. In one embodiment, the patient has an UACR of equal to or below 460 mg / g. In oneembodiment, the patient has an UACR of equal to or below 465 mg / g. In one embodiment, the patient hasan UACR of equal to or below 470 mg / g. In one embodiment, the patient has an UACR of equal to orbelow 475 mg / g. In one embodiment, the patient has an UACR of equal to or below 480 mg / g. In oneembodiment, the patient has an UACR of equal to or below 485 mg / g. In one embodiment, the patient hasan UACR of equal to or below 490 mg / g. In one embodiment, the patient has an UACR of equal to or BHC231046 US14 -29-below 495 mg / g. In one embodiment, the patient has an UACR of equal to or below 500 mg / g. In oneembodiment, the patient has an UACR of equal to or below 505 mg / g. In one embodiment, the patient hasan UACR of equal to or below 510 mg / g. In one embodiment, the patient has an UACR of equal to orbelow 515 mg / g. In one embodiment, the patient has an UACR of equal to or below 520 mg / g. In oneembodiment, the patient has an UACR of equal to or below 525 mg / g. In one embodiment, the patient hasan UACR of equal to or below 530 mg / g. In one embodiment, the patient has an UACR of equal to orbelow 535 mg / g. In one embodiment, the patient has an UACR of equal to or below 540 mg / g. In oneembodiment, the patient has an UACR of equal to or below 550 mg / g. In one embodiment, the patient hasan UACR of equal to or below 555 mg / g. In one embodiment, the patient has an UACR of equal to orbelow 560 mg / g. In one embodiment, the patient has an UACR of equal to or below 565 mg / g. In oneembodiment, the patient has an UACR of equal to or below 570 mg / g. In one embodiment, the patient hasan UACR of equal to or below 575 mg / g. In one embodiment, the patient has an UACR of equal to orbelow 580 mg / g. In one embodiment, the patient has an UACR of equal to or below 585 mg / g. In oneembodiment, the patient has an UACR of equal to or below 590mg / g. In one embodiment, the patient hasan UACR of equal to or below 595 mg / g. In one embodiment, the patient has an UACR of equal to orbelow 600 mg / g. In one embodiment, the patient has an UACR of equal to or below 700 mg / g. In oneembodiment, the patient has an UACR of equal to or below 800 mg / g. In one embodiment, the patient hasan UACR of equal to or below 900 mg / g. In one embodiment, the patient has an UACR of equal to orbelow 1000 mg / g. In one embodiment, the patient has an UACR of equal to or below 2000 mg / g. In oneembodiment, the patient has an UACR of equal to or below 3000 mg / g. In one embodiment, the patienthas an UACR of equal to or below 4000 mg / g. In one embodiment, the patient has an UACR of equal toor below 5000 mg / g.In one embodiment, the patient has an UACR of equal to or above 5 to equal to or below 5000 mg / g. Inone embodiment, the patient has an UACR of equal to or above 5 to equal to or below 4000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 5 to equal to or below 3000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 5 to equal to or below 2000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 5 to equal to or below 1000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 5 to equal to or below 500 mg / g. In oneembodiment, the patient has an UACR of equal to or above 5 to equal to or below 400 mg / g. In oneembodiment, the patient has an UACR of equal to or above 5 to equal to or below 300 mg / g. In oneembodiment, the patient has an UACR of equal to or above 5 to equal to or below 200 mg / g. In oneembodiment, the patient has an UACR of equal to or above 5 to equal to or below 100 mg / g. In oneembodiment, the patient has an UACR of equal to or above 10 to equal to or below 5000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 10 to equal to or below 4000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 10 to equal to or below 3000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 10 to equal to or below 2000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 10 to equal to or below 1000 mg / g. In one BHC231046 US14 -30-embodiment, the patient has an UACR of equal to or above 10 to equal to or below 500 mg / g. In oneembodiment, the patient has an UACR of equal to or above 10 to equal to or below 400 mg / g. In oneembodiment, the patient has an UACR of equal to or above 10 to equal to or below 300 mg / g. In oneembodiment, the patient has an UACR of equal to or above 10 to equal to or below 200 mg / g. In oneembodiment, the patient has an UACR of equal to or above 10 to equal to or below 100 mg / g. In oneembodiment, the patient has an UACR of equal to or above 100 to equal to or below 5000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 100 to equal to or below 4000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 100 to equal to or below 3000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 100 to equal to or below 2000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 100 to equal to or below 1000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 100 to equal to or below 500 mg / g. In oneembodiment, the patient has an UACR of equal to or above 100 to equal to or below 400 mg / g. In oneembodiment, the patient has an UACR of equal to or above 100 to equal to or below 300 mg / g. In oneembodiment, the patient has an UACR of equal to or above 100 to equal to or below 200 mg / g. In oneembodiment, the patient has an UACR of equal to or above 200 to equal to or below 5000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 200 to equal to or below 4000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 200 to equal to or below 3000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 200 to equal to or below 2000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 200 to equal to or below 1000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 200 to equal to or below 500 mg / g. In oneembodiment, the patient has an UACR of equal to or above 200 to equal to or below 400 mg / g. In oneembodiment, the patient has an UACR of equal to or above 200 to equal to or below 300 mg / g. In oneembodiment, the patient has an UACR of equal to or above 300 to equal to or below 5000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 300 to equal to or below 4000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 300 to equal to or below 3000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 300 to equal to or below 2000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 300 to equal to or below 1000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 300 to equal to or below 500 mg / g. In oneembodiment, the patient has an UACR of equal to or above 300 to equal to or below 400 mg / g. In oneembodiment, the patient has an UACR of equal to or above 400 to equal to or below 5000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 400 to equal to or below 4000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 400 to equal to or below 3000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 400 to equal to or below 2000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 400 to equal to or below 1000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 400 to equal to or below 500 mg / g. In oneembodiment, the patient has an UACR of equal to or above 500 to equal to or below 5000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 500 to equal to or below 4000 mg / g. In one BHC231046 US14 -31-embodiment, the patient has an UACR of equal to or above 500 to equal to or below 3000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 500 to equal to or below 2000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 500 to equal to or below 1000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 600 to equal to or below 5000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 600 to equal to or below 4000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 600 to equal to or below 3000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 600 to equal to or below 2000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 600 to equal to or below 1000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 700 to equal to or below 5000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 700 to equal to or below 4000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 700 to equal to or below 3000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 700 to equal to or below 2000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 700 to equal to or below 1000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 800 to equal to or below 5000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 800 to equal to or below 4000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 800 to equal to or below 3000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 800 to equal to or below 2000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 800 to equal to or below 1000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 900 to equal to or below 5000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 900 to equal to or below 4000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 900 to equal to or below 3000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 900 to equal to or below 2000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 900 to equal to or below 1000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 1000 to equal to or below 5000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 1000 to equal to or below 4000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 1000 to equal to or below 3000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 1000 to equal to or below 2000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 2000 to equal to or below 5000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 2000 to equal to or below 4000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 2000 to equal to or below 3000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 3000 to equal to or below 4000 mg / g. In oneembodiment, the patient has an UACR of equal to or above 4000 to equal to or below 5000 mg / g.In one embodiment, the patient has an UACR selected from of equal to or above 5, 10, 15, 20, 25, 30, 35,40, 45, 50, 55, 60, 65, 70, 75, 80, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, 300, 305, 310, 315, 320325, 330, 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 395, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, BHC231046 US14 -32- 480, 485, 490, 495, 500, 505, 510, 515, 520, 525, 530, 535, 540, 550, 555, 560, 565, 570, 575, 580, 585, 590, 595 and 600 mg / g.In one embodiment, the patient has an UACR selected from of equal to or below 5, 10, 15, 20, 25, 30, 35,40, 45, 50, 55, 60, 65, 70, 75, 80, 90, 95, 100, 105, 110, 115, 120,125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, 300, 305, 310, 315, 320,325, 330, 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 395, 400, 405, 410, 415, 420,425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 495, 500, 505, 510, 515, 520, 525, 530, 535, 540, 550, 555, 560, 565, 570, 575, 580, 585, 590, 595 and 600 mg / g.In one embodiment, the patient has an UACR of equal to or above 5 to equal to or below 500 mg / g. Inone embodiment, the patient has an UACR of equal to or above 5 to equal to or below 300 mg / g. In oneembodiment, the patient has an UACR of equal to or above 5 to equal to or below 300 mg / g. In oneembodiment, the patient has an UACR of equal to or above 5 to equal to or below 250 mg / g. In oneembodiment, the patient has an UACR of equal to or above 5 to equal to or below 200 mg / g. In oneembodiment, the patient has an UACR of equal to or above 5 to equal to or below 150 mg / g. In oneembodiment, the patient has an UACR of equal to or above 5 to equal to or below 100 mg / g. In oneembodiment, the patient has an UACR of equal to or above 5 to equal to or below 90 mg / g. In oneembodiment, the patient has an UACR of equal to or above 5 to equal to or below 80 mg / g. In oneembodiment, the patient has an UACR of equal to or above 5 to equal to or below 75 mg / g. In oneembodiment, the patient has an UACR of equal to or above 5 to equal to or below 70 mg / g. [Ina: 65 mg / g?]In one embodiment, the patient has an UACR of equal to or above 5 to equal to or below 60 mg / g. In oneembodiment, the patient has an UACR of equal to or above 5 to equal to or below 55 mg / g. In oneembodiment, the patient has an UACR of equal to or above 10 to equal to or below 500 mg / g. In oneembodiment, the patient has an UACR of equal to or above 10 to equal to or below 300 mg / g. In oneembodiment, the patient has an UACR of equal to or above 10 to equal to or below 300 mg / g. In oneembodiment, the patient has an UACR of equal to or above 10 to equal to or below 250 mg / g. In oneembodiment, the patient has an UACR of equal to or above 10 to equal to or below 200 mg / g. In oneembodiment, the patient has an UACR of equal to or above 10 to equal to or below 150 mg / g. In oneembodiment, the patient has an UACR of equal to or above 10 to equal to or below 100 mg / g. In oneembodiment, the patient has an UACR of equal to or above 10 to equal to or below 90 mg / g. In oneembodiment, the patient has an UACR of equal to or above 10 to equal to or below 80 mg / g. In oneembodiment, the patient has an UACR of equal to or above 10 to equal to or below 75 mg / g. In oneembodiment, the patient has an UACR of equal to or above 10 to equal to or below 70 mg / g. [Ina: 65mg / g?] In one embodiment, the patient has an UACR of equal to or above 10 to equal to or below 60mg / g. In one embodiment, the patient has an UACR of equal to or above 10 to equal to or below 55 mg / g. BHC231046 US14 -33- The patient can be characterized by KDIGO Risk Categories as described in The Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of GlomerularDiseases. KDIGO is the global nonprofit organization developing and implementing evidence-basedclinical practice guidelines in kidney disease. Chronic Kidney Disease (CKD) is defined as abnormalitiesof kidney structure or function, present for more than 3 months, with implications for health. CKD isclassified based on Cause, GFR category (G1: Normal or high; G2: Mildly decreased; G3a: Mildly to moderately decreased; G3b: Moderately to severely decreased; G4: Severely decreased; G5: Kidney failure), and Albuminuria category (A1: normal; A2: mildly; A3: Severely increased).In one embodiment, the patient has an eGFR of equal to or below 15 mL / min / 1.73m2 and a UACR ofequal to or below 30 mg / g. In one embodiment, the patient has an eGFR of equal to or below 15mL / min / 1.73m2 and a UACR of equal to or above 30 to equal to or below 300 mg / g. In one embodiment,the patient has an eGFR of equal to or below 15 mL / min / 1.73m2 and a UACR of equal to or above 300mg / g. In one embodiment, the patient has an eGFR of equal to or above 15 to equal to or below 29mL / min / 1.73m2 and a UACR of equal to or below 30 mg / g. In one embodiment, the patient has an eGFRof equal to or above 15 to equal to or below 29 mL / min / 1.73m2 and a UACR of equal to or above 30 toequal to or below 300 mg / g. In one embodiment, the patient has an eGFR equal to or above 15 to equal toor below 29 mL / min / 1.73m2 and a UACR of equal to or below 300 mg / g. In one embodiment, the patienthas an eGFR of equal to or above 15 to equal to or below 30 mL / min / 1.73m2 and a UACR of equal to orbelow 30 mg / g. In one embodiment, the patient has an eGFR of equal to or above 15 to equal to or below30 mL / min / 1.73m2 and a UACR of equal to or above 30 to equal to or below 300 mg / g. In oneembodiment, the patient has an eGFR equal to or above 15 to equal to or below 30 mL / min / 1.73m2 and aUACR of equal to or below 300 mg / g. In one embodiment, the patient has an eGFR of equal to or above30 to equal to or below 44 mL / min / 1.73m2 and a UACR of equal to or below 30 mg / g. In one embodiment,the patient has an eGFR of equal to or above 30 to equal to or below 44 mL / min / 1.73m2 and a UACR ofequal to or above 30 to equal to or below 300 mg / g. In one embodiment, the patient has an eGFR of equalto or above 30 to equal to or below 44 mL / min / 1.73m2 and a UACR of equal to or below 300 mg / g. Inone embodiment, the patient has an eGFR of equal to or above 30 to equal to or below 45 mL / min / 1.73m2and a UACR of equal to or below 30 mg / g. In one embodiment, the patient has an eGFR of equal to orabove 30 to equal to or below 45 mL / min / 1.73m2 and a UACR of equal to or above 30 to equal to or below300 mg / g. In one embodiment, the patient has an eGFR of equal to or above 30 to equal to or below 45mL / min / 1.73m2 and a UACR of equal to or below 300 mg / g. In one embodiment, the patient has an eGFRof equal to or above 45 to equal to or below 59 mL / min / 1.73m2 and a UACR of equal to or below 30 mg / g.In one embodiment, the patient has an eGFR of equal to or above 45 to equal to or below 59mL / min / 1.73m2 and a UACR of equal to or above 30 to equal to or below 300 mg / g. In one embodiment,the patient has an eGFR of equal to or above 45 to equal to or below 59 mL / min / 1.73m2 and a UACR ofequal to or below 300 mg / g. In one embodiment, the patient has an eGFR of equal to or above 45 to equalto or below 60 mL / min / 1.73m2 and a UACR of equal to or below 30 mg / g. In one embodiment, the patient BHC231046 US14 -34-has an eGFR of equal to or above 45 to equal to or below 60 mL / min / 1.73m2 and a UACR of equal to orabove 30 to equal to or below 300 mg / g. In one embodiment, the patient has an eGFR of equal to or above45 to equal to or below 60 mL / min / 1.73m2 and a UACR of equal to or below 300 mg / g. In oneembodiment, the patient has an eGFR of equal to or above 60 to equal to or below 89 mL / min / 1.73m2 anda UACR of equal to or below 30 mg / g. In one embodiment, the patient has an eGFR of equal to or above60 to equal to or below 89 mL / min / 1.73m2 and a UACR of equal to or above 30 to equal to or below 300mg / g. In one embodiment, the patient has an eGFR of equal to or above 60 to equal to or below 89mL / min / 1.73m2 and a UACR of equal to or below 300 mg / g. In one embodiment, the patient has an eGFRof equal to or above 60 to equal to or below 90 mL / min / 1.73m2 and a UACR of equal to or below 30 mg / g.In one embodiment, the patient has an eGFR of equal to or above 60 to equal to or below 90mL / min / 1.73m2 and a UACR of equal to or above 30 to equal to or below 300 mg / g. In one embodiment,the patient has an eGFR of equal to or above 60 to equal to or below 90 mL / min / 1.73m2 and a UACR ofequal to or below 300 mg / g. In one embodiment, the patient has an eGFR of equal to or above 90mL / min / 1.73m2 and a UACR of equal to or below 30 mg / g. In one embodiment, the patient has an eGFRof equal to or above 90 mL / min / 1.73m2 and a UACR of equal to or above 30 to equal to or below 300mg / g. In one embodiment, the patient has an eGFR of equal to or above 90 mL / min / 1.73m2 and a UACRof equal to or below 300 mg / g.The patient can also be characterized by potassium level expressed in “mmol / L”. The potassium level anddistribution among the body compartments depend on a complex interplay of multiple factors including renal and gastrointestinal function; diet, medications, and supplements; neurohormonal status; and acid- base balance. Under normal conditions, the kidneys are responsible for up to 90-95% of potassium elimination, with the colon being responsible for the remainder. Because cardiac repolarization relies on potassium influx, hypokalemia lengthens the cardiac action potential and increases QT dispersion. Hyperkalemia leads to a shortening of the repolarization time, which may lead to QT interval shortening.Both hypo- and hyperkalemia may be life-threatening conditions by increasing the risk of ventriculararrhythmia and sudden cardiac death. Dyskalemia in HF has important prognostic implications. Critical comorbidities include CKD, diabetes mellitus (DM), frailty, and aging. In HF, as in other conditions, for example, myocardial infarction, hypertension, kidney disease, or in the general population, therelationship between diabetes mellitus concentrations and adverse outcomes appears to be U-shaped,where both low- and high-potassium levels are associated with adverse outcomes, although it remainsunclear to what extent dyskalemia is a risk factor itself versus a risk marker representing the patients’ overall clinical status, other comorbidities, and / or use or nonuse of HF medications. Correction of both hypokalemia and hyperkalemia offsets their associated risks. The skilled artisan understands that the potassium test measures the amount of potassium in blood serum. He also knows how to measure serum potassium levels in both patients (especially those with conditionslike heart failure and kidney disease) and healthy individuals according to the following steps and methods BHC231046 US14 -35-typically used (R. A. Garcia et al., J Clin Lab Anal. 2018 Jun 19;32(9):e22594. doi: 10.1002 / jcla.22594):• Sample Collection:o Venipuncture: Blood is drawn from a vein, usually in the arm, using sterile techniques toprevent contamination. oSample Type: Serum is typically used for potassium measurement. After collection, theblood sample is allowed to clot, and then it is centrifuged to separate the serum from the blood cells. •Laboratory Methods:o Ion-Selective Electrode (ISE): This is the most common method for measuring serumpotassium. It uses a specific electrode that responds to potassium ions in the sample, providing a direct measurement. oFlame Photometry: This method measures the concentration of potassium by passing thesample through a flame and detecting the emitted light at a specific wavelength. oColorimetric Methods: These involve chemical reactions that produce a color changeproportional to the potassium concentration, which can be measured spectrophotometrically. Normal serum potassium levels typically range from 3.5 to 5.0 mmol / L. Values outside this range may indicate hyperkalemia (high potassium) or hypokalemia (low potassium), which can have significantclinical implications, especially in patients with underlying conditions. For patients with conditions suchas heart failure or kidney disease, regular monitoring is crucial to manage and adjust treatments effectively.In one embodiment, the patient has a potassium level of above 3 mmol / L. In one embodiment, the patienthas a potassium level of above 3.5 mmol / L. In one embodiment, the patient has a potassium level of above 4 mmol / L. In one embodiment, the patient has a potassium level of above 4.5 mmol / L. In one embodiment, the patient has a potassium level of above 4.8 mmol / L. In one embodiment, the patient has a potassium level of above 5 mmol / L. In one embodiment, the patient has a potassium level of above 5.5 mmol / L. Inone embodiment, the patient has a potassium level of above 6 mmol / L. In one embodiment, the patienthas a potassium level of above 6.5 mmol / L. In one embodiment, the patient has a potassium level of above 7 mmol / L. In one embodiment, the patient has a potassium level of above 7.5 mmol / L. In one embodiment,the patient has a potassium level equal to or above 3 mmol / L. In one embodiment, the patient has apotassium level equal to or above 3.5 mmol / L. In one embodiment, the patient has a potassium level equalto or above 4 mmol / L. In one embodiment, the patient has a potassium level equal to or above 4.5 mmol / L.In one embodiment, the patient has a potassium level equal to or above 4.8 mmol / L. In one embodiment,the patient has a potassium level equal to or above 5 mmol / L. In one embodiment, the patient has a BHC231046 US14 -36-potassium level equal to or above 5.5 mmol / L. In one embodiment, the patient has a potassium level equalto or above 6 mmol / L. In one embodiment, the patient has a potassium level equal to or above 6.5 mmol / L.In one embodiment, the patient has a potassium level equal to or above 7 mmol / L. In one embodiment,the patient has a potassium level equal to or above 7.5 mmol / L. In one embodiment, the patient has apotassium level below 3 mmol / L. In one embodiment, the patient has a potassium level below 3.5 mmol / L. In one embodiment, the patient has a potassium level below 4 mmol / L. In one embodiment, the patient has a potassium level below 4.5 mmol / L. In one embodiment, the patient has a potassium level below 4.8 mmol / L. In one embodiment, the patient has a potassium level below 5 mmol / L. In one embodiment, the patient has a potassium level below 5.5 mmol / L. In one embodiment, the patient has a potassium level below 6 mmol / L. In one embodiment, the patient has a potassium level below 6.5 mmol / L. In oneembodiment, the patient has a potassium level below 7 mmol / L. In one embodiment, the patient has apotassium level below 7.5 mmol / L. In one embodiment, the patient has a potassium level equal to or below3 mmol / L. In one embodiment, the patient has a potassium level equal to or below 3.5 mmol / L. In oneembodiment, the patient has a potassium level equal to or below 4 mmol / L. In one embodiment, the patienthas a potassium level equal to or below 4.5 mmol / L. In one embodiment, the patient has a potassium levelequal to or below 4.8 mmol / L. In one embodiment, the patient has a potassium level equal to or below 5mmol / L. In one embodiment, the patient has a potassium level equal to or below 5.5 mmol / L. In oneembodiment, the patient has a potassium level equal to or below 6 mmol / L. In one embodiment, the patienthas a potassium level equal to or below 6.5 mmol / L. In one embodiment, the patient has a potassium levelequal to or below 7 mmol / L. In one embodiment, the patient has a potassium level equal to or below 7.5mmol / L. In one embodiment, the patient has a potassium level selected from of above 3, 3.5, 4, 4.5, 4.8, 5, 5.5, 6, 6.5, 7 or 7.5 mmol / L. In one embodiment, the patient has a potassium level selected from of equal to or above 3, 3.5, 4, 4.5, 4.8, 5, 5.5, 6, 6.5, 7 or 7.5 mmol / L. In one embodiment, the patient has a potassium level selected from of below 3, 3.5, 4, 4.5, 4.8, 5, 5.5, 6, 6.5, 7 or 7.5 mmol / L. In one embodiment, thepatient has a potassium level selected from of equal to or below 3, 3.5, 4, 4.5, 4.8, 5, 5.5, 6, 6.5, 7 or 7.5mmol / L.In one embodiment, the patient has a potassium level of equal to or above 3 to equal to or below 3.5mmol / L. In one embodiment, the patient has a potassium level of equal to or above 3 to equal to or below4 mmol / L. In one embodiment, the patient has a potassium level of equal to or above 3 to equal to orbelow 4.5 mmol / L. In one embodiment, the patient has a potassium level of equal to or above 3 to equalto or below 4.8 mmol / L. In one embodiment, the patient has a potassium level of equal to or above 3 toequal to or below 5 mmol / L. In one embodiment, the patient has a potassium level of equal to or above 3to equal to or below 5.5 mmol / L. In one embodiment, the patient has a potassium level of equal to orabove 3 to equal to or below 6 mmol / L. In one embodiment, the patient has a potassium level of equal toor above 3 to equal to or below 6.5 mmol / L. In one embodiment, the patient has a potassium level of equal BHC231046 US14 -37-to or above 3 to equal to or below 7 mmol / L. In one embodiment, the patient has a potassium level ofequal to or above 3 to equal to or below 7.5 mmol / L. In one embodiment, the patient has a potassium levelof equal to or above 3.5 to equal to or below 4 mmol / L. In one embodiment, the patient has a potassiumlevel of equal to or above 3.5 to equal to or below 4.5 mmol / L. In one embodiment, the patient has apotassium level of equal to or above 3.5 to equal to or below 4.8 mmol / L. In one embodiment, the patienthas a potassium level of equal to or above 3.5 to equal to or below 5 mmol / L. In one embodiment, thepatient has a potassium level of equal to or above 3.5 to equal to or below 5.5 mmol / L. In one embodiment,the patient has a potassium level of equal to or above 3.5 to equal to or below 6 mmol / L. In oneembodiment, the patient has a potassium level of equal to or above 3.5 to equal to or below 6.5 mmol / L.In one embodiment, the patient has a potassium level of equal to or above 3.5 to equal to or below 7mmol / L. In one embodiment, the patient has a potassium level of equal to or above 3.5 to equal to orbelow 7.5 mmol / L. In one embodiment, the patient has a potassium level of equal to or above 4 to equalto or below 4.5 mmol / L. In one embodiment, the patient has a potassium level of equal to or above 4 toequal to or below 4.8 mmol / L. In one embodiment, the patient has a potassium level of equal to or above4 to equal to or below 5 mmol / L. In one embodiment, the patient has a potassium level of equal to orabove 4 to equal to or below 5.5 mmol / L. In one embodiment, the patient has a potassium level of equalto or above 4 to equal to or below 6 mmol / L. In one embodiment, the patient has a potassium level ofequal to or above 4 to equal to or below 6.5 mmol / L. In one embodiment, the patient has a potassium levelof equal to or above 4 to equal to or below 7 mmol / L. In one embodiment, the patient has a potassiumlevel of equal to or above 4 to equal to or below 7.5 mmol / L. In one embodiment, the patient has apotassium level of equal to or above 4.5 to equal to or below 4.8 mmol / L. In one embodiment, the patienthas a potassium level of equal to or above 4.5 to equal to or below 5 mmol / L. In one embodiment, thepatient has a potassium level of equal to or above 4.5 to equal to or below 5.5 mmol / L. In one embodiment,the patient has a potassium level of equal to or above 4.5 to equal to or below 6 mmol / L. In oneembodiment, the patient has a potassium level of equal to or above 4.5 to equal to or below 6.5 mmol / L.In one embodiment, the patient has a potassium level of equal to or above 4.5 to equal to or below 7mmol / L. In one embodiment, the patient has a potassium level of equal to or above 4.5 to equal to orbelow 7.5 mmol / L. In one embodiment, the patient has a potassium level of equal to or above 4.8 to equalto or below 5 mmol / L. In one embodiment, the patient has a potassium level of equal to or above 4.8 toequal to or below 5.5 mmol / L. In one embodiment, the patient has a potassium level of equal to or above4.8 to equal to or below 6 mmol / L. In one embodiment, the patient has a potassium level of equal to orabove 4.8 to equal to or below 6.5 mmol / L. In one embodiment, the patient has a potassium level of equalto or above 4.8 to equal to or below 7 mmol / L. In one embodiment, the patient has a potassium level ofequal to or above 4.8 to equal to or below 7.5 mmol / L. In one embodiment, the patient has a potassiumlevel of equal to or above 5 to equal to or below 5.5 mmol / L. In one embodiment, the patient has apotassium level of equal to or above 5 to equal to or below 6 mmol / L. In one embodiment, the patient hasa potassium level of equal to or above 5 to equal to or below 6.5 mmol / L. In one embodiment, the patient BHC231046 US14 -38-has a potassium level of equal to or above 5 to equal to or below 7 mmol / L. In one embodiment, the patienthas a potassium level of equal to or above 5 to equal to or below 7.5 mmol / L. In one embodiment, thepatient has a potassium level of equal to or above 5.5 to equal to or below 6 mmol / L. In one embodiment,the patient has a potassium level of equal to or above 5.5 to equal to or below 6.5 mmol / L. In oneembodiment, the patient has a potassium level of equal to or above 5.5 to equal to or below 7 mmol / L. Inone embodiment, the patient has a potassium level of equal to or above 5.5 to equal to or below 7.5mmol / L. In one embodiment, the patient has a potassium level of equal to or above 6 to equal to or below6.5 mmol / L. In one embodiment, the patient has a potassium level of equal to or above 6 to equal to orbelow 7 mmol / L. In one embodiment, the patient has a potassium level of equal to or above 6 to equal toor below 7.5 mmol / L. In one embodiment, the patient has a potassium level of equal to or above 6.5 toequal to or below 7 mmol / L. In one embodiment, the patient has a potassium level of equal to or above6.5 to equal to or below 7.5 mmol / L. In one embodiment, the patient has a potassium level of equal to orabove 7 to equal to or below 7.5 mmol / L.Measurement of serum sodium is routine in assessing electrolyte, acid-base, and water balance, as well as renal function. The sodium level is expressed in mmol / L. The reference range for serum sodium is 135- 147 mmol / L, although different assays establish their own reference ranges, which may differ slightly. Sodium excretion via the urine ('natriuresis') is a particular therapeutic target for cardiovascular diseases.For example, neurohumoral stimulation by the renin–angiotensin–aldosterone system (RAAS) contributesto permanent sodium retention and an associated extracellular volume load in the development of chronic heart and kidney failure. In particular, neurohumoral stimulation by the renin–angiotensin–aldosterone system (RAAS) or elevation of sodium-glucose-transporter-2 (SGLT2) expression in the proximal tubule contributes to permanent sodium retention and an associated extracellular volume load in the development of chronic heart and kidney failure. The body is no longer able to perform effective natriuresis, especially when there is impaired kidney function, which is often associated with heart failure. Therefore, maintaining an effective natriuresis would be useful in treatment and / or prevention of cardiovascular and / or renal diseases. The patient can be characterized by the sodium level.In one embodiment, the patient has a sodium level selected from of equal to or above 100, 110, 115, 117,120, 125, 130, 135, 138, 140, 141, 144, 145, 150, 154 and 155 mmol / L. In one embodiment, the patienthas a sodium level selected from of equal to or below 100, 110, 115, 117, 120, 125, 130, 135, 138, 140,144, 145, 150, 154 and 155 mmol / L.In one embodiment, the patient has a sodium level of equal to or above 100 mmol / L. In one embodiment,the patient has a sodium level of equal to or above 110 mmol / L. In one embodiment, the patient has asodium level of equal to or above 115 mmol / L. In one embodiment, the patient has a sodium level of equal BHC231046 US14 -39-to or above 120 mmol / L. In one embodiment, the patient has a sodium level of equal to or above 125mmol / L. In one embodiment, the patient has a sodium level of equal to or above 130 mmol / L. In oneembodiment, the patient has a sodium level of equal to or above 135 mmol / L. In one embodiment, thepatient has a sodium level of equal to or above 138 mmol / L. In one embodiment, the patient has a sodiumlevel of equal to or above 140 mmol / L. In one embodiment, the patient has a sodium level of equal to orabove 144 mmol / L. In one embodiment, the patient has a sodium level of equal to or above 145 mmol / L.In one embodiment, the patient has a sodium level of equal to or above 150 mmol / L. In one embodiment,the patient has a sodium level of equal to or below 154 mmol / L. In one embodiment, the patient has asodium level of equal to or above 155 mmol / L. In one embodiment, the patient has a sodium level of equalto or below 100 mmol / L. In one embodiment, the patient has a sodium level of equal to or below 110mmol / L. In one embodiment, the patient has a sodium level of equal to or below 115 mmol / L. In oneembodiment, the patient has a sodium level of equal to or below 120 mmol / L. In one embodiment, thepatient has a sodium level of equal to or below 125 mmol / L. In one embodiment, the patient has a sodiumlevel of equal to or below 130 mmol / L. In one embodiment, the patient has a sodium level of equal to orbelow 135 mmol / L. In one embodiment, the patient has a sodium level of equal to or below 138 mmol / L.In one embodiment, the patient has a sodium level of equal to or below 140 mmol / L. In one embodiment,the patient has a sodium level of equal to or below 144 mmol / L. In one embodiment, the patient has asodium level of equal to or below 145 mmol / L. In one embodiment, the patient has a sodium level of equalto or below 150 mmol / L. In one embodiment, the patient has a sodium level of equal to or below 154mmol / L. In one embodiment, the patient has a sodium level of equal to or below 155 mmol / L.In one embodiment, the patient has a sodium level of equal to or above 100 to equal to or below 110mmol / L. In one embodiment, the patient has a sodium level of equal to or above 100 to equal to or below115 mmol / L. In one embodiment, the patient has a sodium level of equal to or above 100 to equal to orbelow 117 mmol / L. In one embodiment, the patient has a sodium level of equal to or above 100 to equalto or below 120 mmol / L. In one embodiment, the patient has a sodium level of equal to or above 100 toequal to or below 125 mmol / L. In one embodiment, the patient has a sodium level of equal to or above100 to equal to or below 130 mmol / L. In one embodiment, the patient has a sodium level of equal to orabove 100 to equal to or below 135 mmol / L. In one embodiment, the patient has a sodium level of equalto or above 100 to equal to or below 138 mmol / L. In one embodiment, the patient has a sodium level ofequal to or above 100 to equal to or below 140 mmol / L. In one embodiment, the patient has a sodiumlevel of equal to or above 100 to equal to or below 141 mmol / L. In one embodiment, the patient has asodium level of equal to or above 100 to equal to or below 144 mmol / L. In one embodiment, the patienthas a sodium level of equal to or above 100 to equal to or below 145 mmol / L. In one embodiment, thepatient has a sodium level of equal to or above 100 to equal to or below 150 mmol / L. In one embodiment,the patient has a sodium level of equal to or above 100 to equal to or below 154 mmol / L. In oneembodiment, the patient has a sodium level of equal to or above 100 to equal to or below 155 mmol / L. Inone embodiment, the patient has a sodium level of equal to or above 110 to equal to or below 115 mmol / L. BHC231046 US14 -40-In one embodiment, the patient has a sodium level of equal to or above 110 to equal to or below 117mmol / L. In one embodiment, the patient has a sodium level of equal to or above 110 to equal to or below120 mmol / L. In one embodiment, the patient has a sodium level of equal to or above 110 to equal to orbelow 125 mmol / L. In one embodiment, the patient has a sodium level of equal to or above 110 to equalto or below 130 mmol / L. In one embodiment, the patient has a sodium level of equal to or above 110 toequal to or below 135 mmol / L. In one embodiment, the patient has a sodium level of equal to or above110 to equal to or below 138 mmol / L. In one embodiment, the patient has a sodium level of equal to orabove 110 to equal to or below 140 mmol / L. In one embodiment, the patient has a sodium level of equalto or above 110 to equal to or below 141 mmol / L. In one embodiment, the patient has a sodium level ofequal to or above 110 to equal to or below 144 mmol / L. In one embodiment, the patient has a sodiumlevel of equal to or above 110 to equal to or below 145 mmol / L. In one embodiment, the patient has asodium level of equal to or above 110 to equal to or below 150 mmol / L. In one embodiment, the patienthas a sodium level of equal to or above 110 to equal to or below 154 mmol / L. In one embodiment, thepatient has a sodium level of equal to or above 110 to equal to or below 155 mmol / L. In one embodiment,the patient has a sodium level of equal to or above 117 to equal to or below 120 mmol / L. In oneembodiment, the patient has a sodium level of equal to or above 117 to equal to or below 125 mmol / L. Inone embodiment, the patient has a sodium level of equal to or above 117 to equal to or below 130 mmol / L.In one embodiment, the patient has a sodium level of equal to or above 117 to equal to or below 135mmol / L. In one embodiment, the patient has a sodium level of equal to or above 117 to equal to or below138 mmol / L. In one embodiment, the patient has a sodium level of equal to or above 117 to equal to orbelow 140 mmol / L. In one embodiment, the patient has a sodium level of equal to or above 117 to equalto or below 141 mmol / L. In one embodiment, the patient has a sodium level of equal to or above 117 toequal to or below 144 mmol / L. In one embodiment, the patient has a sodium level of equal to or above117 to equal to or below 145 mmol / L. In one embodiment, the patient has a sodium level of equal to orabove 117 to equal to or below 150 mmol / L. In one embodiment, the patient has a sodium level of equalto or above 117 to equal to or below 154 mmol / L. In one embodiment, the patient has a sodium level ofequal to or above 117 to equal to or below 155 mmol / L.In one embodiment, the patient has a sodium levelof equal to or above 120 to equal to or below 125 mmol / L. In one embodiment, the patient has a sodiumlevel of equal to or above 120 to equal to or below 130 mmol / L. In one embodiment, the patient has asodium level of equal to or above 120 to equal to or below 135 mmol / L. In one embodiment, the patienthas a sodium level of equal to or above 120 to equal to or below 138 mmol / L. In one embodiment, thepatient has a sodium level of equal to or above 120 to equal to or below 140 mmol / L. In one embodiment,the patient has a sodium level of equal to or above 120 to equal to or below 141 mmol / L. In oneembodiment, the patient has a sodium level of equal to or above 120 to equal to or below 144 mmol / L. Inone embodiment, the patient has a sodium level of equal to or above 120 to equal to or below 145 mmol / L.In one embodiment, the patient has a sodium level of equal to or above 120 to equal to or below 150mmol / L. In one embodiment, the patient has a sodium level of equal to or above 120 to equal to or below BHC231046 US14 -41-154 mmol / L. In one embodiment, the patient has a sodium level of equal to or above 120 to equal to orbelow 155 mmol / L. In one embodiment, the patient has a sodium level of equal to or above 125 to equalto or below 130 mmol / L. In one embodiment, the patient has a sodium level of equal to or above 125 toequal to or below 135 mmol / L. In one embodiment, the patient has a sodium level of equal to or above125 to equal to or below 138 mmol / L. In one embodiment, the patient has a sodium level of equal to orabove 125 to equal to or below 140 mmol / L. In one embodiment, the patient has a sodium level of equalto or above 125 to equal to or below 141 mmol / L. In one embodiment, the patient has a sodium level ofequal to or above 125 to equal to or below 144 mmol / L. In one embodiment, the patient has a sodiumlevel of equal to or above 125 to equal to or below 145 mmol / L. In one embodiment, the patient has asodium level of equal to or above 125 to equal to or below 150 mmol / L. In one embodiment, the patienthas a sodium level of equal to or above 125 to equal to or below 154 mmol / L. In one embodiment, thepatient has a sodium level of equal to or above 125 to equal to or below 155 mmol / L. In one embodiment,the patient has a sodium level of equal to or above 130 to equal to or below 135 mmol / L. In oneembodiment, the patient has a sodium level of equal to or above 130 to equal to or below 138 mmol / L. Inone embodiment, the patient has a sodium level of equal to or above 130 to equal to or below 140 mmol / L.In one embodiment, the patient has a sodium level of equal to or above 130 to equal to or below 141mmol / L. In one embodiment, the patient has a sodium level of equal to or above 130 to equal to or below144 mmol / L. In one embodiment, the patient has a sodium level of equal to or above 130 to equal to orbelow 145 mmol / L. In one embodiment, the patient has a sodium level of equal to or above 130 to equalto or below 150 mmol / L. In one embodiment, the patient has a sodium level of equal to or above 130 toequal to or below 154 mmol / L. In one embodiment, the patient has a sodium level of equal to or above130 to equal to or below 155 mmol / L. In one embodiment, the patient has a sodium level of equal to orabove 135 to equal to or below 138 mmol / L. In one embodiment, the patient has a sodium level of equalto or above 135 to equal to or below 140 mmol / L. In one embodiment, the patient has a sodium level ofequal to or above 135 to equal to or below 141 mmol / L. In one embodiment, the patient has a sodiumlevel of equal to or above 135 to equal to or below 144 mmol / L. In one embodiment, the patient has asodium level of equal to or above 135 to equal to or below 145 mmol / L. In one embodiment, the patienthas a sodium level of equal to or above 135 to equal to or below 150 mmol / L. In one embodiment, thepatient has a sodium level of equal to or above 135 to equal to or below 154 mmol / L. In one embodiment,the patient has a sodium level of equal to or above 135 to equal to or below 155 mmol / L.In oneembodiment, the patient has a sodium level of equal to or above 138 to equal to or below 140 mmol / L. Inone embodiment, the patient has a sodium level of equal to or above 138 to equal to or below 141 mmol / L.In one embodiment, the patient has a sodium level of equal to or above 138 to equal to or below 144mmol / L. In one embodiment, the patient has a sodium level of equal to or above 138 to equal to or below145 mmol / L. In one embodiment, the patient has a sodium level of equal to or above 138 to equal to orbelow 150 mmol / L. In one embodiment, the patient has a sodium level of equal to or above 138 to equalto or below 154 mmol / L. In one embodiment, the patient has a sodium level of equal to or above 138 to BHC231046 US14 -42-equal to or below 155 mmol / L. In one embodiment, the patient has a sodium level of equal to or above140 to equal to or below 141 mmol / L. In one embodiment, the patient has a sodium level of equal to orabove 140 to equal to or below 144 mmol / L. In one embodiment, the patient has a sodium level of equalto or above 140 to equal to or below 145 mmol / L. In one embodiment, the patient has a sodium level ofequal to or above 140 to equal to or below 150 mmol / L. In one embodiment, the patient has a sodiumlevel of equal to or above 140 to equal to or below 154 mmol / L. In one embodiment, the patient has asodium level of equal to or above 140 to equal to or below 155 mmol / L. In one embodiment, the patienthas a sodium level of equal to or above 141 to equal to or below 144 mmol / L. In one embodiment, thepatient has a sodium level of equal to or above 141 to equal to or below 145 mmol / L. In one embodiment,the patient has a sodium level of equal to or above 141 to equal to or below 150 mmol / L. In oneembodiment, the patient has a sodium level of equal to or above 141 to equal to or below 154 mmol / L. Inone embodiment, the patient has a sodium level of equal to or above 141 to equal to or below 155 mmol / L.In one embodiment, the patient has a sodium level of equal to or above 144 to equal to or below 145mmol / L. In one embodiment, the patient has a sodium level of equal to or above 144 to equal to or below150 mmol / L. In one embodiment, the patient has a sodium level of equal to or above 144 to equal to orbelow 154 mmol / L. In one embodiment, the patient has a sodium level of equal to or above 144 to equalto or below 155 mmol / L. In one embodiment, the patient has a sodium level of equal to or above 145 toequal to or below 150 mmol / L. In one embodiment, the patient has a sodium level of equal to or above145 to equal to or below 154 mmol / L. In one embodiment, the patient has a sodium level of equal to orabove 145 to equal to or below 155 mmol / L. In one embodiment, the patient has a sodium level of equalto or above 150 to equal to or below 154 mmol / L. In one embodiment, the patient has a sodium level ofequal to or above 150 to equal to or below 155 mmol / L. In one embodiment, the patient has a sodiumlevel of equal to or above 154 to equal to or below 155 mmol / L.The chloride level can be used as a prognostic marker in HF. Chloride is among the major electrolytes that play a unique role in fluid homeostasis and is associated with cardiorenal and neurohormonal systems. Hypochloremia (low serum chloride level) can be an independent predictor of adverse outcomes in acute or chronic HF. Various HF therapies may cause hypochloremia, and hypochloremia itself can initiate and exacerbate diuretic resistance in HF. The chloride concentration is also used to calculate the anion gap, the difference between the main cation sodium and the two main anions chloride and bicarbonate. The chloride level is expressed in mmol / L. Lower chloride levels are associated with a worse prognosis in HF. Further, low chloride levels may have a prominent contribution to the pathophysiology. Chloride, rather than sodium, modulates the reninsecretion and tubuloglomerular feedback in the kidney and regulates sodium transport pathway in theLoop of Henle and distal convoluted tube. The relationship between chloride levels and prognosis wasobserved in both HF with reduced ejection fraction (HFrEF) and HF with mildly reduced or preserved ejection fraction (HFmrEF / HFpEF), and cam have a contribution to the pathophysiology and prognosis in BHC231046 US14 -43- HF. Higher chloride levels may potentially alleviatie hypochloremia-related HF symptoms and prognosis.In one embodiment, the patient has a chloride level selected from of equal to or above 90, 95, 100, 105,110 mmol / L. In one embodiment, the patient has a chloride level selected from of equal to or below 90,95, 100, 105, 110 mmol / L.In one embodiment, the patient has a chloride level of equal to or below 90 mmol / L. In one embodiment,the patient has a chloride level of equal to or below 95 mmol / L. In one embodiment, the patient has achloride level of equal to or below 100 mmol / L. In one embodiment, the patient has a chloride level ofequal to or below 105 mmol / L. In one embodiment, the patient has a chloride level of equal to or below110 mmol / L. In one embodiment, the patient has a chloride level of equal to or above 90 mmol / L. In oneembodiment, the patient has a chloride level of equal to or above 95 mmol / L. In one embodiment, thepatient has a chloride level of equal to or above 100 mmol / L. In one embodiment, the patient has a chloridelevel of equal to or above 105 mmol / L. In one embodiment, the patient has a chloride level of equal to orabove 110 mmol / L.In one embodiment, the patient has a chloride level of equal to or above 90 to equal to or below 110mmol / L. In one embodiment, the patient has a chloride level of equal to or above 90 to equal to or below105 mmol / L. In one embodiment, the patient has a chloride level of equal to or above 90 to equal to orbelow 100 mmol / L. In one embodiment, the patient has a chloride level of equal to or above 90 to equalto or below 95 mmol / L.Blood urea refers to the concentration of urea, a waste product produced when proteins break down in the bloodstream. It is a frequently measured parameter in clinical settings to evaluate the overall health and function of the kidneys. The kidneys remove urea from the blood after it is created in the liver as a byproduct of protein breakdown. Blood urea levels offer important information about kidney function. The ranges can vary slightly depending on age, gender, and health status or depending on the lab performing the test.The urea level in serum is expressed in mg / dL.In one embodiment the patient has a urea level of equal to or above 6 to equal to or below 24 mg / dL. Inone embodiment the patient has a urea level of equal to or above 6 to equal to or below 21 mg / dL. In oneembodiment the patient has a urea level of equal to or above 6 mg / dL. In one embodiment the patient hasa urea level of equal to or below 6 mg / dL. In one embodiment the patient has a urea level of equal to orabove 21 mg / dL. In one embodiment the patient has a urea level of equal to or below 21 mg / dL. In oneembodiment the patient has a urea level of equal to or above 24 mg / dL. In one embodiment the patienthas a urea level of equal to or below 24 mg / dL.In one embodiment, the patient has a urea level selected from of equal to or below 1, 2, 3, 4, 5, 6, 7, 8, 9,10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37,38, 39, 40, 41, 42, 43, 44, 45, 46, 48, 49, 50, 55, 60, 65, 70, 75, 80, 85, 90, 94, 95 and 100 mg / dL. In one BHC231046 US14 -44-embodiment, the patient has a urea level selected from of equal to or above 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11,12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 48, 49, 50, 55, 60, 65, 70, 75, 80, 85, 90, 94, 95 and 100 mg / dL.In one embodiment the patient has a urea level of equal to or above 4 to equal to or below 94 mg / dL.In one embodiment the patient has a urea level of equal to or above 4 mg / dL. In one embodiment thepatient has a urea level of equal to or above 6 mg / dL. In one embodiment the patient has a urea level ofequal to or above 8 mg / dL. In one embodiment the patient has a urea level of equal to or above 13 mg / dL.In one embodiment the patient has a urea level of equal to or above 16 mg / dL. In one embodiment thepatient has a urea level of equal to or above 20 mg / dL. In one embodiment the patient has a urea level ofequal to or above 23 mg / dL. In one embodiment the patient has a urea level of equal to or above 27 mg / dL.In one embodiment the patient has a urea level of equal to or above 33 mg / dL. In one embodiment thepatient has a urea level of equal to or above 35 mg / dL. In one embodiment the patient has a urea level ofequal to or above 40 mg / dL. In one embodiment the patient has a urea level of equal to or above 45 mg / dL.In one embodiment the patient has a urea level of equal to or above 50 mg / dL. In one embodiment thepatient has a urea level of equal to or above 55 mg / dL. In one embodiment the patient has a urea level ofequal to or above 60 mg / dL. In one embodiment the patient has a urea level of equal to or above 65 mg / dL.In one embodiment the patient has a urea level of equal to or above 70 mg / dL. In one embodiment thepatient has a urea level of equal to or above 75 mg / dL. In one embodiment the patient has a urea level ofequal to or above 80 mg / dL. In one embodiment the patient has a urea level of equal to or above 85 mg / dL.In one embodiment the patient has a urea level of equal to or above 90 mg / dL. In one embodiment thepatient has a urea level of equal to or above 94 mg / dL. In one embodiment the patient has a urea level ofequal to or above 95 mg / dL.In one embodiment the patient has a urea level of equal to or below 4 mg / dL. In one embodiment thepatient has a urea level of equal to or below 6 mg / dL. In one embodiment the patient has a urea level ofequal to or below 8 mg / dL. In one embodiment the patient has a urea level of equal to or below 13 mg / dL.In one embodiment the patient has a urea level of equal to or below 16 mg / dL. In one embodiment thepatient has a urea level of equal to or below 20 mg / dL. In one embodiment the patient has a urea level ofequal to or below 23 mg / dL. In one embodiment the patient has a urea level of equal to or below 27 mg / dL.In one embodiment the patient has a urea level of equal to or below 33 mg / dL. In one embodiment thepatient has a urea level of equal to or below 35 mg / dL. In one embodiment the patient has a urea level ofequal to or below 40 mg / dL. In one embodiment the patient has a urea level of equal to or below 45 mg / dL.In one embodiment the patient has a urea level of equal to or below 50 mg / dL. In one embodiment thepatient has a urea level of equal to or below 55 mg / dL. In one embodiment the patient has a urea level ofequal to or below 60 mg / dL. In one embodiment the patient has a urea level of equal to or below 65 mg / dL.In one embodiment the patient has a urea level of equal to or below 70 mg / dL. In one embodiment the BHC231046 US14 -45-patient has a urea level of equal to or below 75 mg / dL. In one embodiment the patient has a urea level ofequal to or below 80 mg / dL. In one embodiment the patient has a urea level of equal to or below 85 mg / dL.In one embodiment the patient has a urea level of equal to or below 90 mg / dL. In one embodiment thepatient has a urea level of equal to or below 94 mg / dL. In one embodiment the patient has a urea level ofequal to or below 95 mg / dL.Blood urea nitrogen (BUN) is a medical test that measures the amount of urea nitrogen found in blood.The test for measuring urea in the blood is similar worldwide, but the results are reported in two differentways depending on the country doing the lab testing. In some instances, the urea level in plasma or serum is measured as nitrogen and is called "Blood Urea Nitrogen" or BUN. The unit used for BUN is mg / dL.In other instances, the whole urea molecule is measured, not just the nitrogen, and is reported in StandardInternational units of mmol / L. This measurement is about twice as high as the BUN measurement because BUN only measures the nitrogen part of the molecule (having a Molecular Weight of 28), while urea measures the whole molecule (having a Molecular weight of 60). Thus, urea is approximately twice that of BUN (60 / 28 = 2.14). For example, a BUN result of 10 mg / dL is equal to a urea result of 21.4 mg / dL. Converting BUN (mg / dl) to Urea (mmol / L). The liver produces urea in the urea cycle as a waste product of the digestion of protein. Normal human adult blood should contain 6 to 20 mg / dL (2.1 to 7.1 mmol / L) of urea nitrogen. Individual laboratories will have different reference ranges, as the assay used can vary between laboratories. The test is used to detect renal problems. It is not considered as reliable as creatinine or BUN / creatinine ratio blood studies. Troponin is a protein found in the body, specifically in heart muscle cells. The three main types of cardiactroponin proteins are I, T, and C. During, e.g., a heart attack, troponin spills into the bloodstream and it isa biomarker that can indicate cardiac injury. The high-sensitivity cardiac troponin test allows for detectionof very low levels of troponin T, helping to diagnose, e.g., heart attacks, diagnose other heart-relatedconditions, Obstructive coronary artery disease (CAD), stable angina, congestive heart failure (CHF), cardiomyopathy and the like. Since the first use of troponin testing, several generations of more refined and more reliable tests have been developed and used to help diagnose heart attack more rapidly and accurately.Assessed values of hs-Troponin T (high-sensitivity Cardiac Troponin T) in patients with chronic heartfailure have recently emerged as an independent predictor of all cause mortality, cardiovascular mortalityas well as hospitalization for cardiovascular causes. The prognostic value of hs-Troponin T is unaffectedby heart failure etiology. (Aimo et al. Prognostic value of high-sensitivity Troponin-T in chronic heartfailure: an individual patient data meta-analysis. Circulation. 2018;137:286-297. doi:10.1161 / CIRCULATIONAHA.117.031560.). High-sensitivity Troponin T is expressed in ng / L. BHC231046 US14 -46-In one embodiment, the patient has a High-sensitivity Troponin T level from equal to or above 5 to equalto or below 95000 ng / L. In one embodiment, the patient has a High-sensitivity Troponin T level fromequal to or above 5 to equal to or below 8000 ng / L. In one embodiment, the patient has a High-sensitivityTroponin T level from equal to or above 5 to equal to or below 7000 ng / L. In one embodiment, the patienthas a High-sensitivity Troponin T level from equal to or above 5 to equal to or below 6000 ng / L. In oneembodiment, the patient has a High-sensitivity Troponin T level from equal to or above 5 to equal to orbelow 5000 ng / L. In one embodiment, the patient has a High-sensitivity Troponin T level from equal toor above 5 to equal to or below 4000 ng / L. In one embodiment, the patient has a High-sensitivity TroponinT level from equal to or above 5 to equal to or below 3000 ng / L. In one embodiment, the patient has aHigh-sensitivity Troponin T level from equal to or above 5 to equal to or below 2000 ng / L. In oneembodiment, the patient has a High-sensitivity Troponin T level from equal to or above 5 to equal to orbelow 1000 ng / L. In one embodiment, the patient has a High-sensitivity Troponin T level from equal toor above 5 to equal to or below 900 ng / L. In one embodiment, the patient has a High-sensitivity TroponinT level from equal to or above 5 to equal to or below 800 ng / L. In one embodiment, the patient has a High-sensitivity Troponin T level from equal to or above 5 to equal to or below 700 ng / L. In one embodiment,the patient has a High-sensitivity Troponin T level from equal to or above 5 to equal to or below 600 ng / L.In one embodiment, the patient has a High-sensitivity Troponin T level from equal to or above 5 to equalto or below 500 ng / L. In one embodiment, the patient has a High-sensitivity Troponin T level from equalto or above 5 to equal to or below 400 ng / L. In one embodiment, the patient has a High-sensitivityTroponin T level from equal to or above 5 to equal to or below 300 ng / L. In one embodiment, the patienthas a High-sensitivity Troponin T level from equal to or above 5 to equal to or below 200 ng / L. In oneembodiment, the patient has a High-sensitivity Troponin T level from equal to or above 5 to equal to orbelow 100 ng / L. In one embodiment, the patient has a High-sensitivity Troponin T level from equal to orabove 5 to equal to or below 50 ng / L. In one embodiment, the patient has a High-sensitivity Troponin Tlevel from equal to or above 5 to equal to or below 40 ng / L. In one embodiment, the patient has a High-sensitivity Troponin T level from equal to or above 5 to equal to or below 30 ng / L. In one embodiment,the patient has a High-sensitivity Troponin T level from equal to or above 5 to equal to or below 20 ng / L.In one embodiment, the patient has a High-sensitivity Troponin T level from equal to or above 5 to equalto or below 10 ng / L.In one embodiment, the patient has a High-sensitivity Troponin T level from equal to or above 100 toequal to or below 95000 ng / L. In one embodiment, the patient has a High-sensitivity Troponin T levelfrom equal to or above 100 to equal to or below 8000 ng / L. In one embodiment, the patient has a High-sensitivity Troponin T level from equal to or above 100 to equal to or below 7000 ng / L. In oneembodiment, the patient has a High-sensitivity Troponin T level from equal to or above 100 to equal to orbelow 6000 ng / L. In one embodiment, the patient has a High-sensitivity Troponin T level from equal toor above 100 to equal to or below 5000 ng / L. In one embodiment, the patient has a High-sensitivityTroponin T level from equal to or above 100 to equal to or below 4000 ng / L. In one embodiment, the BHC231046 US14 -47-patient has a High-sensitivity Troponin T level from equal to or above 100 to equal to or below 3000 ng / L.In one embodiment, the patient has a High-sensitivity Troponin T level from equal to or above 100 toequal to or below 2000 ng / L. In one embodiment, the patient has a High-sensitivity Troponin T level fromequal to or above 100 to equal to or below 1000 ng / L. In one embodiment, the patient has a High-sensitivity Troponin T level from equal to or above 100 to equal to or below 900 ng / L. In one embodiment,the patient has a High-sensitivity Troponin T level from equal to or above 100 to equal to or below 800ng / L. In one embodiment, the patient has a High-sensitivity Troponin T level from equal to or above 100to equal to or below 700 ng / L. In one embodiment, the patient has a High-sensitivity Troponin T levelfrom equal to or above 100 to equal to or below 600 ng / L. In one embodiment, the patient has a High-sensitivity Troponin T level from equal to or above 100 to equal to or below 500 ng / L. In one embodiment,the patient has a High-sensitivity Troponin T level from equal to or above 100 to equal to or below 400ng / L. In one embodiment, the patient has a High-sensitivity Troponin T level from equal to or above 100to equal to or below 300 ng / L. In one embodiment, the patient has a High-sensitivity Troponin T levelfrom equal to or above 100 to equal to or below 200 ng / L.In one embodiment, the patient has a High-sensitivity Troponin T level from equal to or above 1000 toequal to or below 95000 ng / L. In one embodiment, the patient has a High-sensitivity Troponin T levelfrom equal to or above 1000 to equal to or below 8000 ng / L. In one embodiment, the patient has a High-sensitivity Troponin T level from equal to or above 1000 to equal to or below 7000 ng / L. In oneembodiment, the patient has a High-sensitivity Troponin T level from equal to or above 1000 to equal toor below 6000 ng / L. In one embodiment, the patient has a High-sensitivity Troponin T level from equalto or above 1000 to equal to or below 5000 ng / L. In one embodiment, the patient has a High-sensitivityTroponin T level from equal to or above 1000 to equal to or below 4000 ng / L. In one embodiment, thepatient has a High-sensitivity Troponin T level from equal to or above 1000 to equal to or below 3000ng / L. In one embodiment, the patient has a High-sensitivity Troponin T level from equal to or above 1000to equal to or below 2000 ng / L.In one embodiment, the patient has a High-sensitivity Troponin T level from equal to or above 6 to equalto or below 30 ng / L. In one embodiment, the patient has a High-sensitivity Troponin T level from equalto or above 6.5 to equal to or below 30 ng / L.In one embodiment, the patient has a High-sensitivity Troponin T level selected from of equal to or above5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 40, 50, 60, 70, 80, 90, 100, 20, 300, 400, 500, 600, 700, 900, 1000, 1500, 2000, 2500, 3000, 3500, 4000, 4500, 5000,5500, 6000, 6500, 7000, 7500, 8000, 8500, 9000 and 9500 ng / L. In one embodiment, the patient has aHigh-sensitivity Troponin T level selected from of equal to or above 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15,16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, and 30 ng / LIn one embodiment, the patient has a High-sensitivity Troponin T level selected from the group consisting BHC231046 US14 -48- of 6.5 ng / L, 17.7 ng / L, 26.1 ng / L, 28.2 ng / L, and 7610.0 ng / L The N-terminal prohormone of brain natriuretic peptide (NT-proBNP) is a prohormone with a 76 amino acid N-terminal inactive protein that is cleaved from the molecule to release brain natriuretic peptide 32(BNP, also known as B-type natriuretic peptide). Both BNP and NT-proBNP levels in the blood are usedfor screening, diagnosis and prognosis of CHF in both acute and non-acute settings. Elevated plasmaconcentrations of NT-proBNP correlate with the onset of heart failure hospitalization and cardiovasculardeath (Mueller et al. “Heart Failure association of the European Society of cardiology practical guidanceon the use of natriuretic peptide concentrations. European Journal of Heart Failure 2019; 21, 715-731doi:10.1002 / ejhf.1494).NT-proBNP is expressed in pg / mL.In one embodiment, the patient has a N-terminal prohormone of brain natriuretic peptide (NT-proBNP)level of equal to or above 300 pg / mL.In one embodiment, the patient has a NT-proBNP level selected from of equal to or above 300, 350, 400,450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000, 3100, 3200, 3300, 3400,3500, 3600, 3700, 3800, 3900, 400, 4100, 4200, 4300, 4400 or 4500 pg / mL.In one embodiment, the patient has a NT-proBNP level selected from of equal to or below 300, 350, 400,450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1100, 1200, 1300, 1400, 1500, 1600, 1700, 1800, 1900, 2000, 2100, 2200, 2300, 2400, 2500, 2600, 2700, 2800, 2900, 3000, 3100, 3200, 3300, 3400, 3500, 3600, 3700, 3800, 3900, 400, 4100, 4200, 4300, 4400 or 4500 pg / mL.In one embodiment, the patient has a NT-proBNP level of equal to or above 300 to equal to or below 4300pg / mL. In one embodiment, the patient has a NT-proBNP level of equal to or above 300 to equal to orbelow 2200 pg / mL. In one embodiment, the patient has a NT-proBNP level of equal to or above 300 toequal to or below 2000 pg / mL. In one embodiment, the patient has a NT-proBNP level of equal to orabove 300 to equal to or below 1900 pg / mL. In one embodiment, the patient has a NT-proBNP level ofequal to or above 300 to equal to or below 1600 pg / mL. In one embodiment, the patient has a NT-proBNPlevel of equal to or above 500 to equal to or below 3000 pg / mL.In one embodiment, the patient has a Brain natriuretic Peptide (BNP) of equal to or above 100 pg / mL. Inone embodiment, the patient has a Brain natriuretic Peptide (BNP) of equal to or above 300 pg / mL.Blood pressure (BP) is the pressure of circulating blood against the walls of blood vessels. Most of this pressure results from the heart pumping blood through the circulatory system. When used without BHC231046 US14 -49- qualification, the term "blood pressure" refers to the pressure in a brachial artery, where it is most commonly measured. Blood pressure is usually expressed in terms of the systolic pressure (maximum pressure during one heartbeat) over diastolic pressure (minimum pressure between two heartbeats) in the cardiac cycle. It is expressed in millimeters of mercury (mmHg) above the surrounding atmospheric pressure, or in kilopascals (kPa). The difference between the systolic and diastolic pressures is known as pulse pressure, while the average pressure during a cardiac cycle is known as mean arterial pressure.In one embodiment, the patient has a systolic blood pressure selected from equal to or above 40, 45, 50,55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 114, 115, 120, 125, 129, 130, 135, 140, 144, 145, 150, 155, 160, 165, 170, 175, 180, 185, and 190 mmHg. In one embodiment, the patient has a systolic bloodpressure selected from equal to or below 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 114,115, 120, 125, 129, 130, 135, 140, 144, 145, 150, 155, 160, 165, 170, 175, 180, 185, and 190 mmHg.In one embodiment, the patient has a systolic blood pressure of equal to or above 40 mmHg. In oneembodiment, the patient has a systolic blood pressure of equal to or above 45 mmHg. In one embodiment,the patient has a systolic blood pressure of equal to or above 50 mmHg. In one embodiment, the patienthas a systolic blood pressure of equal to or above 55 mmHg. In one embodiment, the patient has a systolicblood pressure of equal to or above 60 mmHg. In one embodiment, the patient has a systolic blood pressureof equal to or above 65 mmHg. In one embodiment, the patient has a systolic blood pressure of equal toor above 70 mmHg. In one embodiment, the patient has a systolic blood pressure of equal to or above 75mmHg. In one embodiment, the patient has a systolic blood pressure of equal to or above 80 mmHg. Inone embodiment, the patient has a systolic blood pressure of equal to or above 85 mmHg. In oneembodiment, the patient has a systolic blood pressure of equal to or above 90 mmHg. In one embodiment,the patient has a systolic blood pressure of equal to or above 100 mmHg. In one embodiment, the patienthas a systolic blood pressure of equal to or above 105 mmHg. In one embodiment, the patient has a systolicblood pressure of equal to or above 110 mmHg. In one embodiment, the patient has a systolic bloodpressure of equal to or above 114 mmHg. In one embodiment, the patient has a systolic blood pressure ofequal to or above 115 mmHg. In one embodiment, the patient has a systolic blood pressure of equal to orabove 120 mmHg. In one embodiment, the patient has a systolic blood pressure of equal to or above 125mmHg. In one embodiment, the patient has a systolic blood pressure of equal to or above 129 mmHg. Inone embodiment, the patient has a systolic blood pressure of equal to or above 130 mmHg. In oneembodiment, the patient has a systolic blood pressure of equal to or above 135 mmHg. In one embodiment,the patient has a systolic blood pressure of equal to or above 140 mmHg. In one embodiment, the patienthas a systolic blood pressure of equal to or above 144 mmHg. In one embodiment, the patient has a systolicblood pressure of equal to or above 145 mmHg. In one embodiment, the patient has a systolic bloodpressure of equal to or above 150 mmHg. In one embodiment, the patient has a systolic blood pressure ofequal to or above 155 mmHg. In one embodiment, the patient has a systolic blood pressure of equal to orabove 160 mmHg. In one embodiment, the patient has a systolic blood pressure of equal to or above 165 BHC231046 US14 -50-mmHg. In one embodiment, the patient has a systolic blood pressure of equal to or above 170 mmHg. Inone embodiment, the patient has a systolic blood pressure of equal to or above 175 mmHg. In oneembodiment, the patient has a systolic blood pressure of equal to or above 180 mmHg. In one embodiment,the patient has a systolic blood pressure of equal to or above 185 mmHg. In one embodiment, the patienthas a systolic blood pressure of equal to or above 190 mmHg.In one embodiment, the patient has a systolic blood pressure of equal to or below 40 mmHg. In oneembodiment, the patient has a systolic blood pressure of equal to or below 45 mmHg. In one embodiment,the patient has a systolic blood pressure of equal to or below 50 mmHg. In one embodiment, the patienthas a systolic blood pressure of equal to or below 55 mmHg. In one embodiment, the patient has a systolicblood pressure of equal to or below 60 mmHg. In one embodiment, the patient has a systolic blood pressureof equal to or below 65 mmHg. In one embodiment, the patient has a systolic blood pressure of equal toor below 70 mmHg. In one embodiment, the patient has a systolic blood pressure of equal to or below 75mmHg. In one embodiment, the patient has a systolic blood pressure of equal to or below 80 mmHg. Inone embodiment, the patient has a systolic blood pressure of equal to or below 85 mmHg. In oneembodiment, the patient has a systolic blood pressure of equal to or below 90 mmHg. In one embodiment,the patient has a systolic blood pressure of equal to or below 100 mmHg. In one embodiment, the patienthas a systolic blood pressure of equal to or below 105 mmHg. In one embodiment, the patient has a systolicblood pressure of equal to or below 110 mmHg. In one embodiment, the patient has a systolic bloodpressure of equal to or below 114 mmHg. In one embodiment, the patient has a systolic blood pressure ofequal to or below 115 mmHg. In one embodiment, the patient has a systolic blood pressure of equal to orbelow 120 mmHg. In one embodiment, the patient has a systolic blood pressure of equal to or below 125mmHg. In one embodiment, the patient has a systolic blood pressure of equal to or below 129 mmHg. Inone embodiment, the patient has a systolic blood pressure of equal to or below 130 mmHg. In oneembodiment, the patient has a systolic blood pressure of equal to or below 135 mmHg. In one embodiment,the patient has a systolic blood pressure of equal to or below 140 mmHg. In one embodiment, the patienthas a systolic blood pressure of equal to or below 144 mmHg. In one embodiment, the patient has a systolicblood pressure of equal to or below 145 mmHg. In one embodiment, the patient has a systolic bloodpressure of equal to or below 150 mmHg. In one embodiment, the patient has a systolic blood pressure ofequal to or below 155 mmHg. In one embodiment, the patient has a systolic blood pressure of equal to orbelow 160 mmHg. In one embodiment, the patient has a systolic blood pressure of equal to or below 165mmHg. In one embodiment, the patient has a systolic blood pressure of equal to or below 170 mmHg. Inone embodiment, the patient has a systolic blood pressure of equal to or below 175 mmHg. In oneembodiment, the patient has a systolic blood pressure of equal to or below 180 mmHg. In one embodiment,the patient has a systolic blood pressure of equal to or below 185 mmHg. In one embodiment, the patienthas a systolic blood pressure of equal to or below 190 mmHg.In one embodiment, the patient has a systolic blood pressure of 129±15 mmHg. In one embodiment, the BHC231046 US14 -51-patient has a systolic blood pressure of equal to or above 114 to equal to or below 144 mmHg. In oneembodiment, the patient has a systolic blood pressure of equal to or above 114 to equal to or below 129mmHg. In one embodiment, the patient has a systolic blood pressure of equal to or above 129 to equal toor below 144 mmHg. In one embodiment, the patient has a systolic blood pressure of equal to or above110 to equal to or below 114 mmHg. In one embodiment, the patient has a systolic blood pressure of equalto or above 100 to equal to or below 110 mmHg. In one embodiment, the patient has a systolic bloodpressure of equal to or above 90 to equal to or below 100 mmHg.As such, finerenone presents a new opportunity to modify risk of adverse events in patients with HF, including among those with cardio-kidney-metabolic multimorbidity. The patient to be treated may be multimorbid, i.e. the patient may have one or more other diseases. The patient may have a medical history or various medical histories. The medical terms used herein are known to those skilled in the art and are used as common in the art.In one embodiment, the patient has a history of prior MRA use. In one embodiment, the patient has ahistory of atrial flutter. In one embodiment, the patient has a history of atrial fibrillation. In one embodiment, the patient has a history of coronary artery disease (CAD). In one embodiment, the patient has a history of stroke. In one embodiment, the patient has a history of transient ischemic attack (TIA). In one embodiment, the patient has a history of chronic obstructive pulmonary disease (COPD). In one embodiment, the patient has a history of metabolic syndrome. In one embodiment, the patient has a history of frailty. In one embodiment, the patient has a history of peripheral artery disease (PAD). In one embodiment, the patient has a history of obstructive sleep apnea (OSA). In one embodiment, the patient has a history of cancer. In one embodiment, the patient has a history of chronic obstructive pulmonary disease (COPD). In one embodiment, the patient has a history of resistant hypertension. In oneembodiment, the patient has a history of diabetes. In one embodiment, the patient has a history of atrialflutter. In one embodiment, the patient has a history of atrial fibrillation. In one embodiment, the patienthas a history of hypertension. In one embodiment, the patient has a history of myocardial infarction. In one embodiment, the patient has a history of stroke. In one embodiment, the patient has a history of LVEFequal to or below 40%. In one embodiment, the patient was hospitalized prior to treatment or prevention.In one embodiment, the patient was hospitalized for hearth failure (HHF). In one embodiment, the patient has atherosclerotic cardiovascular disease (ASCVD). In one embodiment, the patient has a history ofdiabetes. In one embodiment, the patient has type-2 diabetes (T2D). In one embodiment, the patient haschronic kidney disease. In one embodiment, the patient has a history of chronic kidney disease (CKD). Inone embodiment, the patient has chronic kidney disease (CKD) with an eGFR equal to or above60mL / min / 1.73m2. In one embodiment, the patient a combination of atherosclerotic cardiovascular disease(ASCVD), type-2 diabetes (T2D), and / or chronic kidney disease (CKD; defined aseGFR<60mL / min / 1.73m2). In one embodiment, the patient has sinus rhythm or normal heart rhythm. Inone embodiment, the patient has a history of structural heart disease. The structural heart disease can be BHC231046 US14 -52- indicated by increased left atrial size or left ventricular hypertrophy. Heart rate (or pulse rate) is the frequency of the heartbeat measured by the number of contractions of the heart per minute (beats per minute, beats / min or bpm). The American Heart Association states the normalresting adult human heart rate is 60-100 bpm. Tachycardia is a high heart rate, defined as above 100 bpmat rest. Bradycardia is a low heart rate, defined as below 60 bpm at rest. When the heart is not beating in a regular pattern, this is referred to as an arrhythmia. Abnormalities of heart rate sometimes indicate disease.In one embodiment, the patient has an average heart rate (resting) selected from of equal to or above 40,45, 50, 55, 59, 60, 65, 70, 71, 75, 80, 83, 85, 90, 95, 100, 105, 110, 115, and 120 beats / min. The average heart rate is a resting heart rate.In one embodiment, the patient has an average (resting) heart rate of 71 ± 12 beats / min. In oneembodiment, the patient has an average (resting) heart rate of equal to or above 45 to equal to or below59 beats / min. In one embodiment, the patient has an average (resting) heart rate of equal to or above 59to equal to or below 83 beats / min. In one embodiment, the patient has an average (resting) heart rate ofequal to or above 59 to equal to or below 71 beats / min. In one embodiment, the patient has an average(resting) heart rate of equal to or above 71 to equal to or below 83 beats / min. In one embodiment, thepatient has an average (resting) heart rate of equal to or above 83 beats / min to equal to or below 110beats / min. In one embodiment, the patient has an average (resting) heart rate of equal to or above 90beats / min to equal to or below 110 beats / min. In one embodiment, the patient has an average (resting)heart rate of equal to or above 90 beats / min to equal to or below 100 beats / min.The patient can receive further medication or comedication. This can be, e.g., the case if the patients ismultimorbid. In one embodiment, the patient further receives any one of the medicaments selected from potassium-sparing diuretic, osmotic diuretic, carbonic anhydrase inhibitor, digoxin, nitrates, loop diuretics, thiazidediuretics, beta-blocker, ACE inhibitor (ACEi), angiotension-receptor-blocker (ARB), Angiotensin Receptor-Neprilysin Inhibitor (ARNI), Calcium Channel Blockers, Sodium-glucose Cotransporter-2 Inhibitor (SGLT-2i), Sodium-glucose Cotransporter-1 Inhibitor (SGLT-1i), potassium supplements, potassium lowering agents, potassium binders, centrally acting antihypertensives, cytochrome P450 isoenzyme 3A4 (CYP3A4) inhibitors, CYP3A4 inducers, aspirin, statins, organic anion transporting polypeptides (OATP) substrates, anti-diabetic drugs, insulin, insulin analogues, dipeptidyl peptidase 4 inhibitors, glucagon-like peptide-1 (GLP-1) agonists, biguanides, sulfonylureas, alpha glucosidaseinhibitors, metiglinides, thiazolidinediones, CYP3A4 inducer, CYP3A4 inhibitor and mixtures thereof.In one embodiment, the patient further receives a Sodium-glucose Cotransporter-2 Inhibitor (SGLT-2i) BHC231046 US14 -53- and a glucagon-like peptide-1 (GLP-1) agonist. In one embodiment thereof, the SGLT-2i is selected from is selected from the group consisting of canagliflozin, dapagliflozin, empagliflozin, ertigliflozin, ipragliflozin, luseogliflozin, remogliflozin, tofogliflozin, the pharmaceutical acceptable salts, solvates,hydrates, and polymorphs thereof, and combinations thereof. In one embodiment thereof, the SGLT-2i isdapagliflozin. In one embodiment thereof, the SGLT-2i is empagliflozin. In one embodiment thereof, the SGLT-2i is canagliflozin. In one embodiment thereof, the GLP-1 is selected from dulaglutide, exenatide, liraglutide, lixisenatine,semaglutine, tirzepatide, the pharmaceutical acceptable salts, solvates, hydrates, and polymorphs thereofand combinations thereof. In one embodiment thereof, the SGLT-2i is empagliflozin and the GLP-1 is selected from dulaglutide, exenatide, liraglutide, lixisenatine, semaglutine, tirzepatide, the pharmaceuticalacceptable salts, solvates, hydrates, and polymorphs thereof, and combinations thereof. In oneembodiment thereof, the SGLT-2i is canagliflozin and the GLP-1 is selected from dulaglutide, exenatide, liraglutide, lixisenatine, semaglutine, tirzepatide, the pharmaceutical acceptable salts thereof and combinations thereof. In one embodiment thereof, the SGLT-2i is Dapagliflozin and the GLP-1 is selected from dulaglutide, exenatide, liraglutide, lixisenatine, semaglutine, tirzepatide, the pharmaceutical acceptable salts thereof and combinations thereof. In one embodiment, the patient further receives a potassium-sparing diuretic. In one embodiment, the patient further receives an osmotic diuretic. In one embodiment, the patient further receives a carbonic anhydrase inhibitor. In one embodiment, the patient further receives digoxin. In one embodiment, the patient further receives a nitrate. In one embodiment, the patient further receives a loop diuretic. In one embodiment, the patient further receives a thiazide diuretic. In one embodiment, the patient further receives a beta-blocker. In one embodiment, the patient further receives an ACE inhibitor (ACEi). In one embodiment, the patient further receives an angiotension-receptor-blocker (ARB). In one embodiment, the patient further receives an Angiotensin Receptor-Neprilysin Inhibitor (ARNI). In one embodiment, the patient further receives a Calcium Channel Blockers. In one embodiment, the patient further receives a Sodium-glucose Cotransporter-2 Inhibitor (SGLT-2i). In one embodiment, the patient further receives a Sodium-glucose Cotransporter-1 Inhibitor (SGLT-1i). In one embodiment, the patient further receives a potassium supplement. In one embodiment, the patient further receives a potassium lowering agent. In one embodiment, the patient further receives a potassium binder. In one embodiment, the patient furtherreceives an antihypertensive agent. In one embodiment, the patient further receives a centrally actingantihypertensive. In one embodiment, the patient further receives a cytochrome P450 isoenzyme 3A4(CYP3A4) inhibitor. In one embodiment, the patient further receives a CYP3A4 inducer. In one embodiment, the patient further receives aspirin. In one embodiment, the patient further receives a statine. In one embodiment, the patient further receives an organic anion transporting polypeptides (OATP) substrate. In one embodiment, the patient further receives an anti-diabetic drug. In one embodiment, the patient further receives insulin. In one embodiment, the patient further receives an insulin analogue. In BHC231046 US14 -54- one embodiment, the patient further receives a dipeptidyl peptidase 4 inhibitor. In one embodiment, the patient further receives a glucagon-like peptide-1 agonists. In one embodiment, the patient further receivesa biguanide. In one embodiment, the patient further receives a sulfonylurea. In one embodiment, thepatient further receives an alpha glucosidase inhibitor. In one embodiment, the patient further receives a metiglinide. In one embodiment, the patient further receives a thiazolidinedione. In one embodiment, the patient further receives an alpha blocker. In one embodiment, the patient further receives a beta blocker. In one embodiment the alpha blocker and / or beta blocker is selected from acebutolol, amlodipine, bisoprolol, arotinolol, atenolol, betaxolol, bimatoprost, timolol, bisoprolol, perindopril, bromonidine, brinzolamide, carteolol, lantanoprost, carvediol, ivabradine, dorzolamide, esmolol, hydrochlorothiazide, metroprolol, nebivolol, labetalol, landiolol, nadolol, nebiviolol, pilocarpine, propranolol, sotalol, tafluprost, timolol, travoprost, the pharmaceutical acceptable salts thereof and combinations thereof. In one embodiment, the patient further receives an angiotensin-converting enzyme (ACE) inhibitor. In one embodiment the ACE inhibitor is selected from ramipril, alacepril, amlodipine, perindopril, benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, ramipril, zofenopril, clizapril, imidapril, quinapril, trandolapril, the pharmaceutical acceptable salts thereof and combinations thereof. In one embodiment, the patient further receives an angiotensin receptor blockers (ARBs) selected from allisartan, azilsartan, candesartan, olmesartan, valsartan, irbesartan, losartan, telmisartan, candesartan, eprosartan, fimasartan, the pharmaceutical acceptable salts thereof and combinations thereof. In one embodiment, the patient further receives an angiotensin receptor neprilysin inhibitors (ARNIs). Inone embodiment the ARNI is sacubitril or the pharmaceutical acceptable salts thereof. In one embodimentthe patient receives sacubitril, valsartan or the pharmaceutical acceptable salts thereof.In one embodiment, the patient further receives atorvastatin the pharmaceutical acceptable salts thereof.In one embodiment the patient receives a further medication selected from acetylsalicylic acid,valsartan, clopidogrel, ramipril, perindopril, ezetimibe, the pharmaceutical acceptable salts thereof andcombinations thereof.In one embodiment, the patient further receives a biguanide. In one embodiment the patient receives amedication selected from alogliptin, metformin, canagliflozin, dapagliflozin, empagliflozin, ertugliflozin, gemigliptin, glibenclamide, gliciclazide, linagliptide, pioglitazone, sitagliptin, teneligliptin, vildagliptin, vogliibose, pioglitazin, the pharmaceutical acceptable salts thereof and combinations thereof. In one embodiment, the patient further receives a calcium channel blocker. In one embodiment, the patient BHC231046 US14 -55- further receives a calcium channel blocker selected from amlodipine, azelnidipine, barnidipine, benidipine, bepridil, cilnidipine, diltiazem, efonidipine, lacidinipine, lercanidipine, levamlodipine,manidipine, nicardipine, nifedipine, nilvadepine, nimodipine, nisoldipine, nitrendipine, perhexiline,verapamil, the pharmaceutical acceptable salts thereof and combinations thereof. In one embodiment, thepatient further receives a medication selected from amlodipine, atorvastatin, candesartan,hydrochlorotiazide (HCT), perindopril, azilsartan, benazepril, ramipril, Olmesartan, valsartn, indapipamide, perindopril, irbesartan, lisinopril, lorsartan, azelnidipine, barnidipine, benidipine, bepridil, cilnidipine, diltiazem, efonidipine, lacidinipine, lercanidipine, levamlodipine, manidipine, nicardipine,nifedipine, nilvadepine, nimodipine, nisoldipine, nitrendipine, perhexiline, verapamil, perindopril,ramipril, rosuvastatin, telmisartan, atorvastatin, benazepril, the pharmaceutical acceptable salts thereofand combinations thereof. In one embodiment, the patient further receives a dipeptidyl peptidase-4 (DDP4) inhibitor. In one embodiment, the DDP4 inhibitor is selected from alogliptin, anagliptin, tenegliptin, saxagliptin, linagliptin, gemigliptin, gosogliptin, sitagliptin, tenegliptin, vildagliptin, the pharmaceutical acceptablesalts thereof and combinations thereof. In one embodiment, the patient reeives a medication selected fromalogliptin, anagliptin, tenegliptin, saxagliptin, linagliptin, gemigliptin, gosogliptin, sitagliptin, tenegliptin, vildagliptin, metformin, pioglitazone, cangliflozin, dapagliflozin, empagliflozin, ipragliflozin, the pharmaceutical acceptable salts thereof and combinations thereof. In one embodiment, the patient further receives a diuretic. In one embodiment, the diuretic is selected from tropolone, acetazolamide, altizide, sprionolacton, amiloride, hydrochlorotiaazide, clopamide, chlorthalidone, indapamide, furosemide, azosemide, glycerol, cendroflumethiazide, brimonidine, bumetanide, butizide, chlorothiazide, isosorbide, triamterene, dorzolamide, metolazone, protheobromide, torasemide, tolvaptan, trochloromethiazid, xipamide, theobromide, hydrocortisone, pharmaceutical acceptable salts thereof and combinations thereof. In one embodiment, the patient further receives a medicationelected from tropolone, acetazolamide, altizide, sprionolacton, amiloride, hydrochlorotiaazide, chlorthalidone, indapamide, furosemide, azosemide, glycerol, cendroflumethiazide, brimonidine, bumetanide, butizide, chlorothiazide, isosorbide, triamterene, dorzolamide, metolazone, protheobromide, torasemide, tolvaptan, trochloromethiazid, xipamide, theobromide, hydrocortisone, tolvaptan, torasemide, trichloromethiazide, urea, xipamide, amlodipine, olmesatran, perindopril, atenolol, azosemide, benazepril, potassium chloride, bisoprololm timolol, candesartan, captopril, cetomacrogel, cilapril, clobetasol, clopamide, clotrimazole, timolol, enalapril, etacrynic acid, irbesartan, losartan, telmisartan, nebivolol, zofenopril, rosuvastatin, the pharmaceutical acceptable salts thereof and combinations thereof.In one embodiment, the patient further receives a stain. In one embodiment, the statin is selected fromfluvastatin, atorvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, astaxanthin, the BHC231046 US14 -56- pharmaceutical acceptable salts thereof and combinations thereof.In one embodiment, the patient further receives a glucagon-like peptide 1 (GLP-1) agonist. In oneembodiment, the GLP-1 agonist is selected from dulaglutide, exenatide, liraglutide, lixisenatine, semaglutine, tirzepatide, the pharmaceutical acceptable salts thereof and combinations thereof. In one embodiment, the patient further receives a sodium-glucose cotransporter-2 (SGLT2) inhibitor. Inone embodiment the SGLT2 inhibitor is selected from canagliflozin, dapagliflozin, empagliflozin,ertigliflozin, ipragliflozin, luseogliflozin, remogliflozin, tofogliflozin, the pharmaceutical acceptable salts thereof and combinations thereof.In one embodiment, the patient further receives a sulphonamide. In one embodiment the sulfonamide isselected from glibenclamide, gliclazide, glimepiride, glipizide, gliquidone, tolbutamide, the pharmaceutical acceptable salts thereof and combinations thereof.In one embodiment, the patient further receives a potassium binder. In one embodiment, the potassiumbinder is selected from potassium polystytrene, calcium polystyrene sulfonate, patiromer calcium, patiromer, sorbitex calcium, sodium polystyrene sulfonate, sodium zirconium cyclosilicate, the pharmaceutical acceptable salts thereof and combinations thereof.In one embodiment, the patient further receives a mineralocorticoid receptor antagonists (MRAs). In oneembodiment the MRA is selected from spironolactone, canrenone, eplerenone, potassium canrenoate, thepharmaceutical acceptable salts thereof and combinations thereof.In one embodiment, the patient further receives a vabradine or the pharmaceutical acceptable salts thereof.In one embodiment, the patient further receives an insulin. In one embodiment, the insulin is selected froma natural, synthetic, modified, procine, bovine, insuline derivatve, insuline analogouea, long acting, shortacting, a pharmaceutical acceptable salt thereof and combinations thereof. In one embodiment, the insulinis selected from insuline aspart, aspart protamine, protamine, dediglec, bovine, procine, glargine, glargine biosimiliar, glusine, human, lispro, lispro bioaimilia, lispro protamine, human, zinc suspension, analogues, the pharmaceutical acceptable salts thereof and combinations thereof. In one embodiment, the patient further receives an oral antidiabetic. In one embodiment, the oral antidiabetic is selected from alpha-glucosidase inhibitors, amylin analogs, dipeptidyl peptidase 4inhibitors, incretin mimetics, insulin, meglitinides, non-sulfonylureas, SGLT-2, sulfonylureas, andthiazolidinediones, the pharmaceutical acceptable salts thereof and combinations thereof. In one embodiment, the oral antidiabetic is selected from acarbose, miglitol, pramlintide, alogliptan, linagliptan, saxagliptin, sitagliptin, albiglutide, dulaglutide, exenatide, liraglutide, lixisenatide, insulins, nateglinide, repaglinide, metformin, canagliflozin, dapagliflozin, empagliflozin, chlorpropamide, glimepiride, BHC231046 US14 -57- glipizide, glyburide, tolazamide, tolbutamide, rosiglitazone, pioglitazone, the pharmaceutical acceptablesalts thereof and combinations thereof. In one embodiment, the further medication is selected from (RS)-3-METHYL-2-OXOVALERIANIC ACID CALCIUM;(RS)-3-METHYL-2-OXOBUTYRIC ACID CALCIUM;CALCIUM (RS)-4-METHYL-2-OXOVALERIANAT;CALCIUM 2-OXO-3- PHENYLPROPIONATE, DESMENINOL CALCIUM, HISTIDINE, LYSINE ACETATE, THREONINE, TRYPTOPHAN, TYROSINE, ACARBOSE, ACETYLCYSTEINE, ALOGLIPTIN, ALOGLIPTIN BENZOATE, ALOGLIPTIN BENZOATE, METFORMIN HYDROCHLORIDE, ALOGLIPTIN BENZOATE, PIOGLITAZONE HYDROCHLORIDE, ANAGLIPTIN, ATORVASTATIN, ATORVASTATIN CALCIUM, BIGUANIDE, CALCIUM CARBONATE, MAGNESIUM CARBONATE, POTASSIUM CARBONATE;SODIUM BICARBONATE, SODIUM PHOSPHATE, CALCIUM DOBESILATE, CANAGLIFLOZIN, CANAGLIFLOZIN HEMIHYDRATE, CANAGLIFLOZIN HEMIHYDRATE, METFORMIN, CANAGLIFLOZIN HEMIHYDRATE,TENELIGLIPTIN HYDROBROMIDE, CHLORPHENAMINE MALEATE, PHENYLEPHRINEHYDROCHLORIDE, PHENYLPROPANOLAMINE HYDROCHLORIDE;PHENYLTOLOXAMINE CITRATE, CYSTEINE, GLYCINE, GLYCYRRHIZIC ACID, AMMONIUM SALT, DAPAGLIFLOZIN, SAXAGLIPTIN, DEXAMETHASONE, DIGOXIN, DULAGLUTIDE, EMPAGLIFLOZIN, ENOXAPARIN, ERTUGLIFLOZIN, EXENATIDE, GEMIGLIPTIN TARTRATE, GEMIGLIPTIN TARTRATE, GLIBENCLAMIDE, GLICLAZIDE, GLIMEPIRIDE, GLIPIZIDE, GLIQUIDONE, GLUCAGON, GLUCOSE, GOSOGLIPTIN, HYDROCHLOROTHIAZIDE, IMEGLIMIN, INSULIN ASPART, INSULIN ASPART PROTAMINE (CRYSTALLINE), INSULIN DEGLUDEC, INSULIN GLARGINE, INSULIN HUMAN, INSULIN HUMAN INJECTION, ISOPHANE, INSULIN HUMAN, INSULIN LISPRO PROTAMINE SUSPENSION, INSULIN LISPRO, IPRAGLIFLOZIN L-PROLINE, IPRAGLIFLOZIN L-PROLINE;SITAGLIPTIN PHOSPHATE MONOHYDRATE, KALLIDINOGENASE, LEVOTHYROXINE SODIUM, LINAGLIPTIN, LIRAGLUTIDE, LIRAGLUTIDE, LIXISENATIDE, LIXISENATIDE, LUSEOGLIFLOZIN, MACROGOL, MECOBALAMIN, MELILOTUS OFFICINALIS EXTRACT, METFORMIN, MIGLITOL, MITIGLINIDE, NATEGLINIDE, , PIOGLITAZONE, PITAVASTATIN, QUETIAPINE FUMARATE, REMOGLIFLOZIN ETABONATE, REPAGLINIDE, ROSUVASTATIN, SAXAGLIPTIN, SEMAGLUTIDE, SITAGLIPTIN, SULTAMICILLIN, TELMISARTAN, THIOCTIC ACID, TIRZEPATIDE, TOFOGLIFLOZIN, TOLBUTAMIDE, VILDAGLIPTIN, VOGLIBOSE, the pharmaceutical acceptable salts thereof and combinations thereof. In one embodiment, the patient further receives a CYP3A4 inducer. The patient can receive the CYP3A4 inducer prior and / or during the treatment. In one embodiment, the patient further receives a weak CYP3A4 inducer. In one embodiment, the patient further receives a moderate CYP3A4 inducer. In one embodiment,the patient further receives a strong CYP3A4 inducer. In one embodiment, the patient further receives aCYP3A4 inducer of unspecified potency. Strong and moderate CYP3A4 inducers are drugs that decrease BHC231046 US14 -58- the AUC of sensitive (index) substrates of a given pathway where CYP3A4 is involved by ≥80 percentand ≥50 to <80 percent, respectively. Weak inducers decrease the AUC by ≥20 to <50 percent.The above definitions of strong and moderate CYP3A4 inducers come from FDA Guidance. SeeClinical Drug Interaction Studies – Cytochrome P450 Enzyme- and Transporter-Mediated DrugInteractions Guidance for Industry, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), January 2020, (https: / / www.fda.gov / Drugs / GuidanceComplianceRegulatoryInformation / Guidances / default.htm) accessed November 1, 2023 and incorporated herein by reference. Other sources may use a different classification system for strong and moderate inducers resulting in some agents being classified differently. Examples, but not limited to, strong CYP3A4 inducers can be carbamazepine, antiandrogens(enzalutamide, apalutamide), primidone, phenytoin (anticonvulsant), rifampin, rifampicin, rifapentine,rifabutin, alogliptin, pioglitazone, aprepitant, carbamazepine, clobazam, eleutherocococcus senticosus,hypericum perforatum, St John’s wort, enzalutamide, apalutamide, methformin, oxcarbazepine,prednisone, quercetin, avasimibe, fosphenytoin, ivosidenib, lumacaftor, and / or mitotane. In one embodiment, the strong CYP3A4 inducer and / or a combination that comprises at least one strong CYP3A4 inducer is selected from: -CARBAMAZEPINE- ELEUTHEROCOCCUS SENTICOSUS ROOT WITH RHIZOME;HYPERICUMPERFORATUM HERB -ENZALUTAMIDE- HYPERICUM PERFORATUM EXTRACT- PHENYTOIN- PHENYTOIN SODIUM- RIFAMPICIN- RIFAMPICIN SODIUMand mixtures thereof. In one embodiment thereof, the patient receives an amount of the compoundaccording to formula (I) of 5 to 80 mg. In one embodiment thereof, the patient receives an amount of thecompound according to formula (I) of 5 mg. In one embodiment thereof, the patient receives an amountof the compound according to formula (I) of 10 mg. In one embodiment thereof, the patient receives anamount of the compound according to formula (I) of 20 mg. In one embodiment thereof, the patientreceives an amount of the compound according to formula (I) of 30 mg. In one embodiment thereof, thepatient receives an amount of the compound according to formula (I) of 40 mg. In one embodiment thereof,the patient receives an amount of the compound according to formula (I) of 60 mg. In one embodimentthereof, the patient receives an amount of the compound according to formula (I) of 80 mg. The amountof the compound according to formula (I) in these embodiments can be adjusted based on the CYP3A4 inducer. The adjustment can be up-titration, down-titration, maintenance or interruption of the treatment with the compound according to formula (I). Multiple embodiments of dose adjustments are described in BHC231046 US14 -59- detail below. These can be applied based on the co-medication with a CYP3A4 inducer. These can also be applied based on the amount and / or type of the CYP3A4 inducer the patient receives.The terms “up-titration” and “down-titration” can be used as synonyms for „increasing“ and „decreasing“,respectively, in a method of treating comprising administering to a patient in need thereof a compound of formula (I).The terms “up-titration” and “down-titration” can be used as synonyms for „increasing“ and „decreasing“,respectively, in a method of preventing or treating heart failure of treating comprising administering to apatient in need thereof a compound of formula (I).The terms “up-titration” and “down-titration” can be used as synonyms for „increasing“ and „decreasing“,respectively, in a method of preventing or treating heart failure comprising administering to a patient inneed thereof a compound of formula (I).The terms “up-titration” and “down-titration” can be used as synonyms for „increasing“ and „decreasing“,respectively, in a method of preventing or treating heart failure comprising administering to a patient inneed thereof a compound of formula (I), wherein the heart failure is selected from symptomatic heartfailure, heart failure with improved ejection fraction (HFimpEF), heart failure with mid-range ejection fraction (HFmrEF), heart failure preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF), chronic heart failure (CHF), congestive heart failure, acute heart failure, chronic heart failure, worsening chronic heart failure (WCHF), hospitalization for heart failure. In one embodiment, the strong CYP3A4 inducer and / or a combination that comprises at least one strong CYP3A4 inducer is selected from: -CARBAMAZEPINE- PHENYTOIN SODIUMand mixtures thereof, wherein the patient receive an amount of the compound according to formula (I) of10 mg.In one embodiment, the strong CYP3A4 inducer and / or a combination that comprises at least one strong CYP3A4 inducer is selected from: -CARBAMAZEPINE- ENZALUTAMIDE- HYPERICUM PERFORATUM EXTRACT- PHENYTOIN- PHENYTOIN SODIUM- RIFAMPICINand mixtures thereof, wherein the patient receive an amount of the compound according to formula (I) of20 mg. BHC231046 US14 -60- In one embodiment, the strong CYP3A4 inducer and / or a combination that comprises at least one strong CYP3A4 inducer is selected from: -CARBAMAZEPINE- PHENYTOIN- RIFAMPICINand mixtures thereof, wherein the patient receive an amount of the compound according to formula (I) of40 mg.Examples, but not limited to, moderate CYP3A4 inducers can be upadacitinib, benzalkomium chloride,dexamethasons, phenylmercuric nitrate, dexamethasone, modafinil, nafcillin, asunaprevir, beclabuvir, daclatasvir, bosentan, cenobamate, dabrafenib, efavirenz, elagolix, etravirine, lersivirine, lesinurad, lopinavir, lorlatinib, metamizole (dipyrone), mitapivat, pexidartinib, phenobarbital, primidone, repotrectinib, rifabutin, semagacestat, sotorasib, talviraline, telotristat ethyl, thioridazine. In one embodiment, the moderate CYP3A4 inducer and / or a combination that comprises at least one moderate CYP3A4 inducer is selected from: -BENZALKONIUM CHLORIDE;DEXAMETHASONE;PHENYLMERCURIC NITRATE- BENZALKONIUM CHLORIDE;DEXAMETHASONE;RESORCINOL;TETRACAINEHYDROCHLORIDE -BENZETHONIUM CHLORIDE;CETYLPYRIDINIUMCHLORIDE;DEXAMETHASONE;HEXYLRESORCINOL -BORIC ACID;DEXAMETHASONE SODIUM PHOSPHATE;SODIUMBORATE;THIOMERSAL -CARMELLOSE;DEXAMETHASONE SODIUM METASULFOBENZOATE- CHLORAMPHENICOL;DEXAMETHASONE- CIPROFLOXACIN HYDROCHLORIDE;DEXAMETHASONE- CYANOCOBALAMIN;DEXAMETHASONE SODIUM PHOSPHATE;PYRIDOXINEHYDROCHLORIDE;THIAMINE HYDROCHLORIDE -DEXAMETHASONE- DEXAMETHASONE ACETATE- DEXAMETHASONE DIPROPIONATE- DEXAMETHASONE PHOSPHATE- DEXAMETHASONE PHOSPHATE;POLYMYXIN B SULFATE;TRIMETHOPRIM- DEXAMETHASONE PHOSPHATE;TOBRAMYCIN- DEXAMETHASONE SODIUM METASULFOBENZOATE- DEXAMETHASONE SODIUM PHOSPHATE- DEXAMETHASONE SODIUM PHOSPHATE;LEVOFLOXACIN HEMIHYDRATE- DEXAMETHASONE SODIUM PHOSPHATE;NEOMYCIN SULFATE- DEXAMETHASONE SODIUM PHOSPHATE;NEOMYCIN SULFATE;POLYMYXIN BSULFATE -DEXAMETHASONE SODIUM PHOSPHATE;NETILMICIN SULFATE- DEXAMETHASONE SODIUM PHOSPHATE;TOBRAMYCIN- DEXAMETHASONE SODIUM SUCCINATE- DEXAMETHASONE VALERATE- DEXAMETHASONE;FRAMYCETIN SULFATE;GRAMICIDIN BHC231046 US14 -61- -DEXAMETHASONE;GENTAMICIN- DEXAMETHASONE;MOXIFLOXACIN- DEXAMETHASONE;MOXIFLOXACIN HYDROCHLORIDE- DEXAMETHASONE;NEOMYCIN SULFATE;POLYMYXIN B SULFATE- DEXAMETHASONE;NEOMYCIN;POLYMYXIN B- DEXAMETHASONE;TOBRAMYCIN- MODAFINIL- NAFCILLINand mixtures thereof. In one embodiment thereof, the patient receives an amount of the compoundaccording to formula (I) of 5 to 80 mg. In one embodiment thereof, the patient receives an amount of thecompound according to formula (I) of 5 mg. In one embodiment thereof, the patient receives an amountof the compound according to formula (I) of 10 mg. In one embodiment thereof, the patient receives anamount of the compound according to formula (I) of 20 mg. In one embodiment thereof, the patientreceives an amount of the compound according to formula (I) of 30 mg. In one embodiment thereof, thepatient receives an amount of the compound according to formula (I) of 40 mg. In one embodimentthereof, the patient receives an amount of the compound according to formula (I) of 60 mg. In oneembodiment thereof, the patient receives an amount of the compound according to formula (I) of 80 mg.The amount of the compound according to formula (I) in these embodiments can be adjusted based on the CYP3A4 inducer. The adjustment can be up-titration, down-titration, maintenance or interruption of the treatment with the compound according to formula (I). Multiple embodiments of dose adjustments are described in detail below. These can be applied based on the co-medication with a CYP3A4 inducer. These can also be applied based on the amount and / or type of the CYP3A4 inducer the patient receives. In one embodiment, the moderate CYP3A4 inducer and / or a combination that comprises at least one moderate CYP3A4 inducer is selected from: -BENZALKONIUMCHLORIDE;DEXAMETHASONE;RESORCINOL;TETRACAINE HYDROCHLORIDE -DEXAMETHASONE- DEXAMETHASONE ACETATE- DEXAMETHASONE DIPROPIONATE- DEXAMETHASONE PHOSPHATE- DEXAMETHASONE SODIUM PHOSPHATE- DEXAMETHASONE SODIUM PHOSPHATE;NEOMYCINSULFATE -DEXAMETHASONE SODIUM PHOSPHATE;NETILMICINSULFATE -DEXAMETHASONE SODIUM PHOSPHATE;TOBRAMYCIN- DEXAMETHASONE;NEOMYCIN SULFATE;POLYMYXIN BSULFATE -DEXAMETHASONE;TOBRAMYCIN- MODAFINILand mixtures thereof, wherein the patient receive an amount of the compound according to formula (I) of10 mg. BHC231046 US14 -62- In one embodiment, the moderate CYP3A4 inducer and / or a combination that comprises at least one moderate CYP3A4 inducer is selected from: -BENZETHONIUM CHLORIDE;CETYLPYRIDINIUMCHLORIDE;DEXAMETHASONE;HEXYLRESORCINOL -CHLORAMPHENICOL;DEXAMETHASONE- CYANOCOBALAMIN;DEXAMETHASONE SODIUMPHOSPHATE;PYRIDOXINE HYDROCHLORIDE;THIAMINE HYDROCHLORIDE -DEXAMETHASONE- DEXAMETHASONE ACETATE- DEXAMETHASONE DIPROPIONATE- DEXAMETHASONE PHOSPHATE- DEXAMETHASONE PHOSPHATE;TOBRAMYCIN- DEXAMETHASONE SODIUM PHOSPHATE- DEXAMETHASONE SODIUM PHOSPHATE;NEOMYCINSULFATE -DEXAMETHASONE SODIUM PHOSPHATE;NEOMYCINSULFATE;POLYMYXIN B SULFATE -DEXAMETHASONE SODIUM PHOSPHATE;NETILMICINSULFATE -DEXAMETHASONE SODIUM SUCCINATE- DEXAMETHASONE VALERATE- DEXAMETHASONE;FRAMYCETINSULFATE;GRAMICIDIN -DEXAMETHASONE;GENTAMICIN- DEXAMETHASONE;MOXIFLOXACIN- DEXAMETHASONE;MOXIFLOXACIN HYDROCHLORIDE- DEXAMETHASONE;NEOMYCIN SULFATE;POLYMYXINB SULFATE -DEXAMETHASONE;NEOMYCIN;POLYMYXIN B- DEXAMETHASONE;TOBRAMYCIN- MODAFINILand mixtures thereof, wherein the patient receive an amount of the compound according to formula (I) of20 mg.In one embodiment, the moderate CYP3A4 inducer and / or a combination that comprises at least one moderate CYP3A4 inducer is selected from: -BENZALKONIUM CHLORIDE;DEXAMETHASONE;PHENYLMERCURIC NITRATE- CARMELLOSE;DEXAMETHASONE SODIUM METASULFOBENZOATE- CIPROFLOXACIN HYDROCHLORIDE;DEXAMETHASONE- DEXAMETHASONE- DEXAMETHASONE ACETATE- DEXAMETHASONE DIPROPIONATE- DEXAMETHASONE PHOSPHATE- DEXAMETHASONE PHOSPHATE;POLYMYXIN B SULFATE;TRIMETHOPRIM- DEXAMETHASONE SODIUM METASULFOBENZOATE- DEXAMETHASONE SODIUM PHOSPHATE BHC231046 US14 -63- -DEXAMETHASONE SODIUM PHOSPHATE;NEOMYCIN SULFATE- DEXAMETHASONE VALERATE- DEXAMETHASONE;FRAMYCETIN SULFATE;GRAMICIDIN- DEXAMETHASONE;MOXIFLOXACIN HYDROCHLORIDE- DEXAMETHASONE;NEOMYCIN SULFATE;POLYMYXIN B SULFATE- DEXAMETHASONE;TOBRAMYCINand mixtures thereof, wherein the patient receive an amount of the compound according to formula (I) of40 mg.In one embodiment, the moderate CYP3A4 inducer and / or a combination that comprises at least one moderate CYP3A4 inducer is selected from: -DEXAMETHASONE;TOBRAMYCINand mixtures thereof, wherein the patient receive an amount of the compound according to formula (I) of80 mg.Examples, but not limited to, CYP3A4 inducers of unspecified potency can be anticonvulsants, moodstabilizers (oxcarbazepine, topiramate), barbiturates (phenobarbital, butalbital), bactericidals (rifampicin,rifabutin), non-nucleoside reverse-transcriptase inhibitors (efavirenz, nevirapine), troglitazone(hypoglycemic), glucocorticoids (blood glucose increase, immunosuppressive), capsaicin, brigatinib,clobazam, dabrafenib, elagolix, eslicarbazepine, letermovir, lorlatinib, oritavancin, perampanel, and / ortelotristat. In one embodiment, the CYP3A4 inducer of unspecified potency and / or a combination that comprises at least one CYP3A4 inducer of unspecified potency is selected from: -AMOBARBITAL;CAFFEINE;CODEINE PHOSPHATE;OCTIBENZONIUMBROMIDE;PARACETAMOL -CLOTRIMAZOLE;HEXAMIDINE ISETIONATE;PREDNISOLONE ACETATE- CYPROTERONE- GINKGO BILOBA LEAF;LIGUSTRAZINE PHOSPHATE- LIGUSTRAZINE HYDROCHLORIDE- LIGUSTRAZINE HYDROCHLORIDE;SALVIA MILTIORRHIZA- LIGUSTRAZINE HYDROCHLORIDE;SALVIA MILTIORRHIZA ROOT WITHRHIZOME -LIGUSTRAZINE PHOSPHATE- PHENYLBUTAZONE;PREDNISOLONE- PREDNISOLONE- PREDNISOLONE ACETATE- PREDNISOLONE ACETATE;SULFACETAMIDE SODIUM- PREDNISOLONE PHOSPHATE- PREDNISOLONE SODIUM PHOSPHATE- PREDNISOLONE SODIUM SUCCINATE- PREDNISOLONE STEAGLATE BHC231046 US14 -64- -PREDNISOLONE VALEROACETATE- PREDNISOLONE;TETRYZOLINE HYDROCHLORIDE- RELUGOLIX- RIFAMYCIN SODIUMand mixtures thereof. In one embodiment thereof, the patient receives an amount of the compoundaccording to formula (I) of 5 to 80 mg. In one embodiment thereof, the patient receives an amount of thecompound according to formula (I) of 5 mg. In one embodiment thereof, the patient receives an amountof the compound according to formula (I) of 10 mg. In one embodiment thereof, the patient receives anamount of the compound according to formula (I) of 20 mg. In one embodiment thereof, the patientreceives an amount of the compound according to formula (I) of 30 mg. In one embodiment thereof, thepatient receives an amount of the compound according to formula (I) of 40 mg. In one embodiment thereof,the patient receives an amount of the compound according to formula (I) of 60 mg. In one embodimentthereof, the patient receives an amount of the compound according to formula (I) of 80 mg. The amountof the compound according to formula (I) in these embodiments can be adjusted based on the CYP3A4 inducer. The adjustment can be up-titration, down-titration, maintenance or interruption of the treatment with the compound according to formula (I). Multiple embodiments of dose adjustments are described indetail below. These can be applied based on the co-medication with a CYP3A4 inducer. These can alsobe applied based on the amount and / or type of the CYP3A4 inducer the patient receives. In one embodiment, the CYP3A4 inducer of unspecified potency and / or a combination that comprises at least one CYP3A4 inducer of unspecified potency is selected from: -LIGUSTRAZINE HYDROCHLORIDE;SALVIAMILTIORRHIZA -LIGUSTRAZINE HYDROCHLORIDE;SALVIAMILTIORRHIZA ROOT WITH RHIZOME -PREDNISOLONE- PREDNISOLONE ACETATE- PREDNISOLONE SODIUM PHOSPHATE- PREDNISOLONE SODIUM SUCCINATE- PREDNISOLONE VALEROACETATE- PREDNISOLONE;TETRYZOLINE HYDROCHLORIDEand mixtures thereof, wherein the patient receive an amount of the compound according to formula (I) of10 mg.In one embodiment, the CYP3A4 inducer of unspecified potency and / or a combination that comprises at least one CYP3A4 inducer of unspecified potency is selected from: -CYPROTERONE- PHENYLBUTAZONE;PREDNISOLONE- PREDNISOLONE- PREDNISOLONE ACETATE BHC231046 US14 -65- -PREDNISOLONE SODIUM PHOSPHATE- PREDNISOLONE VALEROACETATE- PREDNISOLONE;TETRYZOLINE HYDROCHLORIDEand mixtures thereof, wherein the patient receive an amount of the compound according to formula (I) of20 mg.In one embodiment, the CYP3A4 inducer of unspecified potency and / or a combination that comprises at least one CYP3A4 inducer of unspecified potency is selected from: -CYPROTERONE- LIGUSTRAZINE HYDROCHLORIDE- LIGUSTRAZINE HYDROCHLORIDE;SALVIA MILTIORRHIZA ROOT WITH RHIZOME- LIGUSTRAZINE PHOSPHATE- PREDNISOLONE- PREDNISOLONE ACETATE- PREDNISOLONE SODIUM PHOSPHATE- PREDNISOLONE STEAGLATE- PREDNISOLONE VALEROACETATEand mixtures thereof, wherein the patient receive an amount of the compound according to formula (I) of40 mg.Examples, but not limited to, weak CYP3A4 inducers can be alogliptin, pioglitazone, aprepitant, clobazam, metformin, oxcabazepine, prednisone, quercetin. In one embodiment, the weak CYP3A4 inducer and / or a combination that comprises at least one weak CYP3A4 inducer is selected from: -ALOGLIPTIN BENZOATE;PIOGLITAZONE HYDROCHLORIDE- APREPITANT- CLOBAZAM- METFORMIN HYDROCHLORIDE;PIOGLITAZONE HYDROCHLORIDE- METFORMIN;PIOGLITAZONE- OXCARBAZEPINE- PIOGLITAZONE- PIOGLITAZONE HYDROCHLORIDE- PREDNISONE- PREDNISONE ACETATE- QUERCETINand mixtures thereof. In one embodiment thereof, the patient receives an amount of the compound BHC231046 US14 -66-according to formula (I) of 5 to 80 mg. In one embodiment thereof, the patient receives an amount of thecompound according to formula (I) of 5 mg. In one embodiment thereof, the patient receives an amountof the compound according to formula (I) of 10 mg. In one embodiment thereof, the patient receives anamount of the compound according to formula (I) of 20 mg. In one embodiment thereof, the patientreceives an amount of the compound according to formula (I) of 30 mg. In one embodiment thereof, thepatient receives an amount of the compound according to formula (I) of 40 mg. In one embodiment thereof,the patient receives an amount of the compound according to formula (I) of 60 mg. In one embodimentthereof, the patient receives an amount of the compound according to formula (I) of 80 mg. The amountof the compound according to formula (I) in these embodiments can be adjusted based on the CYP3A4 inducer. The adjustment can be up-titration, down-titration, maintenance or interruption of the treatment with the compound according to formula (I). Multiple embodiments of dose adjustments are described in detail below. These can be applied based on the co-medication with a CYP3A4 inducer. These can also be applied based on the amount and / or type of the CYP3A4 inducer the patient receives. In one embodiment, the weak CYP3A4 inducer and / or a combination that comprises at least one weak CYP3A4 inducer is selected from: -PREDNISONEwherein the patient receive an amount of the compound according to formula (I) of 5 mg.In one embodiment, the weak CYP3A4 inducer and / or a combination that comprises at least one weak CYP3A4 inducer is selected from: -ALOGLIPTIN BENZOATE;PIOGLITAZONE HYDROCHLORIDE- METFORMIN HYDROCHLORIDE;PIOGLITAZONE HYDROCHLORIDE- OXCARBAZEPINE- PIOGLITAZONE- PIOGLITAZONE HYDROCHLORIDE- PREDNISONE- PREDNISONE ACETATE- QUERCETINand mixtures thereof, wherein the patient receive an amount of the compound according to formula (I) of10 mg.In one embodiment, the weak CYP3A4 inducer and / or a combination that comprises at least one weak CYP3A4 inducer is selected from: -ALOGLIPTIN BENZOATE;PIOGLITAZONE HYDROCHLORIDE- APREPITANT- CLOBAZAM BHC231046 US14 -67- -METFORMIN HYDROCHLORIDE;PIOGLITAZONE HYDROCHLORIDE- OXCARBAZEPINE- PIOGLITAZONE- PIOGLITAZONE HYDROCHLORIDE- PREDNISONE- PREDNISONE ACETATE- QUERCETINand mixtures thereof, wherein the patient receive an amount of the compound according to formula (I) of20 mg.In one embodiment, the weak CYP3A4 inducer and / or a combination that comprises at least one weak CYP3A4 inducer is selected from: -METFORMIN HYDROCHLORIDE;PIOGLITAZONE HYDROCHLORIDE- METFORMIN;PIOGLITAZONE- OXCARBAZEPINE- PIOGLITAZONE- PIOGLITAZONE HYDROCHLORIDE- PREDNISONE- PREDNISONE ACETATE- QUERCETINand mixtures thereof, wherein the patient receive an amount of the compound according to formula (I) of40 mg.In one embodiment, the patient further receives a CYP3A4 inhibitor. The patient can receive the CYP3A4 inhibitor prior and / or during the treatment. In one embodiment, the patient further receives a weak CYP3A4 inhibitor. In one embodiment, the patient further receives a moderate CYP3A4 inhibitor. In oneembodiment, the patient further receives a strong CYP3A4 inhibitor. Inhibitors of CYP3A4 are classifiedby potency. A strong inhibitor causes at least a 5-fold increase in the plasma AUC values, or equal to orcorresponding to more than 80% decrease in clearance, of CYP3A4 sensitive (index) substrate of a givenmetabolic pathway. A moderate inhibitor causes at least a 2-fold but less than 5-fold increase in the plasmaAUC values of sensitive index substrates of a given metabolic pathway or corresponding to 50–80%decrease in clearance. A weak inhibitor causes at least a 1.25-fold but less than 2-fold increase in theplasma AUC values or corresponding to 20–50% decrease in clearance.The above definitions of strong and moderate CYP3A4 inhibitors come from FDA Guidance. See ClinicalDrug Interaction Studies – Cytochrome P450 Enzyme- and Transporter-Mediated Drug InteractionsGuidance for Industry, U.S. Department of Health and Human Services, Food and Drug Administration, BHC231046 US14 -68- Center for Drug Evaluation and Research (CDER), January 2020, (https: / / www.fda.gov / Drugs / GuidanceComplianceRegulatoryInformation / Guidances / default.htm)accessed January 04, 2024 and incorporated herein by reference. Other sources may use a differentclassification system for strong and moderate inducers resulting in some agents being classified differently. Examples, but not limited to, strong CYP3A4 inhibitors can be boceprevir, protease inhibitors (ritonavir [and combination drugs thereof], indinavir, nelfinavir, saquinavir, amprenavir, atazanavir, darunavir), cobicistat, clarithromycin, telithromycin, nefazodone, ceritinib, mibefradil, ribociclib, tucatinib, chloramphenicol (antibiotic), some azole antifungals (ketoconazole, itraconazole, posaconazole, voriconazole), green tea extract, grape seed extract, dillapiole, apigenin, Artemisia annua, aluminium chlorhydrate, micoconazol, hydrocortisone, josamycin, mazipredone, nirmatrelvir, , adagrasib, conivaptan, delavirdine, ensitrelvir, grapefruit, idelalisib, indinavir, levoketoconazole, lonafarnib,lopinavir, mifepristone, nelfinavir, saquinavir, telaprevir, tipranavir, and / or troleandomycin.In one embodiment, the strong CYP3A4 inhibitor and / or a combination that comprises at least one strong CYP3A4 inhibitor is selected from: -ALUMINIUM CHLOROHYDRATE;MICONAZOLE- CLARITHROMYCIN- CLARITHROMYCIN LACTOBIONATE- HYDROCORTISONE;MICONAZOLE- HYDROCORTISONE;MICONAZOLE NITRATE- ITRACONAZOLE- JOSAMYCIN- KETOCONAZOLE- MAZIPREDONE HYDROCHLORIDE;MICONAZOLE NITRATE- MICONAZOLE- MICONAZOLE NITRATE- NIRMATRELVIR;RITONAVIR- RITONAVIR- VORICONAZOLEand mixtures thereof. In one embodiment thereof, the patient receives an amount of the compoundaccording to formula (I) of 0.5 to 80 mg. In one embodiment thereof, the patient receives an amount ofthe compound according to formula (I) of 0.5 mg. In one embodiment thereof, the patient receives anamount of the compound according to formula (I) of 1.25 mg. In one embodiment thereof, the patientreceives an amount of the compound according to formula (I) of 2.5 mg. In one embodiment thereof, thepatient receives an amount of the compound according to formula (I) of 5 mg. In one embodiment thereof,the patient receives an amount of the compound according to formula (I) of 10 mg. In one embodimentthereof, the patient receives an amount of the compound according to formula (I) of 20 mg. In oneembodiment thereof, the patient receives an amount of the compound according to formula (I) of 30 mg.In one embodiment thereof, the patient receives an amount of the compound according to formula (I) of BHC231046 US14 -69-40 mg. In one embodiment thereof, the patient receives an amount of the compound according to formula(I) of 60 mg. In one embodiment thereof, the patient receives an amount of the compound according toformula (I) of 80 mg. The amount of the compound according to formula (I) in these embodiments can beadjusted based on the CYP3A4 inhibitor. The adjustment can be up-titration, down-titration, maintenanceor interruption of the treatment with the compound according to formula (I). Multiple embodiments of dose adjustments are described in detail below. These can be applied based on the co-medication with aCYP3A4 inhibitor. These can also be applied based on the amount and / or type of the CYP3A4 inhibitorthe patient receives. In one embodiment, the strong CYP3A4 inhibitor and / or a combination that comprises at least one strong CYP3A4 inhibitor is selected from: -ALUMINIUM CHLOROHYDRATE;MICONAZOLE- CLARITHROMYCIN- ITRACONAZOLE- KETOCONAZOLE- MICONAZOLE NITRATE- RITONAVIR- VORICONAZOLEand mixtures thereof, wherein the patient receive an amount of the compound according to formula (I) of10 mg.In one embodiment, the strong CYP3A4 inhibitor and / or a combination that comprises at least one strong CYP3A4 inhibitor is selected from: -ALUMINIUM CHLOROHYDRATE;MICONAZOLE- CLARITHROMYCIN- CLARITHROMYCIN LACTOBIONATE- HYDROCORTISONE;MICONAZOLE- HYDROCORTISONE;MICONAZOLE NITRATE- ITRACONAZOLE- KETOCONAZOLE- MAZIPREDONE HYDROCHLORIDE;MICONAZOLENITRATE -MICONAZOLE- MICONAZOLE NITRATE- NIRMATRELVIR;RITONAVIR- RITONAVIRand mixtures thereof, wherein the patient receive an amount of the compound according to formula (I) of20 mg.In one embodiment, the strong CYP3A4 inhibitor and / or a combination that comprises at least one strong CYP3A4 inhibitor is selected from: BHC231046 US14 -70- -CLARITHROMYCIN- HYDROCORTISONE;MICONAZOLE- HYDROCORTISONE;MICONAZOLE NITRATE- ITRACONAZOLE- KETOCONAZOLE- MICONAZOLE- NIRMATRELVIR;RITONAVIR- RITONAVIR- VORICONAZOLEand mixtures thereof, wherein the patient receive an amount of the compound according to formula (I) of40 mg.Examples, but not limited to, moderate CYP3A4 inhibitors can be aprepitant, ciprofloxacin, conivaptan,crizotinib, rutin, tofisopam, some calcium channel blockers (verapamil, diltiazem), some azole antifungals(fluconazole, miconazole), bergamottin, cyclosporine, donedarone, fluvoxamine, imatinib, valerian,and / or erythromycin. In one embodiment, the moderate CYP3A4 inhibitor and / or a combination that comprises at least one moderate CYP3A4 inhibitor is selected from: -APREPITANT- ATAZANAVIR- ATAZANAVIR SULFATE- BETAMETHASONE DIPROPIONATE;CLOTRIMAZOLE- BETAMETHASONE DIPROPIONATE;CLOTRIMAZOLE;GENTAMICIN SULFATE- BETAMETHASONE DIPROPIONATE;CLOTRIMAZOLE;NEOMYCIN SULFATE- BETAMETHASONE;CHLORAMPHENICOL- BETAMETHASONE;CLOTRIMAZOLE- CHLORAMPHENICOL- CHLORAMPHENICOL PALMITATE- CHLORAMPHENICOL;COLLAGENASE- CHLORAMPHENICOL;DEXAMETHASONE- CHLORAMPHENICOL;METHYLURACIL- CICLOSPORIN- CIMETIDINE- CIPROFLOXACIN- CIPROFLOXACIN HYDROCHLORIDE- CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE- CIPROFLOXACIN HYDROCHLORIDE;DEXAMETHASONE- CIPROFLOXACIN HYDROCHLORIDE;FLUOCINOLONE ACETONIDE- CIPROFLOXACIN HYDROCHLORIDE;TINIDAZOLE- CIPROFLOXACIN LACTATE- CIPROFLOXACIN;FLUOCINOLONE ACETONIDE- CLOTRIMAZOLE BHC231046 US14 -71- -CLOTRIMAZOLE;HEXAMIDINE ISETIONATE;PREDNISOLONE ACETATE- CLOTRIMAZOLE;HYDROCORTISONE- CLOTRIMAZOLE;HYDROCORTISONE;ZINC OXIDE- COLISTIMETHATE SODIUM;ERYTHROMYCIN LACTOBIONATE- COLISTIN;ERYTHROMYCIN LACTOBIONATE- DILTIAZEM- DILTIAZEM HYDROCHLORIDE- DRONEDARONE- DRONEDARONE HYDROCHLORIDE- ERYTHROMYCIN- ERYTHROMYCIN ETHYLSUCCINATE- ERYTHROMYCIN LACTOBIONATE- ERYTHROMYCIN PROPIONATE- FLUCONAZOLE- FLUVOXAMINE- IMATINIB MESILATE- TOFISOPAM- TRANDOLAPRIL;VERAPAMIL HYDROCHLORIDE- VERAPAMIL- VERAPAMIL HYDROCHLORIDEand mixtures thereof. In one embodiment thereof, the patient receives an amount of the compoundaccording to formula (I) of 5 to 80 mg. In one embodiment thereof, the patient receives an amount of thecompound according to formula (I) of 5 mg. In one embodiment thereof, the patient receives an amountof the compound according to formula (I) of 10 mg. In one embodiment thereof, the patient receives anamount of the compound according to formula (I) of 20 mg. In one embodiment thereof, the patientreceives an amount of the compound according to formula (I) of 30 mg. In one embodiment thereof, thepatient receives an amount of the compound according to formula (I) of 40 mg. In one embodimentthereof, the patient receives an amount of the compound according to formula (I) of 60 mg. In oneembodiment thereof, the patient receives an amount of the compound according to formula (I) of 80 mg.The amount of the compound according to formula (I) in these embodiments can be adjusted based on the CYP3A4 inhibitor. The adjustment can be up-titration, down-titration, maintenance or interruption of the treatment with the compound according to formula (I). Multiple embodiments of dose adjustmentsare described in detail below. These can be applied based on the co-medication with a CYP3A4 inhibitor.These can also be applied based on the amount and / or type of the CYP3A4 inhibitor the patient receives. In one embodiment, the moderate CYP3A4 inhibitor and / or a combination that comprises at least one moderate CYP3A4 inhibitor is selected from: -BETAMETHASONE;CHLORAMPHENICOL- BETAMETHASONE;CLOTRIMAZOLE- CHLORAMPHENICOL- CICLOSPORIN BHC231046 US14 -72- -CIMETIDINE- CIPROFLOXACIN- CIPROFLOXACIN HYDROCHLORIDE- CLOTRIMAZOLE- DILTIAZEM- DILTIAZEM HYDROCHLORIDE- DRONEDARONE- DRONEDARONE HYDROCHLORIDE- ERYTHROMYCIN- ERYTHROMYCIN PROPIONATE- FLUCONAZOLE- FLUVOXAMINE- TOFISOPAM- TRANDOLAPRIL;VERAPAMIL HYDROCHLORIDE- VERAPAMIL- VERAPAMIL HYDROCHLORIDEand mixtures thereof, wherein the patient receive an amount of the compound according to formula (I) of10 mg.In one embodiment, the moderate CYP3A4 inhibitor and / or a combination that comprises at least one moderate CYP3A4 inhibitor is selected from: -APREPITANT- BETAMETHASONE DIPROPIONATE;CLOTRIMAZOLE- BETAMETHASONE DIPROPIONATE;CLOTRIMAZOLE;NEOMYCIN SULFATE- BETAMETHASONE;CLOTRIMAZOLE- CHLORAMPHENICOL- CHLORAMPHENICOL PALMITATE- CHLORAMPHENICOL;COLLAGENASE- CHLORAMPHENICOL;DEXAMETHASONE- CICLOSPORIN- CIMETIDINE- CIPROFLOXACIN- CIPROFLOXACIN HYDROCHLORIDE- CIPROFLOXACIN HYDROCHLORIDE;FLUOCINOLONE ACETONIDE- CIPROFLOXACIN HYDROCHLORIDE;TINIDAZOLE- CIPROFLOXACIN LACTATE BHC231046 US14 -73- -CIPROFLOXACIN;FLUOCINOLONE ACETONIDE- CLOTRIMAZOLE- COLISTIMETHATE SODIUM;ERYTHROMYCIN LACTOBIONATE- COLISTIN;ERYTHROMYCIN LACTOBIONATE- DILTIAZEM- DILTIAZEM HYDROCHLORIDE- DRONEDARONE HYDROCHLORIDE- ERYTHROMYCIN- ERYTHROMYCIN ETHYLSUCCINATE- FLUCONAZOLE- FLUVOXAMINE- IMATINIB MESILATE- TOFISOPAM- VERAPAMIL- VERAPAMIL HYDROCHLORIDEand mixtures thereof, wherein the patient receive an amount of the compound according to formula (I) of20 mg.In one embodiment, the moderate CYP3A4 inhibitor and / or a combination that comprises at least one moderate CYP3A4 inhibitor is selected from: -BETAMETHASONE DIPROPIONATE;CLOTRIMAZOLE- BETAMETHASONE DIPROPIONATE;CLOTRIMAZOLE;NEOMYCIN SULFATE- CHLORAMPHENICOL- CHLORAMPHENICOL;COLLAGENASE- CHLORAMPHENICOL;METHYLURACIL- CICLOSPORIN- CIPROFLOXACIN- CIPROFLOXACIN HYDROCHLORIDE- CIPROFLOXACIN HYDROCHLORIDE MONOHYDRATE- CIPROFLOXACIN HYDROCHLORIDE;DEXAMETHASONE- CIPROFLOXACIN HYDROCHLORIDE;FLUOCINOLONE ACETONIDE- CIPROFLOXACIN LACTATE- CLOTRIMAZOLE- CLOTRIMAZOLE;HYDROCORTISONE- COLISTIMETHATE SODIUM;ERYTHROMYCIN LACTOBIONATE- COLISTIN;ERYTHROMYCIN LACTOBIONATE BHC231046 US14 -74- -DILTIAZEM- DILTIAZEM HYDROCHLORIDE- DRONEDARONE HYDROCHLORIDE- ERYTHROMYCIN- FLUCONAZOLE- VERAPAMIL- VERAPAMIL HYDROCHLORIDEand mixtures thereof, wherein the patient receive an amount of the compound according to formula (I) of40 mg.Examples, but not limited to, weak CYP3A4 inhibitors can be berberine, buprenorphine, cafestol, cilostazol, cimetidine, fosaprepitant, lomitapide, orphenadrine, omeprazole, quercetin, ranitidine, ranolazine, tacrolimus, ticagrelor, valproic acid, amlodipine, azithromycin, cimetidine, fluvoxamine, and / or amiodarone. In one embodiment, the weak CYP3A4 inhibitor and / or a combination that comprises at least one weak CYP3A4 inhibitor is selected from: -ACETYLSALICYLIC ACID;ATORVASTATIN- ACETYLSALICYLIC ACID;ATORVASTATIN CALCIUM- ACETYLSALICYLIC ACID;ATORVASTATIN CALCIUM;CLOPIDOGREL BISULFATE- ACETYLSALICYLIC ACID;ATORVASTATIN CALCIUM;RAMIPRIL- ALLIUM SATIVUM BULB;BLUMEA BALSAMIFERA LEAF;CRATAEGUSPINNATIFIDA FRUIT;ERIGERON BREVISCAPUS WHOLE PLANT;GINKGO BILOBA LEAF;GYNOSTEMMA PENTAPHYLLUM HERB;PANAX NOTOGINSENG ROOT WITH RHIZOME;SALVIA MILTIORRHIZA ROOT WITH RHIZOME -ALLIUM SPP. BULB;BUXUS SPP. LEAF WITH TWIG;CINNAMOMUM MIGAOFRUIT;GINKGO BILOBA LEAF;SALVIA MILTIORRHIZA ROOT WITH RHIZOME -ALPRAZOLAM- AMBROXOL HYDROCHLORIDE;ROXITHROMYCIN- AMIODARONE- AMIODARONE HYDROCHLORIDE- AMLODIPINE- AMLODIPINE BENZOATE- AMLODIPINE BESILATE- AMLODIPINE BESILATE;ATORVASTATIN CALCIUM- AMLODIPINE BESILATE;ATORVASTATIN CALCIUM TRIHYDRATE;PERINDOPRILARGININE -AMLODIPINE BESILATE;ATORVASTATIN CALCIUM;PERINDOPRIL ARGININE- AMLODIPINE BESILATE;ATORVASTATIN L-LYSINE- AMLODIPINE BESILATE;AZILSARTAN- AMLODIPINE BESILATE;BENAZEPRIL HYDROCHLORIDE- AMLODIPINE BESILATE;BISOPROLOL FUMARATE- AMLODIPINE BESILATE;CANDESARTAN CILEXETIL BHC231046 US14 -75-- AMLODIPINE BESILATE;HYDROCHLOROTHIAZIDE;OLMESARTAN MEDOXOMIL- AMLODIPINE BESILATE;HYDROCHLOROTHIAZIDE;VALSARTAN- AMLODIPINE BESILATE;INDAPAMIDE- AMLODIPINE BESILATE;INDAPAMIDE;PERINDOPRIL ARGININE- AMLODIPINE BESILATE;INDAPAMIDE;PERINDOPRIL ERBUMINE- AMLODIPINE BESILATE;IRBESARTAN- AMLODIPINE BESILATE;LISINOPRIL- AMLODIPINE BESILATE;LISINOPRIL DIHYDRATE- AMLODIPINE BESILATE;LOSARTAN POTASSIUM- AMLODIPINE BESILATE;OLMESARTAN MEDOXOMIL- AMLODIPINE BESILATE;PERINDOPRIL ARGININE- AMLODIPINE BESILATE;PERINDOPRIL ERBUMINE- AMLODIPINE BESILATE;PERINDOPRIL TOSILATE- AMLODIPINE BESILATE;RAMIPRIL- AMLODIPINE BESILATE;ROSUVASTATIN CALCIUM;TELMISARTAN- AMLODIPINE BESILATE;TELMISARTAN- AMLODIPINE BESILATE;VALSARTAN- AMLODIPINE CAMSILATE- AMLODIPINE MALEATE- AMLODIPINE MESILATE- AMLODIPINE;ATORVASTATIN CALCIUM- AMLODIPINE;BENAZEPRIL HYDROCHLORIDE- AMLODIPINE;HYDROCHLOROTHIAZIDE;OLMESARTAN- AMLODIPINE;HYDROCHLOROTHIAZIDE;VALSARTAN- AMLODIPINE;INDAPAMIDE- AMLODIPINE;PERINDOPRIL- AMLODIPINE;RAMIPRIL- AMLODIPINE;VALSARTAN- ASTAXANTHIN;BERBERINE;FOLIC ACID;MONASCUSPURPUREUS;POLICOSANOL;UBIDECARENONE- ATORVASTATIN- ATORVASTATIN CALCIUM- ATORVASTATIN CALCIUM TRIHYDRATE- ATORVASTATIN CALCIUM TRIHYDRATE;EZETIMIBE- ATORVASTATIN CALCIUM;EZETIMIBE- ATORVASTATIN CALCIUM;PERINDOPRIL ARGININE- ATORVASTATIN;EZETIMIBE- BACOPA MONNIERI;CITICOLINE SODIUM;GINKGO BILOBA;PHOSPHATIDYLSERINE;SALVIA OFFICINALIS;THIOCTIC ACID- BERBERINE- BERBERINE CHLORIDE HYDRATE- BERBERINE HYDROCHLORIDE- BERBERINE HYDROCHLORIDE;DOLOMIAEA COSTUS ROOT;TETRADIUMRUTICARPUM FRUIT- BERBERINE HYDROCHLORIDE;RHEUM SPP. ROOT WITH RHIZOME;SCUTELLARIABAICALENSIS ROOT- BERBERINE;CINNAMOMUM VERUM;GYMNEMA SYLVESTRE;LAGERSTROEMIASPECIOSA;PICRASMA EXCELSA;SYZYGIUM CUMINI;URTICA DIOICA;VACCINIUM MYRTILLUS- BICALUTAMIDE BHC231046 US14 -76- -BORNEOL;GINKGO BILOBA LEAF;GYNOSTEMMA PENTAPHYLLUM WHOLEPLANT;SALVIA YUNNANENSIS ROOT -CAFFEINE;CHLORZOXAZONE;PARACETAMOL;THIAMINE- CHLORZOXAZONE- CHLORZOXAZONE;PARACETAMOL- CHOLINE;GINKGO BILOBA LEAF- CILOSTAZOL- CYANOCOBALAMIN;FISH OIL;FOLIC ACID;GINKGO BILOBA LEAF;PHOSPHATIDYLSERINE;TOCOPHEROL -DIPYRIDAMOLE;GINKGO BILOBA LEAF EXTRACT- ELEUTHEROCOCCUS SENTICOSUS;EUPHRASIA OFFICINALIS;GINKGOBILOBA;VACCINIUM MYRTILLUS -EVEROLIMUS- FLUOXETINE- FLUOXETINE HYDROCHLORIDE- GINKGO BILOBA- GINKGO BILOBA EXTRACT- GINKGO BILOBA LEAF- GINKGO BILOBA LEAF EXTRACT- GINKGO BILOBA LEAF;LIGUSTRAZINE PHOSPHATE- GINKGO BILOBA;GLUCOSAMINE- ISONIAZID- LEVAMLODIPINE- LEVAMLODIPINE BESILATE- LEVAMLODIPINE MALEATE- PROPIVERINE- PROPIVERINE HYDROCHLORIDE- RANITIDINE- RANITIDINE HYDROCHLORIDE- RANITIDINE HYDROCHLORIDE;SUCRALFATE;TRIPOTASSIUMDICITRATOBISMUTHATE -RANOLAZINE- ROXITHROMYCIN- TACROLIMUS- TACROLIMUS MONOHYDRATE- TICAGRELOR- TOLVAPTAN- TOLVAPTAN DISODIUM PHOSPHATEand mixtures thereof. In one embodiment thereof, the patient receives an amount of the compoundaccording to formula (I) of 5 to 80 mg. In one embodiment thereof, the patient receives an amount of thecompound according to formula (I) of 5 mg. In one embodiment thereof, the patient receives an amountof the compound according to formula (I) of 10 mg. In one embodiment thereof, the patient receives anamount of the compound according to formula (I) of 20 mg. In one embodiment thereof, the patientreceives an amount of the compound according to formula (I) of 30 mg. In one embodiment thereof, thepatient receives an amount of the compound according to formula (I) of 40 mg. In one embodiment thereof,the patient receives an amount of the compound according to formula (I) of 60 mg. In one embodiment BHC231046 US14 -77-thereof, the patient receives an amount of the compound according to formula (I) of 80 mg. The amountof the compound according to formula (I) in these embodiments can be adjusted based on the CYP3A4 inhibitor. The adjustment can be up-titration, down-titration, maintenance or interruption of the treatment with the compound according to formula (I). Multiple embodiments of dose adjustments are described in detail below. These can be applied based on the co-medication with a CYP3A4 inhibitor. These can also be applied based on the amount and / or type of the CYP3A4 inhibitor the patient receives. In one embodiment, the weak CYP3A4 inhibitor and / or a combination that comprises at least one weak CYP3A4 inhibitor is selected from: -ATORVASTATINand mixtures thereof, wherein the patient receive an amount of the compound according to formula (I) of5 mg.In one embodiment, the weak CYP3A4 inhibitor and / or a combination that comprises at least one weak CYP3A4 inhibitor is selected from: -ACETYLSALICYLIC ACID;ATORVASTATIN- ACETYLSALICYLIC ACID;ATORVASTATIN CALCIUM;CLOPIDOGREL BISULFATE- ALPRAZOLAM- AMIODARONE- AMIODARONE HYDROCHLORIDE- AMLODIPINE- AMLODIPINE BESILATE- AMLODIPINE BESILATE;ATORVASTATIN CALCIUM- AMLODIPINE BESILATE;ATORVASTATIN CALCIUM TRIHYDRATE;PERINDOPRILARGININE -AMLODIPINE BESILATE;AZILSARTAN- AMLODIPINE BESILATE;BENAZEPRIL HYDROCHLORIDE- AMLODIPINE BESILATE;HYDROCHLOROTHIAZIDE;OLMESARTAN MEDOXOMIL- AMLODIPINE BESILATE;HYDROCHLOROTHIAZIDE;VALSARTAN- AMLODIPINE BESILATE;INDAPAMIDE- AMLODIPINE BESILATE;INDAPAMIDE;PERINDOPRIL ARGININE- AMLODIPINE BESILATE;INDAPAMIDE;PERINDOPRIL ERBUMINE- AMLODIPINE BESILATE;IRBESARTAN- AMLODIPINE BESILATE;LISINOPRIL BHC231046 US14 -78-- AMLODIPINE BESILATE;LISINOPRIL DIHYDRATE- AMLODIPINE BESILATE;LOSARTAN POTASSIUM- AMLODIPINE BESILATE;OLMESARTAN MEDOXOMIL- AMLODIPINE BESILATE;PERINDOPRIL ARGININE- AMLODIPINE BESILATE;PERINDOPRIL ERBUMINE- AMLODIPINE BESILATE;PERINDOPRIL TOSILATE- AMLODIPINE BESILATE;RAMIPRIL- AMLODIPINE BESILATE;ROSUVASTATIN CALCIUM;TELMISARTAN- AMLODIPINE BESILATE;TELMISARTAN- AMLODIPINE BESILATE;VALSARTAN- AMLODIPINE MALEATE- AMLODIPINE MESILATE- AMLODIPINE;ATORVASTATIN CALCIUM- AMLODIPINE;INDAPAMIDE- AMLODIPINE;VALSARTAN- ATORVASTATIN- ATORVASTATIN CALCIUM- ATORVASTATIN CALCIUM TRIHYDRATE- ATORVASTATIN CALCIUM TRIHYDRATE;EZETIMIBE- ATORVASTATIN CALCIUM;EZETIMIBE- ATORVASTATIN;EZETIMIBE- BERBERINE HYDROCHLORIDE;DOLOMIAEA COSTUS ROOT;TETRADIUMRUTICARPUM FRUIT- BICALUTAMIDE- BORNEOL;GINKGO BILOBA LEAF;GYNOSTEMMA PENTAPHYLLUM WHOLEPLANT;SALVIA YUNNANENSIS ROOT- CHLORZOXAZONE- CHLORZOXAZONE;PARACETAMOL- CILOSTAZOL- EVEROLIMUS- FLUOXETINE- FLUOXETINE HYDROCHLORIDE- GINKGO BILOBA- GINKGO BILOBA EXTRACT- GINKGO BILOBA LEAF EXTRACT- GINKGO BILOBA;GLUCOSAMINE- ISONIAZID BHC231046 US14 -79- -LEVAMLODIPINE- LEVAMLODIPINE BESILATE- LEVAMLODIPINE MALEATE- PROPIVERINE HYDROCHLORIDE- RANITIDINE- RANITIDINE HYDROCHLORIDE- RANOLAZINE- ROXITHROMYCIN- TACROLIMUS- TACROLIMUS MONOHYDRATE- TICAGRELOR- TOLVAPTAN- TOLVAPTAN DISODIUM PHOSPHATEand mixtures thereof, wherein the patient receive an amount of the compound according to formula (I) of10 mg.In one embodiment, the weak CYP3A4 inhibitor and / or a combination that comprises at least one weak CYP3A4 inhibitor is selected from: -ACETYLSALICYLIC ACID;ATORVASTATIN- ACETYLSALICYLIC ACID;ATORVASTATIN CALCIUM;CLOPIDOGREL BISULFATE- ACETYLSALICYLIC ACID;ATORVASTATIN CALCIUM;RAMIPRIL- ALPRAZOLAM- AMIODARONE- AMIODARONE HYDROCHLORIDE- AMLODIPINE- AMLODIPINE BENZOATE- AMLODIPINE BESILATE- AMLODIPINE BESILATE;ATORVASTATIN CALCIUM- AMLODIPINE BESILATE;ATORVASTATIN CALCIUM TRIHYDRATE;PERINDOPRILARGININE -AMLODIPINE BESILATE;ATORVASTATIN CALCIUM;PERINDOPRIL ARGININE- AMLODIPINE BESILATE;ATORVASTATIN L-LYSINE- AMLODIPINE BESILATE;BENAZEPRIL HYDROCHLORIDE- AMLODIPINE BESILATE;BISOPROLOL FUMARATE- AMLODIPINE BESILATE;HYDROCHLOROTHIAZIDE;OLMESARTAN MEDOXOMIL- AMLODIPINE BESILATE;HYDROCHLOROTHIAZIDE;VALSARTAN BHC231046 US14 -80-- AMLODIPINE BESILATE;INDAPAMIDE- AMLODIPINE BESILATE;INDAPAMIDE;PERINDOPRIL ARGININE- AMLODIPINE BESILATE;INDAPAMIDE;PERINDOPRIL ERBUMINE- AMLODIPINE BESILATE;IRBESARTAN- AMLODIPINE BESILATE;LISINOPRIL- AMLODIPINE BESILATE;LISINOPRIL DIHYDRATE- AMLODIPINE BESILATE;LOSARTAN POTASSIUM- AMLODIPINE BESILATE;OLMESARTAN MEDOXOMIL- AMLODIPINE BESILATE;PERINDOPRIL ARGININE- AMLODIPINE BESILATE;PERINDOPRIL ERBUMINE- AMLODIPINE BESILATE;PERINDOPRIL TOSILATE- AMLODIPINE BESILATE;RAMIPRIL- AMLODIPINE BESILATE;ROSUVASTATIN CALCIUM;TELMISARTAN- AMLODIPINE BESILATE;TELMISARTAN- AMLODIPINE BESILATE;VALSARTAN- AMLODIPINE CAMSILATE- AMLODIPINE MALEATE- AMLODIPINE MESILATE- AMLODIPINE;ATORVASTATIN CALCIUM- AMLODIPINE;HYDROCHLOROTHIAZIDE;OLMESARTAN- AMLODIPINE;HYDROCHLOROTHIAZIDE;VALSARTAN- AMLODIPINE;PERINDOPRIL- AMLODIPINE;VALSARTAN- ASTAXANTHIN;BERBERINE;FOLIC ACID;MONASCUSPURPUREUS;POLICOSANOL;UBIDECARENONE- ATORVASTATIN- ATORVASTATIN CALCIUM- ATORVASTATIN CALCIUM TRIHYDRATE- ATORVASTATIN CALCIUM TRIHYDRATE;EZETIMIBE- ATORVASTATIN CALCIUM;EZETIMIBE- ATORVASTATIN CALCIUM;PERINDOPRIL ARGININE- ATORVASTATIN;EZETIMIBE- BACOPA MONNIERI;CITICOLINE SODIUM;GINKGO BILOBA;PHOSPHATIDYLSERINE;SALVIA OFFICINALIS;THIOCTIC ACID- BERBERINE CHLORIDE HYDRATE- BERBERINE HYDROCHLORIDE- BERBERINE;CINNAMOMUM VERUM;GYMNEMA SYLVESTRE;LAGERSTROEMIA BHC231046 US14 -81- SPECIOSA;PICRASMA EXCELSA;SYZYGIUM CUMINI;URTICA DIOICA;VACCINIUM MYRTILLUS -BICALUTAMIDE- BORNEOL;GINKGO BILOBA LEAF;GYNOSTEMMA PENTAPHYLLUM WHOLEPLANT;SALVIA YUNNANENSIS ROOT -CAFFEINE;CHLORZOXAZONE;PARACETAMOL;THIAMINE- CHLORZOXAZONE- CHLORZOXAZONE;PARACETAMOL- CHOLINE;GINKGO BILOBA LEAF- CILOSTAZOL- ELEUTHEROCOCCUS SENTICOSUS;EUPHRASIA OFFICINALIS;GINKGOBILOBA;VACCINIUM MYRTILLUS -EVEROLIMUS- FLUOXETINE- FLUOXETINE HYDROCHLORIDE- GINKGO BILOBA- GINKGO BILOBA EXTRACT- GINKGO BILOBA LEAF- GINKGO BILOBA LEAF EXTRACT- GINKGO BILOBA;GLUCOSAMINE- ISONIAZID- LEVAMLODIPINE- LEVAMLODIPINE BESILATE- LEVAMLODIPINE MALEATE- PROPIVERINE HYDROCHLORIDE- RANITIDINE- RANITIDINE HYDROCHLORIDE- RANOLAZINE- ROXITHROMYCIN- TACROLIMUS- TACROLIMUS MONOHYDRATE- TICAGRELOR- TOLVAPTAN- TOLVAPTAN DISODIUM PHOSPHATEand mixtures thereof, wherein the patient receive an amount of the compound according to formula (I) of20 mg. BHC231046 US14 -82- In one embodiment, the weak CYP3A4 inhibitor and / or a combination that comprises at least one weak CYP3A4 inhibitor is selected from: -ALPRAZOLAM- ATORVASTATIN;EZETIMIBEand mixtures thereof, wherein the patient receive an amount of the compound according to formula (I) of30 mg.In one embodiment, the weak CYP3A4 inhibitor and / or a combination that comprises at least one weak CYP3A4 inhibitor is selected from: -ACETYLSALICYLIC ACID;ATORVASTATIN CALCIUM;RAMIPRIL- ALLIUM SPP. BULB;BUXUS SPP. LEAF WITH TWIG;CINNAMOMUM MIGAOFRUIT;GINKGO BILOBA LEAF;SALVIA MILTIORRHIZA ROOT WITH RHIZOME -ALPRAZOLAM- AMBROXOL HYDROCHLORIDE;ROXITHROMYCIN- AMIODARONE- AMIODARONE HYDROCHLORIDE- AMLODIPINE- AMLODIPINE BESILATE- AMLODIPINE BESILATE;ATORVASTATIN CALCIUM- AMLODIPINE BESILATE;ATORVASTATIN CALCIUM;PERINDOPRIL ARGININE- AMLODIPINE BESILATE;ATORVASTATIN L-LYSINE- AMLODIPINE BESILATE;BENAZEPRIL HYDROCHLORIDE- AMLODIPINE BESILATE;BISOPROLOL FUMARATE- AMLODIPINE BESILATE;CANDESARTAN CILEXETIL- AMLODIPINE BESILATE;HYDROCHLOROTHIAZIDE;OLMESARTAN MEDOXOMIL- AMLODIPINE BESILATE;HYDROCHLOROTHIAZIDE;VALSARTAN- AMLODIPINE BESILATE;INDAPAMIDE- AMLODIPINE BESILATE;INDAPAMIDE;PERINDOPRIL ARGININE- AMLODIPINE BESILATE;INDAPAMIDE;PERINDOPRIL ERBUMINE- AMLODIPINE BESILATE;LISINOPRIL- AMLODIPINE BESILATE;LISINOPRIL DIHYDRATE- AMLODIPINE BESILATE;OLMESARTAN MEDOXOMIL- AMLODIPINE BESILATE;PERINDOPRIL ARGININE- AMLODIPINE BESILATE;PERINDOPRIL ERBUMINE- AMLODIPINE BESILATE;RAMIPRIL- AMLODIPINE BESILATE;TELMISARTAN BHC231046 US14 -83-- AMLODIPINE BESILATE;VALSARTAN- AMLODIPINE CAMSILATE- AMLODIPINE MALEATE- AMLODIPINE MESILATE- AMLODIPINE;ATORVASTATIN CALCIUM- AMLODIPINE;HYDROCHLOROTHIAZIDE;OLMESARTAN- AMLODIPINE;HYDROCHLOROTHIAZIDE;VALSARTAN- AMLODIPINE;RAMIPRIL- AMLODIPINE;VALSARTAN- ASTAXANTHIN;BERBERINE;FOLIC ACID;MONASCUSPURPUREUS;POLICOSANOL;UBIDECARENONE- ATORVASTATIN- ATORVASTATIN CALCIUM- ATORVASTATIN CALCIUM TRIHYDRATE- ATORVASTATIN CALCIUM;EZETIMIBE- ATORVASTATIN CALCIUM;PERINDOPRIL ARGININE- ATORVASTATIN;EZETIMIBE- BERBERINE- BERBERINE HYDROCHLORIDE- BERBERINE HYDROCHLORIDE;RHEUM SPP. ROOT WITH RHIZOME;SCUTELLARIABAICALENSIS ROOT- BICALUTAMIDE- CHLORZOXAZONE- CHLORZOXAZONE;PARACETAMOL- CILOSTAZOL- CYANOCOBALAMIN;FISH OIL;FOLIC ACID;GINKGO BILOBA LEAF;PHOSPHATIDYLSERINE;TOCOPHEROL- ELEUTHEROCOCCUS SENTICOSUS;EUPHRASIA OFFICINALIS;GINKGOBILOBA;VACCINIUM MYRTILLUS- FLUOXETINE- FLUOXETINE HYDROCHLORIDE- GINKGO BILOBA- GINKGO BILOBA EXTRACT- GINKGO BILOBA LEAF- GINKGO BILOBA LEAF EXTRACT- LEVAMLODIPINE BESILATE- LEVAMLODIPINE MALEATE BHC231046 US14 -84- -PROPIVERINE- PROPIVERINE HYDROCHLORIDE- RANITIDINE- RANITIDINE HYDROCHLORIDE- RANITIDINE HYDROCHLORIDE;SUCRALFATE;TRIPOTASSIUMDICITRATOBISMUTHATE -RANOLAZINE- ROXITHROMYCIN- TACROLIMUS- TICAGRELOR- TOLVAPTANand mixtures thereof, wherein the patient receive an amount of the compound according to formula (I) of40 mg.In one embodiment, the weak CYP3A4 inhibitor and / or a combination that comprises at least one weak CYP3A4 inhibitor is selected from: -ATORVASTATINwherein the patient receives an amount of the compound according to formula (I) of 60 mg.In one embodiment, the weak CYP3A4 inhibitor and / or a combination that comprises at least one weak CYP3A4 inhibitor is selected from: -AMIODARONE HYDROCHLORIDE- AMLODIPINE- AMLODIPINE BESILATE;HYDROCHLOROTHIAZIDE;VALSARTAN- ATORVASTATIN- ATORVASTATIN CALCIUM- ATORVASTATIN CALCIUM TRIHYDRATE- BICALUTAMIDE- TOLVAPTANand mixtures thereof, wherein the patient receive an amount of the compound according to formula (I) of80 mg.Examples, but limited to, CYP3A4 inhibitors of unspecified potency can be bergaptol (a furocoumarin in BHC231046 US14 -85-citrus), cannabidiol, dithiocarbamate (functional group), flavonoids, mifepristone, norfloxacin, some non-nucleoside reverse-transcriptase inhibitors (delavirdine), gestodene, star fruit, milk thistle, niacin,nicotinic acid, niacinamide (nicotinamide), Vitamin B3 (complex), ginkgo biloba, sesamin, piperine,isoniazid, serenoa.In one embodiment, the CYP3A4 inhibitor of unspecified potency and / or a combination that comprises at least one CYP3A4 inhibitor of unspecified potency is selected from: -ALTIZIDE;SPIRONOLACTONE- BILOBALIDE;GINKGOLIDE A;GINKGOLIDE B;GINKGOLIDE C- BUTIZIDE;SPIRONOLACTONE- CAFFEINE;ERGOTAMINE TARTRATE;METAMIZOLE SODIUM- DESOGESTREL;ETHINYLESTRADIOL- ERGOTAMINE TARTRATE- ETHINYLESTRADIOL;NORGESTIMATE- FEXUPRAZAN HYDROCHLORIDE- FUROSEMIDE;SPIRONOLACTONE- HYDROCHLOROTHIAZIDE;SPIRONOLACTONE- MIDAZOLAM- MIDAZOLAM HYDROCHLORIDE- NORFLOXACIN- SERTRALINE- SERTRALINE HYDROCHLORIDE- SPIRONOLACTONE- SPIRONOLACTONE;TORASEMIDEand mixtures thereof. In one embodiment thereof, the patient receives an amount of the compoundaccording to formula (I) of 5 to 80 mg In one embodiment thereof, the patient receives an amount of thecompound according to formula (I) of 5 mg. In one embodiment thereof, the patient receives an amountof the compound according to formula (I) of 10 mg. In one embodiment thereof, the patient receives anamount of the compound according to formula (I) of 20 mg. In one embodiment thereof, the patientreceives an amount of the compound according to formula (I) of 30 mg. In one embodiment thereof, thepatient receives an amount of the compound according to formula (I) of 40 mg. In one embodiment thereof,the patient receives an amount of the compound according to formula (I) of 60 mg. In one embodimentthereof, the patient receives an amount of the compound according to formula (I) of 80 mg. The amountof the compound according to formula (I) in these embodiments can be adjusted based on the CYP3A4 inhibitor. The adjustment can be up-titration, down-titration, maintenance or interruption of the treatment with the compound according to formula (I). Multiple embodiments of dose adjustments are described in detail below. These can be applied based on the co-medication with a CYP3A4 inhibitor. These can also be applied based on the amount and / or type of the CYP3A4 inhibitor the patient receives. In one embodiment, the CYP3A4 inhibitor of unspecified potency and / or a combination that comprises at least one CYP3A4 inhibitor of unspecified potency is selected from: BHC231046 US14 -86- -CAFFEINE;ERGOTAMINE TARTRATE;METAMIZOLE SODIUM- ERGOTAMINE TARTRATE- ETHINYLESTRADIOL;NORGESTIMATE- FEXUPRAZAN HYDROCHLORIDE- FUROSEMIDE;SPIRONOLACTONE- HYDROCHLOROTHIAZIDE;SPIRONOLACTONE- MIDAZOLAM- MIDAZOLAM HYDROCHLORIDE- NORFLOXACIN- SERTRALINE- SERTRALINE HYDROCHLORIDE- SPIRONOLACTONEand mixtures thereof, wherein the patient receive an amount of the compound according to formula (I) of10 mg.In one embodiment, the CYP3A4 inhibitor of unspecified potency and / or a combination that comprises at least one CYP3A4 inhibitor of unspecified potency is selected from: -BILOBALIDE;GINKGOLIDE A;GINKGOLIDE B;GINKGOLIDE C- CAFFEINE;ERGOTAMINE TARTRATE;METAMIZOLE SODIUM- ERGOTAMINE TARTRATE- FEXUPRAZAN HYDROCHLORIDE- FUROSEMIDE;SPIRONOLACTONE- MIDAZOLAM- MIDAZOLAM HYDROCHLORIDE- NORFLOXACIN- SERTRALINE- SERTRALINE HYDROCHLORIDE- SPIRONOLACTONEand mixtures thereof, wherein the patient receive an amount of the compound according to formula (I) of20 mg.In one embodiment, the CYP3A4 inhibitor of unspecified potency and / or a combination that comprises at least one CYP3A4 inhibitor of unspecified potency is selected from: -DESOGESTREL;ETHINYLESTRADIOL- FEXUPRAZAN HYDROCHLORIDE- HYDROCHLOROTHIAZIDE;SPIRONOLACTONE- MIDAZOLAM BHC231046 US14 -87- -MIDAZOLAM HYDROCHLORIDE- NORFLOXACIN- SERTRALINE- SERTRALINE HYDROCHLORIDE- SPIRONOLACTONE- SPIRONOLACTONE;TORASEMIDEand mixtures thereof, wherein the patient receive an amount of the compound according to formula (I) of40 mg.In one embodiment, the patient receives the compound according to formula (I) and at least one further medicament. In one embodiment, the patient receives the compound according to formula (I) and equal toor below 5 medications. In one embodiment, the patient receives the compound according to formula (I)and equal to or above 5 medications. In one embodiment, the patient receives the compound according toformula (I) and equal to or above 5 to equal to or below 9 medications. In one embodiment, the patientreceives the compound according to formula (I) and equal to or above 5 medications. In one embodiment,the patient receives the compound according to formula (I) and equal to or below 9 medications. In oneembodiment, the patient receives the compound according to formula (I) and equal to or above 5medications. In one embodiment, the patient receives the compound according to formula (I) and equal toor above 9 medications. In one embodiment, the patient receives equal to or above 10 medications.Examples of co-medications are described above and below in detail. Examples of co-medications are loop diuretics, beta-blocker, ACE inhibitor (ACEi), angiotension-receptor-blocker (ARB), Angiotensin Receptor-Neprilysin Inhibitor (ARNI), Calcium Channel Blockers, Sodium-glucose Cotransporter-2 Inhibitor (SGLT-2i), glucagon-like peptide-1 (GLP-1) agonists, CYP3A4 inducer, CYP3A4 inhibitor and / or mixtures thereof. These multiple medications may be stated as: “non-polypharmacy": <5 medications; "polypharmacy": 5 to 9 medications; and "hyperpolypharmacy": ≥10 medications. Kansas City Cardiomyopathy Questionnaire (KCCQ) is a standardized patient reported outcomes (PRO) questionnaire which assesses symptoms, physical and social limitations, and quality of life in patients withheart failure (HF). Patients are asked to recall how their HF impacted their life over a 2-week recall period.The KCCQ is composed of different score domains including the Total symptom score (TSS), which depicts patients perceptions on their symptoms related to heart failure (Green CP, Porter CB, Bresnahan DR, Spertus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol.2000 Apr;35(5):1245-55.)In one embodiment, the patient has a KCCQ-TSS of equal to or above 35, 36, 37, 38, 39, 40, 41, 42, 43,44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, BHC231046 US14 -88- 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85 ,86, 87, 88.89. 90. 91, 92, 93, 94, 95, 96, 97, 98, 99,and 100. In one embodiment, the patient has a KCCQ-TSS of equal to or below 35, 36, 37, 38, 39, 40, 41,42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85 ,86, 87, 88.89. 90. 91, 92, 93, 94, 95, 96, 97, 98, 99, and 100.In one embodiment, the patient has a KCCQ-TSS of equal to or above 43 to equal to or below 91. In oneembodiment, the patient has a KCCQ-TSS of equal to or above 43 to equal to or below 67. In oneembodiment, the patient has a KCCQ-TSS of equal to or above 67 to equal to or below 91. In oneembodiment, the patient has a KCCQ-TSS of 69+ / - 24. In one embodiment, the patient has a KCCQ-TSSof equal to or above 45 to equal to or below 93. In one embodiment, the patient has a KCCQ-TSS of qualor above 45 to equal to or below 69. In one embodiment, the patient has a KCCQ-TSS of equal to or above69 to equal to or below 93. In one embodiment, the patient has a KCCQ-TSS of 66+ / - 24. In oneembodiment, the patient has a KCCQ-TSS of equal to or above 42 to equal to or below 90. In oneembodiment, the patient has a KCCQ-TSS of equal to or above 42 to equal to or below 66. In oneembodiment, the patient has a KCCQ-TSS of equal to or above 66 to equal to or below 90. In oneembodiment, the patient has a KCCQ-TSS of 68.7+ / -23.1. In one embodiment, the patient has a KCCQ-TSS of 71.2 + / - 22.5. In one embodiment, the patient has a KCCQ-TSS of 66.0 + / -24.5. In oneembodiment, the patient has a KCCQ-TSS of 65.3 ± 23.8. In one embodiment, the patient has a KCCQ-TSS of 68.5+ / - 23.7. In one embodiment, the patient has a KCCQ-TSS of 67.8+ / -22.7. In one embodiment,the patient has a KCCQ-TSS of 62.3+ / - 25.4. In one embodiment, the patient has a KCCQ-TSS of 63.8+ / -25.5. Body mass index (BMI) is a value derived from the mass (weight) and height of a person. The BMI is defined as the body mass divided by the square of the body height, and is expressed in units of kg / m2, resulting from mass in kilograms (kg) and height in metres (m).In one embodiment, the patient has a body-mass-index (BMI) of equal to or above 15 kg / m2.In one embodiment, the patient has a body-mass-index (BMI) selected from of equal to or above 15, 16,17, 18, 18.5, 19, 20, 21, 22, 23, 24, 24.5, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 34.5, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, and 50 kg / m2. In one embodiment, the patient has a body-mass-index(BMI) selected from of equal to or below 15, 16, 17, 18, 18.5, 19, 20, 21, 22, 23, 24, 24.5, 25, 26, 27, 28,29, 30, 31, 32, 33, 34, 34.5, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, and 50 kg / m2. In oneembodiment, the patient has a body-mass-index (BMI) equal to or above 15 kg / m2. In one embodiment,the patient has a body-mass-index (BMI) equal to or above 20 kg / m2. In one embodiment, the patient hasa body-mass-index (BMI) equal to or above 25 kg / m2. In one embodiment, the patient has a body-mass-index (BMI) equal to or above 30 kg / m2. In one embodiment, the patient has a body-mass-index (BMI)equal to or above 35 kg / m2. In one embodiment, the patient has a body-mass-index (BMI) equal to or BHC231046 US14 -89-above 40 kg / m2. In one embodiment, the patient has a body-mass-index (BMI) equal to or above 45 kg / m2.In one embodiment, the patient has a body-mass-index (BMI) equal to or above 50 kg / m2. In oneembodiment, the patient has a body-mass-index (BMI) equal to or below 15 kg / m2. In one embodiment,the patient has a body-mass-index (BMI) equal to or below 20 kg / m2. In one embodiment, the patient hasa body-mass-index (BMI) equal to or below 25 kg / m2. In one embodiment, the patient has a body-mass-index (BMI) equal to or below 30 kg / m2. In one embodiment, the patient has a body-mass-index (BMI)equal to or below 35 kg / m2. In one embodiment, the patient has a body-mass-index (BMI) equal to orbelow 40 kg / m2. In one embodiment, the patient has a body-mass-index (BMI) equal to or below 45kg / m2. In one embodiment, the patient has a body-mass-index (BMI) equal to or below 50 kg / m2.In one embodiment, the patient has a body-mass-index (BMI) of 30+ / -6 kg / m2. In one embodiment, thepatient has a body-mass-index (BMI) of equal to or above 24 to equal to or below 36 kg / m2. In oneembodiment, the patient has a body-mass-index (BMI) of equal to or above 24 to equal to or below 30kg / m2. In one embodiment, the patient has a body-mass-index (BMI) of equal to or above 30 to equal toor below 36 kg / m2. In one embodiment, the patient has a body-mass-index (BMI) of equal to or above 30kg / m2. In one embodiment, the patient has a body-mass-index (BMI) of equal to or above 15 to equal toor below 18.4 kg / m2. In one embodiment, the patient has a body-mass-index (BMI) of equal to or above18.5 to equal to or below 24.9 kg / m2. In one embodiment, the patient has a body-mass-index (BMI) ofequal to or above 25 to equal to or below 29.9 kg / m2. In one embodiment, the patient has a body-mass-index (BMI) of equal to or above 30 to equal to or below 34.9 kg / m2. In one embodiment, the patient hasa body-mass-index (BMI) of equal to or above 35 to equal to or below 39.9 kg / m2. In one embodiment,the patient has a body-mass-index (BMI) of equal to or above 40 to equal to or below 50 kg / m2.In one embodiment, the patient was hospitalized for heart failure (HHF) and has at least one of KCCQ-TSS: 53±24, or 70±23, or 71±22, eGFR (mL / min / 1.73m2): 60±20, or 63±20, or 62±19,NT-proBNP (ng / L) (median): 1790, or 1691, or 1322,History of Atrial Flutter History of Atrial fibrillation,History of Diabetes. History of coronary artery disease (CAD) History of chronic kidney disease (CKD) History of stroke History of transient ischemic attack (TIA) History of chronic obstructive pulmonary disease (COPD) History of metabolic syndrome History of frailty BHC231046 US14 -90- History of peripheral artery disease (PAD), and / or History of obstructive sleep apnea (OSA)In one embodiment, the patient is selected from one ore more of the following subgroups:Potassium subgroups are specified above according to the following cutpoints (≤4.5, >4.5 mmol / L). Additional subgroups can be defined by median, quantiles, and other standard definitions of hypo-,hyper- and normokalemia.Sodium subgroups defined by the median, quantiles, and standard definitions of hypo-, hyper- andnormonatremia. Chloride subgroups defined by the median, quantiles, and standard definitions of hypo-, hyper- andnormo-chloremia. Hemoglobin and hematocrit subgroups defined by the median, quantiles, and standard definitions of anemia. eGFR subgroups can be specified above according to the following cutpoints <60, ≥60 mL / min / 1.73m2. Focused examination of Stage 4 CKD (if eGFR was less than 30mL / min / 1.73m2) UACR subgroups are specified above according to the following cutpoints (<30 vs. ≥30 mg / g). BUN and BUN / creatinine ratio subgroups defined by the median and quantiles. Patients suspected to have primary hyperaldosteronism based on renin and aldosterone levels BMI subgroups are specified above according to the following cutpoints (<30kg / m2≥30kg / m2) Subgroups defined by standard nutritional indices e.g., the geriatric nutritional risk index (GNRI), prognostic nutritional index (PNI), and controlling nutritional status (CONUT), examining these as categorical variables using recognized cut points, medians, quantiles, and as continuous variables. Age subgroups are specified above according to the following cutpoints (median age). Systolic blood pressure subgroups are specified above according to the following cutpoints (median age). SBP and DBP can be assessed at the median, quantiles, and various global definitions ofhypertension (based on both SBP and DBP). Patients with apparent treatment resistant hypertension Atrial fibrillation Atrial fibrillation or atrial flutter on baseline ECG aprevious history of atrial fibrillation / flutter, optionally together with the overlap between medicalhistory and baseline ECG and derived history of persistent / permanent AF versus paroxysmal AF. Patients with improved / recovered LVEF (those who had LVEF ≤40% at any time prior to randomization) LVEF at the following cutpoint: <60%, ≥60%), ≤ 49%, 50 to 59%, ≥60% - to examine those with HFwith mildly reduced ejection fraction. BHC231046 US14 -91- two-way interaction between sex and LVEF will be examined. Other anthropometric indices e.g., waist-to-hip ratio, waist-to-height ratio using quantiles and recognized cutpoints Time from prior HF hospitalization Time from index HF diagnosis Patients with COPD Patients with OSA Patients with cirrhosis Patients with any atherosclerotic cardiovascular disease Patients with history of stroke / TIA Patients with history of coronary artery disease / prior MI Patients with history of coronary artery bypass graft surgery Patients with peripheral artery disease Patients with metabolic syndrome (using standard definitions) Subgroups based on baseline use and dosing of diuretics Patients with multimorbidity and frailty Patients with cardio-renal-metabolic overlap (intersection of atherosclerotic cardiovascular disease, CKD, and diabetes) Total baseline medications will be categorized as ("non-polypharmacy": <5 medications; "polypharmacy": 5 to 9 medications; and "hyperpolypharmacy": ≥10 medications) Number of blood pressure lowering therapies at baseline Patients with baseline risk as determined by the Meta‐Analysis Global Group in Chronic (MAGGIC) Heart Failure Risk Score and other HF risk scores Patients with baseline risk as determined by the Kidney Failure Risk Equation Subgroups based on baseline evidence of congestion and congestion scores Regional subgroups based on socioeconomic differences based on the GINI coefficient Subgroups based on KCCQ-TSS and other KCCQ domains at baseline. Subgroups based on EQ-5D-5L VAS and index scores at baseline. Time from diagnosis of heart failure, analyzed as both a continuous and a categorical variable Time from HF hospitalization continuously and focused examination for those never hospitalizedNT-proBNP and high-sensitivity troponin will be examined at median, quantiles, and as continuouseasures History of any prior MRA use prior to randomization Background HF therapies including focused examination of patients on various combinations of therapies (including the Heart Failure Collaboratory score) Patients on or off betablockers BHC231046 US14 -92- Patients on or off potassium supplements Patients on or off potassium lowering therapies Patients with phenotypic characteristics of amyloid cardiomyopathy, based on validated clinical models / scores In the following, embodiments of the dose, dosing scheme, titration, up-titration and / or down-titration of the compound according to formula (I) are described. These embodiments also apply to embodiments, in which a hydrate, solvate, pharmaceutically acceptable salt thereof, a polymorph thereof or polymorph (I) is used. The term “dose” is used as typically used in the art. The term “dose” is usually applied to the quantity of a drug or other agent administered for therapeutic purposes to the body. The term “dose” and the term “the amount the patient receives” can be used synonymously. In one example, a dose of 10 mg of the compound according to formula (I) is administered to the patient. In other words: the patient receives an amount of 10 mg of the compound of formula (I). The term "dose" can include a quantity of the drug that the patient takes at the same time. The term "dose"can include a quantity of the drug that the patient takes consecutively. The respective amount of the drugcan be taken immediately one after the other or they can be taken at a time interval. This interval can be the same or different.The “dose” or the “amount the patient receives” can also refer to a single dose, a daily dose or multipledaily doses. For example, if the patient receives 10 mg of the compound according to formula (I) twice a day, this is a single dose of 10 mg, but a daily dose of 20 mg. The term “dose” / “the amount the patient receives” can, thus, refer to the single dose (10 mg) or the total daily dose (20 mg). A dose can be a once daily, twice daily, four times daily or multiple daily dose. The amount or dose can be delivered to the patient, for example, using one pharmaceutical compositionor one or more pharmaceutical compositions. Pharmaceutical compositions are described in detail below.For example, a dose of 40 mg of the compound according to formula (I) can be administered to the patient using four tablets comprising 10 mg each. These four tablets can be taken at the same time or consecutively. In another example, a dose of 40 mg of the compound according to formula (I) can be administered to the patient using two tablets comprising 20 mg each. For example, a dose of 40 mg of the compound according to formula (I) can be administered to the patient using two tablets comprising 10 mg each and one tablet comprising 20 mg. In one embodiment, the compound according to formula (I) is used in an amount of 0.25 mg to 80 mg. In one embodiment, the compound according to formula (I) is used in an amount of 0.25 mg to 40 mg. In BHC231046 US14 -93- one embodiment, the compound according to formula (I) is used in an amount of 0.25 mg to 20 mg. In one embodiment, the compound according to formula (I) is used in an amount of 0.25 mg to 10 mg. In one embodiment, the compound according to formula (I) is used in an amount of 0.25 mg to 5 mg. In one embodiment, the compound according to formula (I) is used in an amount of 5 to 80 mg. In one embodiment, the compound according to formula (I) is used in an amount of 5 to 80 mg, 5 to 70 mg, 5 to 60 mg, 5 to 50 mg, 5 to 40 mg, 10 to 80 mg, 10 to 70 mg, 10 to 60 mg, 10 to 50 mg or 10 to 40 mg. In one embodiment, the compound according to formula (I) is used in an amount of 10 to 40 mg. In oneembodiment, the compound according to formula (I) is used in an amount of 20 to 40 mg. In oneembodiment, the compound according to formula (I) is used in an amount of 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75, 4, 4.25, 4.5, 4.75, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75 or 80 mg. In one embodiment, the compound according to formula (I) is used in an amount of 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75 or 80 mg. In one embodiment, the compoundaccording to formula (I) is used in an amount of 5 mg. In one embodiment, the compound according toformula (I) is used in an amount of 10 mg. In one embodiment, the compound according to formula (I) is used in an amount of 15 mg. In one embodiment, the compound according to formula (I) is used in an amount of 20 mg. In one embodiment, the compound according to formula (I) is used in an amount of 25 mg. In one embodiment, the compound according to formula (I) is used in an amount of 30 mg. In one embodiment, the compound according to formula (I) is used in an amount of 35 mg. In one embodiment, the compound according to formula (I) is used in an amount of 40 mg. In one embodiment, the compound according to formula (I) is used in an amount of 5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg or 40 mg. In one embodiment, the compound according to formula (I) is used in an amount of 5 mg, 10 mg, 20 mg, 30 mg or 40 mg.The amount of the compound according to formula (I) can be adjusted. In one embodiment thereof, thedose is adjusted by up-titration. In one embodiment thereof, the dose is adjusted by down-titration. In one embodiment thereof, the dose is continued. In one embodiment thereof, the treatment is interrupted. In one embodiment the treatment or prevention is interrupted due to hyperkalaemia, renal impairment, diarrhoea, nausea, asthenia, dyspnoea, hypotension, sepsis, septic shock, COVID-19, Cardiac arrest, COVID-19 pneumonia, Cardiac failure, Respiratory failure, Lung neoplasm malignant, Pneumonia, Atrial fibrillation, COVID-19, Acute kidney injury, Angina unstable, Anaemia, COVID-19 pneumonia, Urinary tract infection, Syncope, Chest pain, Chronic obstructive pulmonary disease, Angina pectoris, Cellulitis, Sepsis, Coronary artery disease, Cardiac failure, Sudden death, Femur fracture, Fall, Gastrointestinal haemorrhage, hypokalemia and / or Hyperkalaemia.In one embodiment the dose is adjusted based on one or more of the factors selected from LVEF, NYAH,eGFR, UACR, Potassium level, sodium level, chloride level, urea level, blood urea nitrogen (BUN), high- BHC231046 US14 -94- sensitivity Troponin T level, natriuretic peptide (NT-proBNP), blood pressure (BP), systolic blood pressure, average heart rate (resting), previous diseases, prior MRA use, heart rate (or pulse rate),comedication, KCCQ-TSS, Body mass index (BMI), comedication, CYP3A4 inhibitor, CYP3A4 inducer,loop diuretics, beta-blocker, ACE inhibitor (ACEi), angiotension-receptor-blocker (ARB), Angiotensin Receptor-Neprilysin Inhibitor (ARNI), Calcium Channel Blockers, Sodium-glucose Cotransporter-2 Inhibitor (SGLT-2i), and mixtures thereof. In one embodiment thereof, the dose is adjusted by up-titration. In one embodiment thereof, the dose is adjusted by down-titration. In one embodiment thereof, the doseis continued (or maintained). In one embodiment thereof, the treatment is interrupted.The dose can be adjusted based on the eGFR.In one embodiment thereof, the dose is adjusted by up-titration. In one embodiment thereof, the dose is adjusted by down-titration. In one embodiment thereof, the dose is continued. In one embodiment thereof, the treatment is interrupted. In one embodiment, the patient receives the compound according to formula (I) in an amount of 10 mg, ifthe patient has an eGFR of equal to or below 60 mL / min / 1.73 m2. In one embodiment, the patient receivesthe compound according to formula (I) starting dose in an amount of 10 mg, if the patient has an eGFR ofequal to or below 60 mL / min / 1.73 m2.In one embodiment, the patient receives the compound according to formula (I) in an amount of 20 mg, ifthe patient has an eGFR of equal to or above 60 mL / min / 1.73 m2. In one embodiment, the patient receivesthe compound according to formula (I) starting dose in an amount of 20 mg, if the patient has an eGFR ofequal to or above 60 mL / min / 1.73 m2.In one embodiment, the patient receives the compound according to formula (I) in an amount of 40 mg, ifthe patient has an eGFR of equal to or above 60 mL / min / 1.73 m2. In one embodiment, the patient receivesthe compound according to formula (I) as starting dose in an amount of 40 mg, if the patient has an eGFRof equal to or above 60 mL / min / 1.73 m2.In one embodiment, the patient receives a lower dose of the compound according to formula (I), andpatient has an eGFR of equal to or below 60 mL / min / 1.73 m2, then the dose is up-titrated to the next higherdose. In one embodiment, the patient receives a higher dose of the compound according to formula (I),and patient has an eGFR of equal to or above 60 mL / min / 1.73 m2, then the dose is down-titrated to thenext lower dose. Further examples for “lower dose” are described below. The term “lower dose” and “nextlower dose”, “down-titrated dose” and “down-titrated daily dose” are interchangeable and can be usedsynonymously. Accordingly, the term “higher dose” and “next higher dose” is synonymous with “up- titrated dose” or “up-titrated daily dose”. BHC231046 US14 -95- In one embodiment, “next higher dose” or “next lower dose” refer to the dose that is immediately higher or lower, respectively, compared to a previously mentioned dose within a previously defined dose range.This range may include for example the following doses: 2.5, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60,65, 70, 75 or 80 mg. For example, if 75 mg is the current, first or previously mentioned dose, then 80 mg is considered the next higher dose. Conversely, if 80 mg is the current, first or previously mentioned dose, then 75 mg is considered the next lower dose.In one embodiment, “next higher dose” or “next lower dose” refers to a dosage that is administered as thethird step in a treatment sequence after a patient has already received a first and second dose for the treatment of a disease as previously outlined. For instance, if a patient is treated with the compound of formula (I), starting with a 40 mg dose in the first step, the "next higher dose" scenario would involve administering 60 mg in the second step, followed by an increase to 80 mg in the third step, marking it as the next higher dose relative to the initial 40 mg. Conversely, in the "next lower dose" scenario, after the initial 40 mg dose, the patient would receive 20 mg in the second step, and then the dosage would be further reduced to 10 mg in the third step, establishing it as the next lower dose in relation to the starting dose. In one embodiment, the dose the patient is receiving is up-titrated. In one embodiment, the dose the patient is receiving is up-titrated depending on the potassium level. In one embodiment, the dose the patient is receiving is up-titrated, if the potassium level is equal to orbelow 3, 3.5, 4, 4.5, 4.8, 5, or 5.5 mmol / L. In one embodiment, the dose the patient is receiving is up-titrated, if the potassium level is equal to or below 3, 3.5, 4, 4.5, 4.7, 4.8, 4.9, 5, 5.1, 5.4, 5.5, or 5.6mmol / L. In one embodiment, the dose the patient is receiving is up-titrated, if the potassium level is equalto or above 3, 3.5, 4, 4.5, 4.8, 5 or 5.5 mmol / L. In one embodiment, the dose the patient is receiving is up-titrated, if the potassium level is equal to or above 3, 3.5, 4, 4.5, 4.8, or 5 or 5.5 mmol / L, but below 6mmol / L. In one embodiment, the dose the patient is receiving is up-titrated, if the potassium level is equal to or below 4.0 mmol / L. In one embodiment, the dose the patient is receiving is up-titrated, if the potassiumlevel is equal to or below 4.5 mmol / L. In one embodiment, the dose the patient is receiving is up-titrated,if the potassium level is equal to or below 4.8 mmol / L. In one embodiment, the dose the patient is receivingis up-titrated, if the potassium level is equal to or below 5 mmol / L. In one embodiment, the dose thepatient is receiving is up-titrated, if the potassium level is equal to or below 5.5 mmol / L.In one embodiment, the dose the patient is receiving is up-titrated, if the potassium level is equal to orabove 4.5 mmol / L to equal to or below to below 5.5 mmol / L. In one embodiment, the dose the patient is BHC231046 US14 -96-receiving is up-titrated, if the potassium level is equal to or above 4.8 mmol / L to below 5.5 mmol / L. Inone embodiment, the dose the patient is receiving is up-titrated, if the potassium level is equal to or above5 mmol / L to below 5.5 mmol / L. In one embodiment, the dose the patient is receiving is up-titrated, if thepotassium level is equal to or above 4.5 mmol / L to equal to or below to equal to or below 5 mmol / L. Inone embodiment, the dose the patient is receiving is up-titrated, if the potassium level is equal to or above4.8 mmol / L to equal to or equal to or below 5 mmol / L.In one embodiment, the dose the patient is receiving is maintained of the potassium level is equal to orabove 5 to below 5.5 mmol / L. A synonym for “maintained” is for example “continued”.In one embodiment, the dose the patient is receiving is continued.In one embodiment, the dose the patient is receiving is continued is depending on the potassium level.In one embodiment, the dose the patient is receiving is continued, if the potassium level is equal to orbelow 3, 3.5, 4, 4.5, 4.8, 5 or 5.5 mmol / L. In one embodiment, the dose the patient is receiving iscontinued, if the potassium level is equal to or above 3, 3.5, 4, 4.5, 4.8, 5 or 5.5 mmol / L, but below 6mmol / L. In one embodiment, the dose the patient is receiving is continued, if the potassium level is equalto or above 3, 3.5, 4, 4.5, 4.8, or 5 or 5.5 mmol / L, but below 6 mmol / L. The dose the patient is receivingcan be selected from 10 mg, 20 mg and 40 mg. The dose the patient is receiving can be 10 mg. The dose the patient is receiving can be 20 mg. The dose the patient is receiving can be 40 mg. In one embodiment, the dose the patient is receiving is continued, if the potassium level is equal to or below 4.5, 4.8, 5 or 5.5 mmol / L. In one embodiment, the dose the patient is receiving is continued, if thepotassium level is equal to or above 4.5, 4.8, 5 or 5.5 mmol / L. In one embodiment, the dose the patient isreceiving is continued, if the potassium level is equal to or above 4.5, 4.8, or 5 or 5.5 mmol / L, but below6 mmol / L. The dose the patient is receiving can be selected from 10 mg, 20 mg and 40 mg. The dose thepatient is receiving can be 10 mg. The dose the patient is receiving can be 20 mg. The dose the patient is receiving can be 40 mg. In one embodiment, the dose the patient is receiving is continued, if the potassium level is equal to or below 4.8, 5 or 5.5 mmol / L. In one embodiment, the dose the patient is receiving is continued, if thepotassium level is equal to or above 4.8, 5 or 5.5 mmol / L. In one embodiment, the dose the patient isreceiving is continued, if the potassium level is equal to or above 4.8, or 5 or 5.5 mmol / L, but below 6mmol / L. The dose the patient is receiving can be selected from 10 mg, 20 mg and 40 mg. The dose thepatient is receiving can be 10 mg. The dose the patient is receiving can be 20 mg. The dose the patient is receiving can be 40 mg. In one embodiment, the dose the patient is receiving is continued, if the potassium level is equal to or BHC231046 US14 -97- below 4.8 mmol / L. In one embodiment, the dose the patient is receiving is continued, if the potassiumlevel is equal to or above 4.8 mmol / L. In one embodiment, the dose the patient is receiving is continued,if the potassium level is equal to or above 4.8 mmol / L, but below 5.5 mmol / L. The dose the patient isreceiving can be selected from 10 mg, 20 mg and 40 mg. The dose the patient is receiving can be 10 mg. The dose the patient is receiving can be 20 mg. The dose the patient is receiving can be 40 mg. In one embodiment, the dose the patient is receiving is continued, if the potassium level is equal to or below 5 mmol / L. In one embodiment, the dose the patient is receiving is continued, if the potassium levelis equal to or above 5 mmol / L. In one embodiment, the dose the patient is receiving is continued, if thepotassium level is equal to or above 5 mmol / L, but below 6 mmol / L. The dose the patient is receiving canbe selected from 10 mg, 20 mg and 40 mg. The dose the patient is receiving can be 10 mg. The dose the patient is receiving can be 20 mg. The dose the patient is receiving can be 40 mg. In one embodiment, the dose the patient is receiving is continued, if the potassium level is equal to or below 5.5 mmol / L. In one embodiment, the dose the patient is receiving is continued, if the potassiumlevel is equal to or above 5.5 mmol / L, but below 6 mmol / L. The dose the patient is receiving can beselected from 10 mg, 20 mg and 40 mg. The dose the patient is receiving can be 10 mg. The dose the patient is receiving can be 20 mg. The dose the patient is receiving can be 40 mg.In one embodiment, the patient the treatment of the patient is interrupted. In one embodiment, the patientthe treatment of the patient is interrupted, if the potassium level is equal to or above 5, 5.5 or 6 mmol / L.In one embodiment, the patient the treatment of the patient is interrupted, if the potassium level is equalto or above 5.5 or 6 mmol / L. In one embodiment, the patient the treatment of the patient is interrupted, ifthe potassium level is equal to or above 5 mmol / L. In one embodiment, the patient the treatment of thepatient is interrupted, if the potassium level is equal to or above 5.5 mmol / L. In one embodiment, thepatient the treatment of the patient is interrupted, if the potassium level is equal to or above 6 mmol / L. Inone embodiment, the patient the treatment of the patient is interrupted, if the potassium level is equal toor above 6.5 mmol / L.In one embodiment, the patient the treatment of the patient is interrupted, if the potassium level is between 5 to 6.5 mmol / L. In one embodiment, the patient the treatment of the patient is interrupted, if the potassiumlevel is between 5 to 6 mmol / L. In one embodiment, the patient the treatment of the patient is interrupted,if the potassium level is between 5.5 to 6.5 mmol / L. In one embodiment, the patient the treatment of the patient is interrupted, if the potassium level is between 5.5 to 6 mmol / L.In one embodiment, the treatment is interrupted, if- the patient receives a dose selected from 10, 20, 30 and 40 mg; and- the potassium level is equal to or above 5, 5.5 or 6 mmol / L. BHC231046 US14 -98- In one embodiment, the treatment is interrupted, if -the patient receives a dose selected from 10, 20, 30 and 40 mg; and- the potassium level is equal to or above 5, 5.5, 5.9, 6, or 6.1 mmol / L.In one embodiment, the treatment is interrupted, if- the patient receives a dose selected from 10, 20, 30 and 40 mg; and- the potassium level is equal to or above 5.5 or 6 mmol / L.In one embodiment, the treatment is interrupted, if- the patient receives a dose selected from 10, 20, 30 and 40 mg; and- the potassium level is equal to or above 5.5 mmol / L.In one embodiment, the treatment is interrupted, if- the patient receives a dose selected from 10, 20, 30 and 40 mg; and- the potassium level is equal to or above 6 mmol / L.In one embodiment, the treatment is interrupted, if- the patient receives a dose selected from 10, 20, 30 and 40 mg; and- the potassium level is between equal to or above 5 to 6.5 mmol / L.In one embodiment, the treatment is interrupted, if- the patient receives a dose selected from 10, 20, 30 and 40 mg; and- the potassium level is between equal to or above 5.5 to 6 mmol / L.In one embodiment, the treatment is interrupted, if- the patient receives a dose of 10 mg; and- the potassium level is equal to or above 5, 5.5 or 6 mmol / L.In one embodiment, the treatment is interrupted, if- the patient receives a dose of 20 mg; and- the potassium level is equal to or above 5, 5.5 or 6 mmol / L.In one embodiment, the treatment is interrupted, if- the patient receives a dose of 30 mg; and- the potassium level is equal to or above 5, 5.5 or 6 mmol / L. BHC231046 US14 -99-In one embodiment, the treatment is interrupted, if- the patient receives a dose of 40 mg; and- the potassium level is equal to or above 5, 5.5 or 6 mmol / L.In one embodiment, the treatment is interrupted, if -the patient receives a dose selected from 10 mg; and- the potassium level is equal to or above 5.5 mmol / L.In one embodiment, the treatment is interrupted, if -the patient receives a dose selected from 10 mg; and- the potassium level is equal to or above 6 mmol / L.In one embodiment, the treatment is interrupted, if -the patient receives a dose selected from 10 mg; and- the potassium level is between equal to or above 5 to 6.5 mmol / L.In one embodiment, the treatment is interrupted, if -the patient receives a dose selected from 10 mg; and- the potassium level is between equal to or above 5.5 to 6 mmol / L.In one embodiment, the treatment is interrupted, if -the patient receives a dose selected from 20 mg; and- the potassium level is equal to or above 5.5 mmol / L.In one embodiment, the treatment is interrupted, if -the patient receives a dose selected from 20 mg; and- the potassium level is equal to or above 6 mmol / L.In one embodiment, the treatment is interrupted, if -the patient receives a dose selected from 20 mg; and- the potassium level is between equal to or above 5 to 6.5 mmol / L.In one embodiment, the treatment is interrupted, if -the patient receives a dose selected from 20 mg; and- the potassium level is between equal to or above 5.5 to 6 mmol / L. BHC231046 US14 -100- In one embodiment, the treatment is interrupted, if -the patient receives a dose selected from 30 mg; and- the potassium level is equal to or above 5.5 mmol / L.In one embodiment, the treatment is interrupted, if -the patient receives a dose selected from 30 mg; and- the potassium level is equal to or above 6 mmol / L.In one embodiment, the treatment is interrupted, if -the patient receives a dose selected from 30 mg; and- the potassium level is between equal to or above 5 to 6.5 mmol / L.In one embodiment, the treatment is interrupted, if -the patient receives a dose selected from 30 mg; and- the potassium level is between equal to or above 5.5 to 6 mmol / L.In one embodiment, the treatment is interrupted, if -the patient receives a dose selected from 40 mg; and- the potassium level is equal to or above 5.5 mmol / L.In one embodiment, the treatment is interrupted, if -the patient receives a dose selected from 40 mg; and- the potassium level is equal to or above 6 mmol / L.In one embodiment, the treatment is interrupted, if -the patient receives a dose selected from 40 mg; and- the potassium level is between equal to or above 5 to 6.5 mmol / L.In one embodiment, the treatment is interrupted, if -the patient receives a dose selected from 40 mg; and- the potassium level is between equal to or above 5.5 to 6 mmol / L.The treatment of the patient can be interrupted and then restarted. In one embodiment, the treatment of thepatient is restarted. BHC231046 US14 -101- In one embodiment, the dose with which the treatment is restarted is selected from 10 mg, 20 mg and 40mg. In one embodiment, the dose with which the treatment is restarted is 10 mg. In one embodiment, thedose with which the treatment is restarted is 20 mg. In one embodiment, the dose with which thetreatment is restarted is 40 mg.In one embodiment, the treatment of the patient is restarted, if the potassium level is equal to or below 3,3.5, 4, 4.5, 4.8, 5 or 5.5 mmol / L. In one embodiment, the treatment of the patient is restarted, if thepotassium level is equal to or above 3, 3.5, 4, 4.5, 4.8, 5 or 5.5 mmol / L. In one embodiment, the treatmentof the patient is restarted, if the potassium level is equal to or above 3, 3.5, 4, 4.5, 4.8, or 5 or 5.5 mmol / L,but below 5.5 mmol / L. The dose with which the treatment is restarted can be selected from 10 mg, 20 mg and 40 mg. The dose with which the treatment is restarted can be 10 mg. The dose with which the treatment is restarted can be 20 mg. The dose with which the treatment is restarted can be 40 mg.In one embodiment, the treatment of the patient is restarted, if the potassium level is equal to or below4.5, 4.8, 5 or 5.5 mmol / L. In one embodiment, the treatment of the patient is restarted, if the potassiumlevel is equal to or above 4.5, 4.8, 5 or 5.5 mmol / L. In one embodiment, the treatment of the patient isrestarted, if the potassium level is equal to or above 4.5, 4.8, or 5 or 5.5 mmol / L, but below 5.5 mmol / L.The dose with which the treatment is restarted can be selected from 10 mg, 20 mg and 40 mg. The dose with which the treatment is restarted can be 10 mg. The dose with which the treatment is restarted can be 20 mg. The dose with which the treatment is restarted can be 40 mg.In one embodiment, the treatment of the patient is restarted, if the potassium level is equal to or below4.8, 5 or 5.5 mmol / L. In one embodiment, the treatment of the patient is restarted, if the potassium levelis equal to or above 4.8, 5 or 5.5 mmol / L. In one embodiment, the treatment of the patient is restarted, ifthe potassium level is equal to or above 4.8, or 5 or 5.5 mmol / L, but below 5.5 mmol / L. The dose withwhich the treatment is restarted can be selected from 10 mg, 20 mg and 40 mg. The dose with which thetreatment is restarted can be 10 mg. The dose with which the treatment is restarted can be 20 mg. The dosewith which the treatment is restarted can be 40 mg.In one embodiment, the treatment of the patient is restarted, if the potassium level is equal to or below 4.8mmol / L. In one embodiment, the treatment of the patient is restarted, if the potassium level is equal to or above 4.8 mmol / L. In one embodiment, the treatment of the patient is restarted, if the potassium level isequal to or above 4.8 mmol / L, but below 5.5 mmol / L. The dose with which the treatment is restarted canbe selected from 10 mg, 20 mg and 40 mg. The dose with which the treatment is restarted can be 10 mg. The dose with which the treatment is restarted can be 20 mg. The dose with which the treatment is restarted can be 40 mg.In one embodiment, the treatment of the patient is restarted, if the potassium level is equal to or below 5mmol / L. In one embodiment, the treatment of the patient is restarted, if the potassium level is equal to or BHC231046 US14 -102- above 5 mmol / L. In one embodiment, the treatment of the patient is restarted, if the potassium level isequal to or above 5 mmol / L, but below 5.5 mmol / L. The dose with which the treatment is restarted can beselected from 10 mg, 20 mg and 40 mg. The dose with which the treatment is restarted can be 10 mg. Thedose with which the treatment is restarted can be 20 mg. The dose with which the treatment is restartedcan be 40 mg.In one embodiment, the treatment of the patient is restarted, if the potassium level is equal to or below 5.5mmol / L. In one embodiment, the treatment of the patient is restarted, if the potassium level is equal to or above 5.5 mmol / L. The dose with which the treatment is restarted can be selected from 10 mg, 20 mg and 40 mg. The dose with which the treatment is restarted can be 10 mg. The dose with which the treatmentis restarted can be 20 mg. The dose with which the treatment is restarted can be 40 mg.In one embodiment, the treatment is restarted, wherein -the patient receives a dose selected from 10, 20, 30, and 40 mg;- the potassium level is equal to or below 4.5, 4.8, 5, 5.5, 6 or 6.5 mmol / L.In one embodiment, the treatment is restarted, wherein -the patient receives a dose selected from 10, 20, 30, and 40 mg;- the potassium level is equal to or below 5 mmol / L.In one embodiment, the treatment is restarted, wherein -the patient receives a dose selected from 10, 20, 30, and 40 mg;- the potassium level is equal to or below 5.5 mmol / L.In one embodiment, the treatment is restarted, wherein -the patient receives a dose selected from 10, 20, 30, and 40 mg;- the potassium level is equal to or below 6 mmol / L.In one embodiment, the treatment is restarted, wherein -the patient receives a dose of 10 mg;- the potassium level is equal to or below 5 mmol / L.In one embodiment, the treatment is restarted, wherein -the patient receives a dose of 20 mg;- the potassium level is equal to or below 5 mmol / L.In one embodiment, the treatment is restarted, wherein -the patient receives a dose of 30 mg; BHC231046 US14 -103- -the potassium level is equal to or below 5mmol / L.In one embodiment, the treatment is restarted, wherein -the patient receives a dose of 40 mg;- the potassium level is equal to or below 5 mmol / L.In one embodiment, the treatment is restarted, wherein -the patient receives a dose of 10 mg;- the potassium level is equal to or below 5.5 mmol / L.In one embodiment, the treatment is restarted, wherein -the patient receives a dose of 20 mg;- the potassium level is equal to or below 5.5 mmol / L.In one embodiment, the treatment is restarted, wherein -the patient receives a dose of 30 mg;- the potassium level is equal to or below 5.5 mmol / L.In one embodiment, the treatment is restarted, wherein -the patient receives a dose of 40 mg;- the potassium level is equal to or below 5.5 mmol / L.Further consideration might apply to the dose adjustment:In case the participant receives the lowest dose, no further decrease might be possible after interruption.The dose level can be 10, 20, 30 or 40 mg. The treatment can be restarted at the same dose level oncepotassium level is equal to or below 4.5, 4.8, 5, 5.5, 6 or 6.5 mmol / L. The treatment can be restarted at thesame dose level once potassium level is equal to or below 4.5, 4.8, 5, or 5.5 mmol / L. The treatment canbe restarted at the same dose level once potassium level is equal to or below 5.5 mmol / L. Serum / plasmapotassium can be measured at a safety visit after re-starting treatment or dose adjustment. Serum / plasmapotassium is to be measured at a safety visit 4 weeks ± 7 days after re-starting treatment or dose adjustment.In case the participant receives the lowest dose, but hyperkalemia recurs soon after a previous event of hyperkalemia leading to interruption of study intervention, and there is no explanation for the recurring hyperkalemia event other than intake of the dose, the treatment can be premature and / or permanent discontinued. In the following, dosing schemes are described. In some embodiment, for the dosing schemes for up- BHC231046 US14 -104- titration and / or down-titration described herein the following embodiments can apply: In some embodiments, the amount of the compound according to formula (I) is adjusted by up-titration. Here, the patient receives a lower dose, which is up-titrated to a higher dose. The patient can receive a lower dose, which is up-titrated to the next higher dose. In some embodiments, the amount of the compound according to formula (I) is adjusted by down-titration. Here, the patient receives a higher dose, which is down-titrated to a lower dose. The patient can receive a higher dose, which is down-titrated to the next lower dose. In one embodiment, the “lower dose” of the compound according to formula (I) is between 0.5 to 60 mg. In one embodiment, the “lower dose” of the compound according to formula (I) is between 2.5 to 60 mg. In one embodiment, the “lower dose” of the compound according to formula (I) is selected from 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, and 60 mg. In one embodiment, the “lower dose” is selected from 5mg, 10 mg, 20 mg, and 30 mg. In one embodiment, the “lower dose” is 5 mg. In one embodiment, the“lower dose” is 10 mg. In one embodiment, the “lower dose” is 20 mg. In one embodiment, the “lowerdose” is 30 mg.The ”next lower dose” can be a dose that is lower than the dose the patient is currently receiving. Forexample, if the currently receiving or the higher dose is 40 mg, the next lower dose can be for example 30 mg, 20 mg, 10 mg, or 5 mg. In one example the higher dose is 40 mg and the next lower dose is 30 mg. In one example the higher dose is 40 mg and the next lower dose is 20 mg. In one example the higher dose is 40 mg and the next lower dose is 10 mg. In one example the higher dose is 40 mg and the next lower dose is 5 mg. In one embodiment, “lower dose” and “next lower dose” are synonyms. In one embodiment, the “next lower dose” is selected from 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, 60 mg, and 80 mg. In one embodiment, the “next lower dose” is selected from 10 mg, 20 mg, and 30 mg. In one embodiment, the “next lower dose” is 5 mg. In one embodiment, the “next lower dose” is 10 mg. In one embodiment, the “next lower dose” is 20 mg. In one embodiment, the “next lower dose” is 30 mg. In one embodiment, the “next lower dose” is 40 mg. In one embodiment, the “next lower dose” is 60 mg. In one embodiment, the “higher dose” of the compound according to formula (I) is between 0.5 to 80 mg. In one embodiment, the “higher dose” of the compound according to formula (I) is between 2.5 to 80 mg. In one embodiment, the “higher dose” of the compound according to formula (I) is selected from 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, 60 mg, and 80 mg. In one embodiment, the “higher dose” is selected from 20 mg, 30 mg, and 40 mg. In one embodiment, the “higher dose” is 20 mg. In one embodiment, the “higher dose” is 30 mg. In one embodiment, the “higher dose” is 40 mg. The ”next higher dose” can be a dose that is higher than the dose the patient is currently receiving. For BHC231046 US14 -105- example, if the currently receiving or the lower dose is 10 mg, the next higher dose can be for example 20 mg, 30 mg or 40 mg. In one example the lower dose 10 mg and the next higher dose is 20 mg. In one example the lower dose 10 mg and the next higher dose is 30 mg. In one example the lower dose 20 mg and the next higher dose is 30 mg. In one example the lower dose 20 mg and the next higher dose is 40 mg. In one embodiment, “higher dose” and “next higher dose” are synonyms. In one embodiment, the “next higher dose” is selected from 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, 60 mg, and 80 mg. In one embodiment, the “next higher dose” is selected from 20 mg, 30 mg, and 40 mg. In oneembodiment, the “next higher dose” is 20 mg. In one embodiment, the “next higher dose” is 30 mg. Inone embodiment, the “next higher dose” is 40 mg. In one embodiment, the “next higher dose” is 60 mg.In one embodiment, the “next higher dose” is 80 mg. In one embodiment, the “next lower dose” is selected from 10 mg, 20 mg, and 30 mg. In one embodiment,the “next lower dose” is 10 mg. In one embodiment, the “next lower dose” is 20 mg. In one embodiment,the “next lower dose” is 30 mg. In some embodiments, The amount of the compound according to formula (I) is adjusted by up-titration. Here, the patient receives a lower dose, which is up-titrated to a higher dose: In one embodiment, the “lower dose” is 5 mg, and the higher dose is selected from 10 mg, 20 mg, 30 mg, 40 mg, 60 mg and 80 mg. In one embodiment, the “lower dose” is 10 mg, and the higher dose is selected from 20 mg, 30 mg, 40 mg, 60 mg and 80 mg. In one embodiment, the “lower dose” is 20 mg, and the higher dose is selected from 30 mg, 40 mg, 60 mg and 80 mg. In one embodiment, the “lower dose” is 30 mg, and the higher dose is selected from 40 mg, 60 mg and 80 mg. In one embodiment, the “lower dose” is 40 mg, and the higher dose is selected from 60 mg and 80 mg. In one embodiment, the “lower dose” is 60 mg, and the higher dose is 80 mg. In these embodiments, the “higher dose” can be the “next higher dose”. In one embodiment, the “lower dose” is 5 mg, and the “higher dose” is 10 mg. In one embodiment, the “lower dose” is 5 mg, and the “higher dose” is 20 mg. In one embodiment, the “lower dose” is 5 mg, and the “higher dose” is 30 mg. In one embodiment, the “lower dose” is 5 mg, and the “higher dose” is 40 mg.In one embodiment, the “lower dose” is 5 mg, and the “higher dose” is 60 mg. In one embodiment, the“lower dose” is 5 mg, and the “higher dose” is 80 mg. In one embodiment, the “lower dose” is 10 mg, andthe “higher dose” is 20 mg. In one embodiment, the “lower dose” is 10 mg, and the “higher dose” is 30mg. In one embodiment, the “lower dose” is 10 mg, and the “higher dose” is 40 mg. In one embodiment,the “lower dose” is 10 mg, and the “higher dose” is 60 mg. In one embodiment, the “lower dose” is 10 mg, and the “higher dose” is 80 mg. In one embodiment, the “lower dose” is 10 mg and the “next higher BHC231046 US14 -106- dose” is 20 mg. In one embodiment, the “lower dose” is 10 mg and the “next higher dose” is 40 mg. Inone embodiment, the “lower dose” is 20 mg, and the “higher dose” is 40 mg. In one embodiment, the“lower dose” is 20 mg, and the “higher dose” is 30 mg. In one embodiment, the “lower dose” is 20 mg, and the “next higher dose” is 40 mg. In one embodiment, the “lower dose” is 20 mg, and the “higher dose”is 60 mg. In one embodiment, the “lower dose” is 20 mg, and the “higher dose” is 80 mg. In oneembodiment, the “lower dose” is 30 mg, and the “next higher dose” is 40 mg. In one embodiment, the “lower dose” is 30 mg, and the “higher dose” is 60 mg. In one embodiment, the “lower dose” is 30 mg,and the “higher dose” is 80 mg. In one embodiment, the “lower dose” is 40 mg, and the “higher dose” is60 mg. In one embodiment, the “lower dose” is 40 mg, and the “higher dose” is 80 mg. In one embodiment,the “lower dose” is 60 mg, and the “higher dose” is 80 mg. In these embodiments, the “higher dose” canbe the “next higher dose”. In some embodiments, The amount of the compound according to formula (I) is adjusted by down- titration. Here, the patient receives a higher dose, which is down-titrated to a lower dose: In one embodiment, the “higher dose” is 80 mg, and the “lower dose” is selected from 2.5 mg, 5 mg, 10 mg, 20 mg, 40 mg, and 60 mg. In one embodiment, the “higher dose” is 60 mg, and the “lower dose” is selected from 5 mg, 10 mg, 20 mg, and 40 mg. In one embodiment, the “higher dose” is 40 mg, and the“lower dose” is selected from 5 mg, 10 mg, and 20 mg. In one embodiment, the “higher dose” is 20 mg,and the “lower dose” is selected from 2.5 mg, 5 mg, and 10 mg. In one embodiment, the “higher dose” is10 mg, and the “lower dose” is selected from 2.5 mg, and 5 mg. In one embodiment, the “higher dose” is10 mg, and the “lower dose” is 5 mg. In these embodiments, the “lower dose” can be the “next lowerdose”. In one embodiment, the “higher dose” is 80 mg, and the “lower dose” is 60 mg. In one embodiment, the “higher dose” is 80 mg, and the “lower dose” is 40 mg. In one embodiment, the “higher dose” is 80 mg,and the “lower dose” is 30 mg. In one embodiment, the “higher dose” is 80 mg, and the “lower dose” is20 mg. In one embodiment, the “higher dose” is 80 mg, and the “lower dose” is 10 mg. In one embodiment, the “higher dose” is 80 mg, and the “lower dose” is 5 mg. In one embodiment, the “higher dose” is 60 mg, and the “lower dose” is 40 mg. In one embodiment, the “higher dose” is 60 mg, and the “lower dose” is30 mg. In one embodiment, the “higher dose” is 60 mg, and the “lower dose” is 20 mg. In one embodiment,the “higher dose” is 60 mg, and the “lower dose” is 10 mg. In one embodiment, the “higher dose” is 60mg, and the “lower dose” is 5 mg. In one embodiment, the “higher dose” is 40 mg and the “lower dose”is 30 mg. In one embodiment, the “higher dose” is 40 mg and the “lower dose” is 20 mg. In one embodiment, the “higher dose” is 40 mg and the “lower dose” is 10 mg. In one embodiment, the “higherdose” is 40 mg and the “lower dose” is 5 mg. In one embodiment, the “higher dose” is 20 mg and the“lower dose” is 10 mg. In one embodiment, the “higher dose” is 20 mg and the “lower dose” is 5 mg. Inone embodiment, the “higher dose” is 20 mg, and the “lower dose” is 2.5 mg. In one embodiment, the BHC231046 US14 -107- “higher dose” is 10 mg and the “lower dose” is 5 mg. In one embodiment, the “higher dose” is 10 mg, andthe “lower dose” is 2.5 mg. In these embodiments, the “lower dose” can be the “next lower dose”.In one embodiment, the “higher dose” is 40 mg and the “next lower dose” is 20 mg. In one embodiment, the “higher dose” is 40 mg and the “next lower dose” is 10 mg. In one embodiment, the “higher dose” is40 mg and the “next lower dose” is 5 mg.In one embodiment, the “higher dose” is 20 mg and the “next lower dose” is 10 mg. In one embodiment,the “higher dose” is 20 mg and the “next lower dose” is 5 mg.In one embodiment, the “higher dose” is 10 mg and the “next lower dose” is 5 mg. In one embodiment,the “higher dose” is 10 mg and the “next lower dose” is 2.5 mg.In some embodiments that dose can be adjusted stepwise. In one embodiment, the dose the patient is receiving is up-titrated stepwise. Stepwise can mean, that the titration is performed in one step. For example, in case that the “lower dose” is 10 mg, and the “higher dose” is 20 mg, than the dose is up-titrated for example from 10 mg to 20 mg. Stepwise can mean, that the titration is performed in at least two steps. For example, in case that the “lower does” is 10 mg, and “the “higher dose” is 40 mg, than the dose is up-titrated for example in the first step from 10 mg to 20 mg and in the second step from 20 mg to 40 mg. Stepwise can mean, that the up-titration is performed in three steps. For example, in case that the “lower does” is 10 mg, and “the “higher dose” is 40 mg, than the dose is up-titrated for example in the first step from 10 mg to 20 mg and in the second step from 20 mg to 30 mg, and in the third step from 30 mg to 40 mg. In some embodiments that dose can be adjusted stepwise. In one embodiment, the dose the patient is receiving is down-titrated stepwise. Stepwise can mean, that the titration is performed in one step. For example, in case that the “lower dose” is 10 mg, and the “higher dose” is 20 mg, than the dose is down- titrated for example from 20 mg to 10 mg. Stepwise can mean, that the titration is performed in at least two steps. For example, in case that the “lower does” is 10 mg, and “the “higher dose” is 40 mg, than the dose is down-titrated for example in the first step from 40 mg to 20 mg and in the second step from 20 mgto 10 mg. Stepwise can mean, that the up-titration is performed in three steps. For example, in case thatthe “lower does” is 10 mg, and “the “higher dose” is 40 mg, than the dose is down-titrated for example inthe first step from 40 mg to 30 mg and in the second step from 30 mg to 20 mg, and in the third step from20 mg to 10 mg. In one embodiment, the patient receives a lower dose of the compound according to formula (I), and -the potassium level is equal to or below 4.5 mmol / L,then the dose is up-titrated to a higher dose. In this embodiment, the lower dose can be selected from 10mg and 20 mg; and the higher dose can be selected from 20 mg and 40 mg. BHC231046 US14 -108- In one embodiment, the patient receives a lower dose of the compound according to formula (I), and -the potassium level is equal to or below 4.5 mmol / L,then the dose is up-titrated to a higher dose stepwise. In this embodiment, the lower dose can be selectedfrom 10 mg and 20 mg; and the higher dose can be selected from 20 mg and 40 mg.In one embodiment, the patient receives a lower dose of the compound according to formula (I), and -the potassium level is equal to or below 4.5 mmol / L,then the dose is up-titrated to the next higher dose. In this embodiment, the lower dose can be selectedfrom 10 mg and 20 mg; and the next higher dose can be selected from 20 mg and 40 mg.In one embodiment, the patient receives a lower dose of the compound according to formula (I), and -the potassium level is equal to or below 4.8 mmol / L,then the dose is up-titrated to a higher dose. In this embodiment, the lower dose can be selected from 10mg and 20 mg; and the higher dose can be selected from 20 mg and 40 mg.In one embodiment, the patient receives a lower dose of the compound according to formula (I), and -the potassium level is equal to or below 4.8 mmol / L,then the dose is up-titrated to a higher dose stepwise. In this embodiment, the lower dose can be selectedfrom 10 mg and 20 mg; and the higher dose can be selected from 20 mg and 40 mg.In one embodiment, the patient receives a lower dose of the compound according to formula (I), and -the potassium level is equal to or below 4.8 mmol / L,then the dose is up-titrated to the next higher dose. In this embodiment, the lower dose can be selectedfrom 10 mg and 20 mg; and the next higher dose can be selected from 20 mg and 40 mg.In one embodiment, the patient receives a lower dose of the compound according to formula (I), and -the potassium level is equal to or below 5 mmol / L,then the dose is up-titrated to a higher dose. In this embodiment, the lower dose can be selected from 10mg and 20 mg; and the higher dose can be selected from 20 mg and 40 mg.In one embodiment, the patient receives a lower dose of the compound according to formula (I), and -the potassium level is equal to or below 5 mmol / L,then the dose is up-titrated to a higher dose stepwise. In this embodiment, the lower dose can be selectedfrom 10 mg and 20 mg; and the higher dose can be selected from 20 mg and 40 mg.In one embodiment, the patient receives a lower dose of the compound according to formula (I), and BHC231046 US14 -109- -the potassium level is equal to or below 5 mmol / L,then the dose is up-titrated to the next higher dose. In this embodiment, the lower dose can be selectedfrom 10 mg and 20 mg; and the next higher dose can be selected from 20 mg and 40 mg.In one embodiment, the patient receives a lower dose of the compound according to formula (I), and -the potassium level is equal to or below 5.5 mmol / L,then the dose is up-titrated to a higher dose. In this embodiment, the lower dose can be selected from 10mg and 20 mg; and the higher dose can be selected from 20 mg and 40 mg.In one embodiment, the patient receives a lower dose of the compound according to formula (I), and -the potassium level is equal to or below 5.5 mmol / L,then the dose is up-titrated to a higher dose stepwise. In this embodiment, the lower dose can be selectedfrom 10 mg and 20 mg; and the higher dose can be selected from 20 mg and 40 mg.In one embodiment, the patient receives a lower dose of the compound according to formula (I), and -the potassium level is equal to or below 5.5 mmol / L,then the dose is up-titrated to the next higher dose. In this embodiment, the lower dose can be selectedfrom 10 mg and 20 mg; and the next higher dose can be selected from 20 mg and 40 mg.In one embodiment, the patient receives a dose of the compound according to formula (I) in an amount of10 mg, and the potassium level is equal to or below 4.5 mmol / L, then the dose is up-titrated to 20 mg. Inone embodiment, the patient receives a dose of the compound according to formula (I) in an amount of 10mg, and the potassium level is equal to or below 4.8 mmol / L, then the dose is up-titrated to 20 mg. In oneembodiment, the patient receives a dose of the compound according to formula (I) in an amount of 10 mg,and the potassium level is equal to or below 5 mmol / L, then the dose is up-titrated to 20 mg. In oneembodiment, the patient receives a dose of the compound according to formula (I) in an amount of 10 mg,and the potassium level is equal to or below 5.5 mmol / L, then the dose is up-titrated to 20 mg.In one embodiment, the patient receives a dose of the compound according to formula (I) in an amount of10 mg, and the potassium level is equal to or below 4.5 mmol / L, then the dose is up-titrated to 40 mg. Inone embodiment, the patient receives a dose of the compound according to formula (I) in an amount of 10mg, and the potassium level is equal to or below 4.8 mmol / L, then the dose is up-titrated to 40 mg. In oneembodiment, the patient receives a dose of the compound according to formula (I) in an amount of 10 mg,and the potassium level is equal to or below 5 mmol / L, then the dose is up-titrated to 40 mg. In oneembodiment, the patient receives a dose of the compound according to formula (I) in an amount of 10 mg,and the potassium level is equal to or below 5.5 mmol / L, then the dose is up-titrated to 40 mg. BHC231046 US14 -110- In one embodiment, the patient receives a dose of the compound according to formula (I) in an amount of10 mg, and the potassium level is equal to or below 4.5 mmol / L, then the dose is up-titrated to 40 mg asfollows:Step 1 from 10 mg to 20 mgStep 2 from 20 mg to 40 mg.In one embodiment, the patient receives a dose of the compound according to formula (I) in an amount of10 mg, and the potassium level is equal to or below 4.8 mmol / L, then the dose is up-titrated to 40 mg asfollows:Step 1 from 10 mg to 20 mgStep 2 from 20 mg to 40 mg.In one embodiment, the patient receives a dose of the compound according to formula (I) in an amount of 10 mg, and the potassium level is below 5 mmol / L, then the dose is up-titrated to 40 mg as follows:Step 1 from 10 mg to 20 mgStep 2 from 20 mg to 40 mg.In one embodiment, the patient receives a dose of the compound according to formula (I) in an amount of10 mg, and the potassium level is equal to or below 5.5 mmol / L, then the dose is up-titrated to 40 mg asfollows:Step 1 from 10 mg to 20 mgStep 2 from 20 mg to 40 mg.In one embodiment, the patient receives a dose of the compound according to formula (I) in an amount of20 mg, and the potassium level is equal to or below 4.5 mmol / L, then the dose is up-titrated to 40 mg. Inone embodiment, the patient receives a dose of the compound according to formula (I) in an amount of 20mg, and the potassium level is equal to or below 4.8 mmol / L, then the dose is up-titrated to 40 mg. In oneembodiment, the patient receives a dose of the compound according to formula (I) in an amount of 20 mg, and the potassium level is below 5 mmol / L, then the dose is up-titrated to 40 mg. In one embodiment, the patient receives a dose of the compound according to formula (I) in an amount of 20 mg, and the potassiumlevel is equal to or below 5.5 mmol / L, then the dose is up-titrated to 40 mg.In one embodiment, the dose the patient is receiving is up-titrated depending on the eGFR decrease. Inone embodiment, the dose the patient is receiving is up-titrated depending on the eGFR decrease, based on the relative eGFR change from baseline or treatment initiation or prior measurement relative eGFR change from baseline or treatment initiation or prior measurement or treatment initiation or prior measurement. BHC231046 US14 -111- In one embodiment, the dose the patient is receiving is up-titrated, if the eGFR decrease is equal to or below 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 57 or 60 %, based on the relative eGFR change from baseline or treatment initiation or prior measurement relative eGFR change from baseline or treatment initiation or prior measurement or treatment initiation or prior measurement . In one embodiment, the dose the patientis receiving is up-titrated, if the eGFR decrease is equal to or above 5, 10, 15, 20, 25, 30, 35, 40, 45, 50,57 or 60 %, based on the relative eGFR change from baseline or treatment initiation or prior measurement relative eGFR change from baseline or treatment initiation or prior measurement or treatment initiation or prior measurement . In one embodiment, the dose the patient is receiving is up-titrated, if the eGFRdecrease is equal to or below 5, 10, 15, 20, 25, 30, 35, or 40 %, based on the relative eGFR change frombaseline or treatment initiation or prior measurement relative eGFR change from baseline or treatment initiation or prior measurement or treatment initiation or prior measurement . In one embodiment, thedose the patient is receiving is up-titrated, if the eGFR decrease is equal to or above 5, 10, 15, 20, 25, 30,35, or 40 %, based on the relative eGFR change from baseline or treatment initiation or prior measurement relative eGFR change from baseline or treatment initiation or prior measurement or treatment initiation or prior measurement . In one embodiment, the dose the patient is receiving is up-titrated, if the eGFRdecrease is equal to or below 5, 10, 15, 20, 25, or 30 %, based on the relative eGFR change from baselineor treatment initiation or prior measurement relative eGFR change from baseline or treatment initiation or prior measurement or treatment initiation or prior measurement . In one embodiment, the dose the patientis receiving is up-titrated, if the eGFR decrease is equal to or above 5, 10, 15, 20, 25, or 30 40 %, basedon the relative eGFR change from baseline or treatment initiation or prior measurement relative eGFR change from baseline or treatment initiation or prior measurement or treatment initiation or prior measurement . In one embodiment, the dose the patient is receiving is up-titrated, if the eGFR decrease is equal to or below 25 %, based on the relative eGFR change from baseline or treatment initiation or prior measurement . In one embodiment, the dose the patient is receiving is up-titrated, if the eGFR decrease is equal to or below 30 %, based on the relative eGFR change from baseline or treatment initiation or prior measurement . In one embodiment, the dose the patient is receiving is up-titrated, if the eGFR decrease is equal to or below 40 %, based on the relative eGFR change from baseline or treatment initiation or prior measurement. In one embodiment, the dose the patient is receiving is up-titrated, if the eGFR decrease is equal to orbelow 50 %, based on the relative eGFR change from baseline or treatment initiation or prior measurement . In one embodiment, the dose the patient is receiving is up-titrated, if the eGFR decrease is equal to or below 57 %, based on the relative eGFR change from baseline or treatment initiation or prior measurement . In one embodiment, the dose the patient is receiving is up-titrated, if the eGFR decrease is equal to or above 25 %, based on the relative eGFR change from baseline or treatment initiation or prior measurement . In one embodiment, the dose the patient is receiving is up-titrated, if the eGFR decrease is equal to or BHC231046 US14 -112- above 30 %, based on the relative eGFR change from baseline or treatment initiation or prior measurement . In one embodiment, the dose the patient is receiving is up-titrated, if the eGFR decrease is equal to or above 40 %, based on the relative eGFR change from baseline or treatment initiation or prior measurement . In one embodiment, the dose the patient is receiving is up-titrated, if the eGFR decrease is equal to or above 50 %, based on the relative eGFR change from baseline or treatment initiation or prior measurement . In one embodiment, the dose the patient is receiving is up-titrated, if the eGFR decrease is equal to or above 57 %, based on the relative eGFR change from baseline or treatment initiation or prior measurement . In one embodiment, the dose the patient is receiving is up-titrated, if the eGFR decrease is equal to orabove 25 % to equal to or below 57 %, based on the relative eGFR change from baseline or treatmentinitiation or prior measurement . In one embodiment, the dose the patient is receiving is up-titrated, if theeGFR decrease is equal to or above 25 % to equal to or below 50 %, based on the relative eGFR changefrom baseline or treatment initiation or prior measurement . In one embodiment, the dose the patient isreceiving is up-titrated, if the eGFR decrease is equal to or above 25 % to equal to or below 40 %, basedon the relative eGFR change from baseline or treatment initiation or prior measurement . In oneembodiment, the dose the patient is receiving is up-titrated, if the eGFR decrease is equal to or above 25% to equal to or below 30%, based on the relative eGFR change from baseline or treatment initiation orprior measurement . In one embodiment, the dose the patient is receiving is up-titrated, if the eGFRdecrease is equal to or above 30 % to equal to or below 57 %, based on the relative eGFR change frombaseline or treatment initiation or prior measurement . In one embodiment, the dose the patient is receivingis up-titrated, if the eGFR decrease is equal to or above 30 % to equal to or below 50 %, based on therelative eGFR change from baseline or treatment initiation or prior measurement . In one embodiment, thedose the patient is receiving is up-titrated, if the eGFR decrease is equal to or above 30 % to equal to orbelow 40 %, based on the relative eGFR change from baseline or treatment initiation or prior measurement. In one embodiment, the dose the patient is receiving is up-titrated, if the eGFR decrease is equal to orabove 40 % to equal to or below 57 %, based on the relative eGFR change from baseline or treatmentinitiation or prior measurement . In one embodiment, the dose the patient is receiving is up-titrated, if theeGFR decrease is equal to or above 40 % to equal to or below 50 %, based on the relative eGFR changefrom baseline or treatment initiation or prior measurement . In one embodiment, the dose the patient isreceiving is up-titrated, if the eGFR decrease is equal to or above 50 % to equal to or below 57 %, basedon the relative eGFR change from baseline or treatment initiation or prior measurement . In one embodiment, the dose can be adjusted based on the potassium level and / or the eGFR decrease. In one embodiment, the patient receives a lower dose of the compound according to formula (I), and -the potassium level is equal to or below 4.5 mmol / L,and if the eGFR decrease is less than 30 %, based on the relative eGFR change from baseline or treatment BHC231046 US14 -113- initiation or prior measurement , then the dose is up-titrated to a higher dose. In this embodiment, thelower dose can be selected from 10 mg and 20 mg; and the higher dose can be selected from 20 mg and40 mg. In one embodiment, the patient receives a lower dose of the compound according to formula (I), and -the potassium level is equal to or below 4.5 mmol / L,and if the eGFR decrease is equal to or below 30 %, based on the relative eGFR change from baseline ortreatment initiation or prior measurement , then the dose is up-titrated to a higher dose stepwise. In thisembodiment, the lower dose can be selected from 10 mg and 20 mg; and the higher dose can be selectedfrom 20 mg and 40 mg. In one embodiment, the patient receives a lower dose of the compound according to formula (I), and -the potassium level is equal to or below 4.5 mmol / L,and if the eGFR decrease is equal below 30 %, based on the relative eGFR change from baseline or treatment initiation or prior measurement , then the dose is up-titrated to the next higher dose. In thisembodiment, the lower dose can be selected from 10 mg and 20 mg; and the next higher dose can beselected from 20 mg and 40 mg. In one embodiment, the patient receives a lower dose of the compound according to formula (I), and -the potassium level is equal to or below 4.8 mmol / L,and if the eGFR decrease is equal to or below 30%, based on the relative eGFR change from baseline ortreatment initiation or prior measurement , then the dose is up-titrated to a higher dose. In this embodiment,the lower dose can be selected from 10 mg and 20 mg; and the higher dose can be selected from 20 mgand 40 mg. In one embodiment, the patient receives a lower dose of the compound according to formula (I), and -the potassium level is equal to or below 4.8 mmol / L,and if the eGFR decrease is equal to or below 30 %, based on the relative eGFR change from baseline ortreatment initiation or prior measurement , then the dose is up-titrated to a higher dose stepwise. In thisembodiment, the lower dose can be selected from 10 mg and 20 mg; and the higher dose can be selectedfrom 20 mg and 40 mg. In one embodiment, the patient receives a lower dose of the compound according to formula (I), and -the potassium level is equal to or below 4.8 mmol / L,and if the eGFR decrease is equal to or below 30%, based on the relative eGFR change from baseline ortreatment initiation or prior measurement , then the dose is up-titrated to the next higher dose. In this embodiment, the lower dose can be selected from 10 mg and 20 mg; and the next higher dose can be selected from 20 mg and 40 mg. BHC231046 US14 -114- In one embodiment, the patient receives a lower dose of the compound according to formula (I), and -the potassium level is below 5 mmol / L,and if the eGFR decrease is equal to or below 30%, based on the relative eGFR change from baseline ortreatment initiation or prior measurement , then the dose is up-titrated to a higher dose stepwise. In this embodiment, the lower dose can be selected from 10 mg and 20 mg; and the higher dose can be selected from 20 mg and 40 mg. In one embodiment, the patient receives a lower dose of the compound according to formula (I), and -the potassium level is below 5 mmol / L,and if the eGFR decrease is equal to or below 30%, based on the relative eGFR change from baseline ortreatment initiation or prior measurement , then the dose is up-titrated to the next higher dose. In this embodiment, the lower dose can be selected from 10 mg and 20 mg; and the next higher dose can be selected from 20 mg and 40 mg. In one embodiment, the patient receives a lower dose of the compound according to formula (I), and -the potassium level is equal to or below 5.5 mmol / L,and if the eGFR decrease is equal to or below 30%, based on the relative eGFR change from baseline ortreatment initiation or prior measurement , then the dose is up-titrated to the next higher dose. In this embodiment, the lower dose can be selected from 10 mg and 20 mg; and the next higher dose can be selected from 20 mg and 40 mg. In one embodiment, the patient receives a dose of 10 mg of the compound according to formula (I), and -the potassium level is equal to or below 4.5 mmol / L,and if the eGFR decrease is equal to or below 30%, based on the relative eGFR change from baseline ortreatment initiation or prior measurement , then the dose is up-titrated to 20mg. In one embodiment, the patient receives a dose of 10 mg of the compound according to formula (I), and -the potassium level is equal to or below 4.8 mmol / L,and if the eGFR decrease is equal to or below 30%, based on the relative eGFR change from baseline ortreatment initiation or prior measurement , then the dose is up-titrated to 20mg. In one embodiment, the patient receives a dose of 10 mg of the compound according to formula (I), and -the potassium level is below 5 mmol / L,and if the eGFR decrease is equal to or below 30%, based on the relative eGFR change from baseline ortreatment initiation or prior measurement , then the dose is up-titrated to 20mg. In one embodiment, the patient receives a dose of 10 mg of the compound according to formula (I), and -the potassium level is equal to or below 5.5 mmol / L,and if the eGFR decrease is equal to or below 30%, based on the relative eGFR change from baseline or BHC231046 US14 -115- treatment initiation or prior measurement , then the dose is up-titrated to 20mg. In one embodiment, the patient receives a dose of 10 mg of the compound according to formula (I), and -the potassium level is equal to or below 4.5 mmol / L,and if the eGFR decrease is equal to or below 30%, based on the relative eGFR change from baseline ortreatment initiation or prior measurement , then the dose is up-titrated to 40 mg. In one embodiment, the patient receives a dose of 10 mg of the compound according to formula (I), and -the potassium level is equal to or below 4.8 mmol / L,and if the eGFR decrease is equal to or below 30%, based on the relative eGFR change from baseline ortreatment initiation or prior measurement , then the dose is up-titrated to 40 mg. In one embodiment, the patient receives a dose of 10 mg of the compound according to formula (I), and -the potassium level is below 5 mmol / L,and if the eGFR decrease is equal to or below 30%, based on the relative eGFR change from baseline ortreatment initiation or prior measurement , then the dose is up-titrated to 40 mg. In one embodiment, the patient receives a dose of 10 mg of the compound according to formula (I), and -the potassium level is equal to or below 5.5 mmol / L,and if the eGFR decrease is equal to or below 30%, based on the relative eGFR change from baseline ortreatment initiation or prior measurement , then the dose is up-titrated to 40 mg. In one embodiment, the patient receives a dose of 20 mg of the compound according to formula (I), and -the potassium level is equal to or below 4.5 mmol / L,and if the eGFR decrease is equal to or below 30%, based on the relative eGFR change from baseline ortreatment initiation or prior measurement , then the dose is up-titrated to 40 mg. In one embodiment, the patient receives a dose of 20 mg of the compound according to formula (I), and -the potassium level is equal to or below 4.8 mmol / L,and if the eGFR decrease is equal to or below 30%, based on the relative eGFR change from baseline ortreatment initiation or prior measurement , then the dose is up-titrated to 40 mg. In one embodiment, the patient receives a dose of 20 mg of the compound according to formula (I), and -the potassium level is below 5 mmol / L,and if the eGFR decrease is equal to or below 30%, based on the relative eGFR change from baseline ortreatment initiation or prior measurement , then the dose is up-titrated to 40 mg. In one embodiment, the patient receives a dose of 20 mg of the compound according to formula (I), and -the potassium level is equal to or below 5.5 mmol / L,and if the eGFR decrease is equal to or below 30%, based on the relative eGFR change from baseline or BHC231046 US14 -116- treatment initiation or prior measurement , then the dose is up-titrated to 40 mg. In one embodiment, the patient receives a dose of 10 mg of the compound according to formula (I), and -the potassium level is equal to or below 4.5 mmol / L,and if the eGFR decrease is equal to or below 30%, based on the relative eGFR change from baseline ortreatment initiation or prior measurement , then the dose is up-titrated to 40 mg as follows:Step 1 10 mg to 20 mgStep 2 20 mg to 40 mg.In one embodiment, the patient receives a dose of 10 mg of the compound according to formula (I), and -the potassium level is equal to or below 4.8 mmol / L,and if the eGFR decrease is equal to or below 30%, based on the relative eGFR change from baseline ortreatment initiation or prior measurement , then the dose is up-titrated to 40 mg as follows:Step 1 10 mg to 20 mgStep 2 20 mg to 40 mg.In one embodiment, the patient receives a dose of 10 mg of the compound according to formula (I), and -the potassium level is below 5 mmol / L,and if the eGFR decrease is equal to or below 30%, based on the relative eGFR change from baseline ortreatment initiation or prior measurement , then the dose is up-titrated to 40 mg as follows:Step 1 10 mg to 20 mgStep 2 20 mg to 40 mg.In one embodiment, the patient...

Claims

BHC 231046 US014 -369 -CLAIMS We claim:

1. A method of preventing or treating heart failure in a patient, comprising administering to the patienta therapeutically effective amount of a compound of Formula (I)or a hydrate thereof, solvate thereof, pharmaceutically acceptable salt thereof, or a polymorphthereof.

2. The method according to claim 1, wherein the heart failure is selected from the group consisting ofsymptomatic heart failure, heart failure with improved ejection fraction (HFimpEF), heart failure with mid-range ejection fraction (HFmrEF), heart failure preserved ejection fraction (HFpEF), heart failure with reduced ejection fraction (HFrEF), chronic heart failure (CHF), congestive heart failure, acute heart failure, chronic heart failure, worsening chronic heart failure (WCHF), andhospitalization for heart failure.

3. The method according to any one of claims 1 to 2, wherein the patient has a left ventricular ejectionfraction (LVEF) of equal to or above 30%, 35%, 39%, 40%, 45%, 49%, 50%, 55%, 60%, 65% or70%.

4. The method according to any one of claims 1 to 3, wherein the patient has an estimated glomerularfiltration rate (eGFR) selected from the group consisting of equal to or above 15, 20, 25, 30, 35, 40,41, 45, 50, 55, 60, 65, 70, 75, 80, 85, and 90 mL / min / 1.73 m2.

5. The method according to any one of claims 1 to 4, wherein the patient has a Urine Albumin toCreatinine Ratio (UACR) of equal to or above 5 to equal to or below 5000 mg / g.

6. The method according to any one of claims 1 to 5, wherein the patient has an eGFR of equal to orbelow 15 mL / min / 1.73 m2 and a UACR of equal to or above 300 mg / g.BHC 231046 US014 -370 -7. The method according to any one of claims 1 to 6, wherein the patient has a potassium level of equalto or above 3, 3.5, 4, 4.5, 4.8, 5, 5.5, 6, 6.5, 7.0 or 7.5 mmol / L.

8. The method according to any one of claims 1 to 7, wherein the patient has a sodium level selectedfrom the group consisting of equal to or above 100, 110, 115, 117, 120, 125, 130, 135, 138, 140, 141,144, 145, 150, 154 and 155 mmol / L.

9. The method according to any one of claims 1 to 8, wherein the patient has an urea level of equal toor above 4 mg / dL.

10. The method according to any one of claims 1 to 9, wherein the patient has a N-terminal prohormoneof brain natriuretic peptide (NT-proBNP) of equal to or above 300 pg / ml.

11. The method according to any one of claims 1 to 10, wherein the patient further receives a medicamentselected from the group consisting of loop diuretics, beta-blockers, ACE inhibitors (ACEi),angiotensin-receptor-blocker (ARB), Angiotensin Receptor-Neprilysin Inhibitor (ARNI), calcium channel blockers, Sodium-glucose Cotransporter-2 Inhibitor (SGLT-2i), glucagon-like peptide-1 (GLP-1) agonists, CYP3A4 inducers, CYP3A4 inhibitors and combinations thereof.

12. The method according to any one of claims 1 to 11, wherein the patient further receives a Sodium-glucose Cotransporter-2 Inhibitor (SGLT-2i) and a glucagon-like peptide-1 (GLP-1) agonist.

13. The method according to any one of claims 1 to 12, wherein the patient further receives any one ofthe medicaments or comedications selected from the group consisting of CYP3A4 inducers, CYP3A4 inhibitors and combinations thereof.

14. The method according to any one of claims 1 to 13, wherein the amount of compound (I) isadministered as a dose of 10, 20, 40 and 60 mg per day.

15. The method according to any one of claims 1 to 14, wherein the amount of compound (I) isadministered as a dose of 10, 20 and 40 mg per day.

16. The method according to any one of claims 1 to 15, wherein the amount of compound (I) isadministered as a dose of 10, 20 and 40 mg per day.

17. The method according to any one of claims 1 to 16, wherein the daily dose the patient receives isadjusted over the course of a treatment regimen.BHC 231046 US014 -<sub>371 -18. The method according to any one of claims 1 to 17, wherein the daily dose is adjusted by down-titration, up-titration, interruption or combinations thereof.

19. The method according to any one of claims 1 to 18, wherein the daily dose the patient receives isadjusted based on the factors selected from the group consisting of -a physiological measure selected from the group consisting of LVEF, NYAH, eGFR, change ineGFR, UACR, serum potassium level, sodium level, chloride level, urea level, blood urea nitrogen(BUN), high-sensitivity Troponin T level, natriuretic peptide (NT-proBNP), blood pressure (BP), systolic blood pressure, average heart rate (resting), previous diseases, prior mineralocorticoid receptor antagonist (MRA) use, heart rate (or pulse rate), KCCQ-TSS, body mass index (BMI);- a comedication selected from the group consisting of loop diuretics, beta-blocker, ACE inhibitor(ACEi), angiotensin-receptor-blocker (ARB), Angiotensin Receptor-Neprilysin Inhibitor (ARNI), calcium channel blockers, Sodium-glucose Cotransporter-2 Inhibitor (SGLT-2i); -coadministration of a CYP3A4 inducer;- coadministration of a CYP3A4 inhibitor;and combinations thereof.

20. The method according to any one of claims 1 to 19, wherein the CYP3A4 inhibitor is a stronginhibitor of CYP3A4.

21. The method according to any one of claims 1 to 20, wherein the CYP3A4 inhibitor is selected fromthe group consisting of itraconazole, ketoconazole, ritonavir, nelfinavir, cobicistat, clarithromycin, telithromycin and nefazodone.

22. The method according to any one of claims 1 to 19, wherein CYP3A4 inhibitor is a moderate inhibitorof CYP3A4.

23. The method according to any one of claims 1 to 19 and 22, wherein CYP3A4 inhibitor is selectedfrom the group consisting of cyclosporin, ciprofloxacin, clotrimazole, diltiazem, dronedarone,erythromycin, fluconazole, and verapamil.

24. The method according to any one of claims 1 to 23, wherein the daily dose the patient receives isdown-titrated if the potassium level is selected from the group consisting of equal or above 5.5, 5.6, 6, 6.5, 7.7.5 and 8 mmol / L.BHC 231046 US014 -372 -25. The method according to any one of claims 1 to 24, wherein the daily dose the patient receives is 40mg or 30 mg, and wherein the dose is down-titrated to 30 mg, 20 mg or 10 mg.

26. The method according to any one of claims 1 to 25, wherein the daily dose the patient receives is up-titrated if the potassium level is equal or below 4.5, 4.8, 4.9, 5 or 5.5 mmol / L.

27. The method according to any one of claims 1 to 26, wherein the daily dose the patient receives is 30mg, 20 mg or 10 mg, and wherein the daily dose is up-titrated to an up-titrated dose of 40 mg, 30 mg or 20 mg.

28. The method according to any one of claims 1 to 27, wherein the daily dose the patient receives isdown-titrated, if the eGFR decrease is selected from the group consisting of equal to or above 25,30, 35, 40, 45, 50, and 57%, based on a relative eGFR change from baseline or treatment initiationor prior measurement.

29. The method according to any one of claims 1 to 28, wherein the daily dose the patient receives isup-titrated, if the eGFR decrease is selected from equal to or below 5, 10, 15, 25, 30, 35 and 40%,based on the relative eGFR change from baseline or treatment initiation or prior measurement.

30. The method according to any one of claims 1 to 29, wherein if the daily dose is 10 or 20 mg, and thepotassium level is below 5 mmol / L, then the daily dose is up-titrated to an up-titrated daily dose of20 mg or 40 mg.

31. The method according to any one of claims 1 to 30, wherein if the daily dose is 40 or 20 mg, and thepotassium level is equal to or above 5.5 mmol / L, but below 6.0 mmol / L, then the daily dose is down-titrated to a down-titrated daily dose of 20 mg or 10 mg.32 The method according to any one of claims 1 to 31, wherein the daily dosing is interrupted, if thepotassium level is equal to or above 6.0 mmol / L.

33. The method according to any one of claims 1 to 32, wherein the daily dose is 10 mg and the patienthas an eGFR of equal or below 60 mL / min / 1.73 m2.

34. The method according to any one of claims 1 to 33, wherein the patient receives a CYP3A4 inhibitor.

35. The method according to any one of claims 1 to 34, wherein the patient receives a CYP3A4 inducer.BHC 231046 US014 -373 -36. The method according to any one of claims 1 to 35, wherein the daily dose is 5 to 80 mg, and thedaily dose is down-titrated to a down-titrated dose of between 5 mg to below 80 mg.

37. The method according to any one of claims 1 to 36, wherein the daily dose is between 5 to below 80mg, and the daily dose is up-titrated to an up-titrated daily dose of between above 5 mg to 80 mg.

38. The method according to any one of claims 1 to 37, wherein the patient receives- a CYP3A4 inducer and- the compound according to formula (I) in a daily dose selected from the group consisting of 5 mg,10 mg, 20 mg, 30 mg, 40 mg, and 60 mgwherein the daily dose is adjusted by up-titration to an up-titrated daily dose selected from 10 mg,20 mg, 30 mg, 40 mg, 60 mg and 80 mg.

39. The method according to any one of claims 1 to 38, wherein the patient receives- a CYP3A4 inhibitor and- the compound according to formula (I) in a daily dose selected from the group consisting of 10 mg,20 mg, 30 mg, 40 mg, 60 mg and 80 mg, wherein the daily dose is adjusted by down-titration to a down-titrated daily dose selected from the group consisting of 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, and 60 mg.

40. The method according to any one of claims 1 to 39, wherein the patient receives a target daily doseof the compound of Formula (I) of 40 mg, and wherein the target daily dose must be down-titratedto 10 mg per day when co-administered with a strong CYP3A4 inhibitor.

41. The method according to any one of claims 1 to 40, wherein the patient receives a target daily doseof the compound of Formula (I) of 40 mg, and wherein the target daily dose must be down-titratedto 20 mg when using with co-administered with a moderate CYP3A4 inhibitor.

42. A method for reducing the risk of cardiovascular death, hospitalization for heart failure, urgentheart failure visits, or combinations thereof in patients with heart failure, comprising administeringto the patient a therapeutically effective amount of a compound of Formula (I)BHC 231046 US014 -374 -or a hydrate thereof, solvate thereof, pharmaceutically acceptable salt thereof, or a polymorphthereof, wherein the patient optionally has left ventricular ejection fraction (LVEF) of equal to or above 40%, wherein the method comprises any one of claims 2 to 38.

43. A method for improving symptoms or preventing worsening of symptoms of heart failure in patientswith heart failure, comprising administering to the patient a therapeutically effective amount of a compound according to Formula (I)or a hydrate thereof, solvate thereof, pharmaceutically acceptable salt thereof, or a polymorphthereof, wherein the patient optionally has left ventricular ejection fraction (LVEF) of equal to or above 40%, wherein the method comprises any one of 2 to 38.

44. The method according to any one of claims 1 to 43 wherein the compound of Formula (I) is acrystalline form of polymorph I.

45. The method according to any one of claims 1 to 44, wherein the compound of Formula (I) is acrystalline form of polymorph Iwherein the x-ray diffractogram of the compound exhibits peak maxima of the 2 theta angle at 8.5O, 14.1O< / sup>, and 19.0O.

46. A method of preventing or treating heart failure in a patient, comprising administering to the patientBHC 231046 US014 -375 -a therapeutically effective amount of a compound of Formula (I)or a hydrate thereof, solvate thereof, pharmaceutically acceptable salt thereof, or a polymorphthereof at a daily dose; andadjusting the daily dose based on physiological parameters.

47. The method of claim 46, wherein the adjusting is selected from the group consisting of reducingthe daily dose, increasing the daily dose, and interrupting the daily dose.

48. The method of claim 47, wherein the physiological parameters are selected from the group consisting of estimated glomerular filtration rate (eGFR), serum potassium level, and combinations thereof.

49. The method of claim 48, wherein the adjusting is reducing the daily dose to a down-titrated dailydose if the serum potassium level is equal to or above 5.5 mmol / L, 5.0 mmol / L, or 4.5 mmol / L; and / or the eGFR is less than or equal to 60 mL / min / 1.73 m2.

50. The method of claim 49, wherein the daily dose is selected from the group consisting of 10 mg, 20 mg, 30 mg, 40 mg, 60 mg and 80 mg; andthe down-titrated daily dose is selected from the group consisting of 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, and 60 mg.

51. A pharmaceutical dose form for administration to a patient in need thereof, comprising: a compoundof Formula (I)BHC 231046 US014 -376 -a pharmaceutically acceptable excipient.

52. The pharmaceutical dosage form of claim 51, wherein the pharmaceutically acceptable excipient is selected from the group consisting of hypromellose, sodium lauryl sulfate, microcrystalline cellulose, lactose monohydrate, croscarmellose, and magnesium stearate.

53. The pharmaceutical dosage form of claim 52, wherein the pharmaceutical dosage form is a tablet.

54. The pharmaceutical dosage form of claim 53, wherein the compound of Formula (I) is present as a granulate of polymorph A of the compound of Formula (I).

55. The pharmaceutical dosage form of claim 54, wherein the compound of Formula (I) is present at a dosage selected from the group consisting of 2.5 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, 60 mg, and